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Summary of Thesis 
Despite improvements in interventional and pharmacological therapy of atherosclerotic disease, 
it is still the leading cause of death in the developed world. Hence there is a need for further 
development of effective therapeutic approaches. This requires better understanding of the 
molecular mechanisms and pathophysiology of the disease. Atherosclerosis has long been 
identified as having an inflammatory component contributing to its pathogenesis, whilst the 
available therapy primarily targets hyperlipidaemia and prevention of thrombosis. 
Acknowledging a pleotropic anti-inflammatory effect to some therapies, such as acetyl salicylic 
acid and the statins, none of the currently approved medicines for management of either stable 
or complicated atherosclerosis has inflammation as a primary target. Monocytes, as 
representatives of the innate immune system, play a major role in the initiation, propagation and 
progression of atherosclerosis from a stable to an unstable state. Animal study data support a 
role of monocytes in acute coronary syndromes and in outcome post infarction; however, limited 
research has been done in humans.  
In this thesis I describe for the first time in a large cohort of ST elevation myocardial infarction 
(STEMI) patients followed up for three years that total monocyte count, monocyte subset 1 
(Mon 1), and monocyte subset 2 (Mon 2) are predictive of major adverse cardiac events (MACE) 
post STEMI (including death, new diagnosis of heart failure, recurrent acute coronary 
syndrome). Both the inflammatory function of monocyte subsets (via assessment and 
quantification of IKKβ as a surrogate for the NFκB inflammatory pathway activation) as well 
as the phagocytic activity of monocytes were studied in order to describe the mechanism through 
which monocytes affect their action. There was no significant difference in the NFκB pathway 
activity between those patients who developed an adverse event and those who did not. Also 
NFκB activity was not predictive of MACE. However the phagocytic activity of Mon 1 and 
Mon 2 were predictive of MACE suggesting that phagocytic activity of monocytes is the 
mechanism through which monocytes implement their action. Also this supports that the newly 
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described monocytes subset 2 (Mon 2) is predominantly an inflammatory monocyte subset, not 
reparative as Mon 3.  
Major adverse cardiac events were driven mainly by heart failure diagnosis and 
echocardiographic findings. Hence the association between ventricular remodelling and 
phenotypic and functional characterisation of monocytes subsets was studied in this thesis. Total 
monocyte count, Mon 1 and Mon 2 were again predictive of negative ventricular remodelling 
with increase in end systolic indexed volume of >15% at 6 months follow up echocardiogram 
post infarction.  Subclinical parameters of systolic dysfunction, namely global longitudinal 
strain and global circumferential strain were also significantly correlated with total monocyte 
count as well as Mon 1 levels.  
Given the above, I studied the effect of incorporating total monocyte count in Thrombolysis in 
Myocardial Infarction (TIMI) STEMI score to predict patient outcome at 30 days post infraction. 
C- statistics indicated improved prognostication of the TIMI STEMI model after incorporation 
of the total monocyte count into the model with improved area under the curve from 0.67 (for 
TIMI STEMI score), to area under the curve of 0.77 (TIMIMon score). This allows individual 
tailoring of secondary preventative therapy in order to improve patient outcome post infarction. 
Having described a potential mechanism through which the innate immune system affects 
outcome in STEMI patients, namely Mon1 and Mon2 through their phagocytic activity, the 
results from this thesis could be a stepping stone into targeted anti-inflammatory therapy in 
management of myocardial infarction.   
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General Aims and hypothesis: 
 
Three monocyte subsets have been recently characterised according to surface markers: 
CD14++CD16-CCR2+ (Mon1), CD14+CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- 
(Mon3) subsets. Little is known of the function of these subsets in humans and especially in 
STEMI patients. Hence, this study aims to:  
(i) Characterise functional activity of different monocyte subsets (via NFκB activation 
and, phagocytosis) in patients with STEMI;  
(ii) Assess the role of monocyte parameters on cardiac function and remodelling at 6 
months post infarction.  
(iii) Assess numbers and functional activity of different monocyte subsets on clinical 
outcome post myocardial recovery and assess their prognostic value. 
 
In chapter one the role of monocytes in atherosclerotic disease and myocardial infarction is 
summarized. In chapter two the phenotype of monocyte subsets in recruited STEMI patients are 
summarized. The hypothesis is that total monocyte count and monocyte subsets are significantly 
increased in the 24 hours post infarction compared to healthy controls and patients with stable 
coronary artery disease. This is investigated in a cross sectional study. In a longitudinal study I 
hypothesise that the level of monocyte subset counts, after increasing acutely in the first 24 
hours post STEMI, reduces after 14 days. 
 
In chapter three, the methodology of measuring phagocytic activity of monocyte subsets is 
validated and the phagocytic function of the different subsets is described in a cross sectional 
study in STEMI patients, healthy controls and stable coronary artery disease subjects. The 
hypothesis is that the phagocytic activity will be significantly higher in the STEMI patients 
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compared to other health states and that phagocytic levels drop at follow up 14 days after 
infarction. 
Chapter four describes the inflammatory effect of monocyte subsets, studying specifically NFκB 
pathway as well as the association with TNF-α and MMP- 9. I hypothesise that acutely, the 
inflammatory pathways are increased in STEMI patients and with inflammatory activity reduced 
at 14 days post infarction.  
 
The effect of monocyte subsets, both in terms of counts as well as functional capacity, on 
ventricular remodelling is studied in chapter 5. Here we hypothesise, that total monocyte counts 
are predictive of negative remodelling. Functionally, NFκB levels and phagocytic activity are 
investigated as potential independent predictors of negative remodelling. 
 
In chapter six, the effect of monocyte subsets and their functional parameters on predicting 
adverse cardiac events post myocardial infarction and after at least 2 years follow up is 
described. It is hypothesised that total monocyte count, and Mon 1 have a negative effect on 
patient outcome with a possible protective role for Mon 2. 
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Preface 
 
As this was a translational medicine study, the PhD was partly spent recruiting, analysing 
patient’s blood samples and performing echocardiograms, and partly in the laboratory 
environment validating the basic science concepts and molecular theories behind the techniques 
used.  
This is reflected in the writing of this thesis. Each chapter contains description of the molecular 
background driving the experiments with detailed account of the methodology used. The results 
section includes both laboratory based validation experiments followed by results in the 
recruited patient population with an aim to translate the molecular theories into patients’ 
profiles. In order to avoid repetition, each chapter includes an aspect of the overall proposed 
hypothesis, e.g.: chapter 2 includes a description of monocyte subsets phenotype in STEMI 
patients with chapters 3 and 4 investigating monocyte subsets functional parameters, namely 
phagocytosis and inflammatory pathways (NFκB) respectively, in STEMI patients. Clinically, 
the implication of monocyte subsets and their function on cardiac performance and ventricular 
remodelling are discussed in chapter 5. Chapter 6 investigates the long term effect of monocyte 
subset in determining patient outcomes and prognosis.   
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Chapter 1 
Introduction 
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 Introduction  
Atherosclerosis accounts for one fifth of all deaths in the world (Logue et al., 2011). It is the leading 
cause of death in the UK with more than 600,000 deaths annually due to its complications (Logue et 
al., 2011). Acute coronary syndrome (ACS) is an acute pathology associated with atherosclerotic 
plaque rupture and interruption of coronary blood supply to myocardial tissue. ACS carries a high 
mortality rate both en route to hospital and after receiving treatment. ACS is also associated with a 
high morbidity, especially when heart failure develops due to an extensive myocardial damage. 
Hence ACS forms an important field for research with an obvious need for improvement of current 
medical management, and introduction of new therapeutic targets. Better understanding of the 
underlying pathophysiological mechanisms leading to plaque development and rupture is essential to 
meet this need.  
 
 Definitions of Acute coronary syndromes 
When myocardial blood flow is acutely impaired (ischaemia), and often not provoked by exertion, a 
person will commonly suffer prolonged pain; this is referred to as acute coronary syndrome (ACS). 
The underlying common pathophysiology of ACS involves the erosion or sudden rupture of an 
atherosclerotic plaque within the wall of a coronary artery. Exposure of the circulating blood to the 
cholesterol-rich material within the plaque stimulates blood clotting (thrombosis), which obstructs 
blood flow within the affected coronary artery. This coronary obstruction may be of short duration, 
and may not result in myocardial cell damage, in which case the clinical syndrome is termed unstable 
angina. Unstable angina may result in reversible changes on the electrocardiogram (ECG) but does 
not cause a rise in troponin, a protein released by infarcting myocardial cells. Ischaemia which causes 
myocardial necrosis (infarction) will result in elevated troponin. When the ischaemia-causing 
infarction is either short-lived or affects only a small territory of myocardium the ECG will often 
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show either no abnormality or subtle changes. This syndrome is termed non-ST-segment elevation 
myocardial infarction (NSTEMI) (Alpert et al., 2000).  
STEMI is caused by complete and persistent occlusion of a coronary artery due to plaque rupture, 
with propagation of thrombus material downstream eventually completely occluding flow. As soon 
as the coronary blood supply is interrupted, myocardial damage ensues. The duration of deprivation 
of blood supply has great implications on recovery of heart muscle afterwards, hence in the modern 
era of cardiovascular medicine, percutaneous coronary intervention is the golden standard for 
restoring blood flow (re-vascularisation) of the infarcted myocardium.  
 
For the purposes of this study, STEMI is diagnosed on the presence of typical chest pain symptoms 
(which may or may not be accompanied by haemodynamic compromise), as well as the typical ST 
elevation ECG changes. As prolonged ischaemia leads to death of cardiomyocyte, current guidelines 
thus recommend percutaneous revascularisation as the recommended treatment acutely for STEMI 
patients.  This is in conjunction with a number of antiplatelet therapies as well as secondary 
prevention medications including, angiotensin receptor inhibits (to improve remodelling), and statin 
therapy for cholesterol management. 
 
 Inflammation in the atherosclerotic heart disease 
Inflammation clearly contributes to the pathophysiology of atherosclerosis. Infectious agents, such 
as Chlamydia pneumoniae, have been detected in coronary atherosclerotic lesions (Kuo et al., 1993). 
Human atherosclerotic plaques contain viruses as well as numerous bacterial signatures, including 
nucleic acids, and peptidoglycan (Laman et al., 2002). In addition several studies suggest positive 
associations between oral bacterial colonization-levels and increased risk of atherosclerosis (e.g., 
coronary artery disease [CAD]) and cerebrovascular events (Zeituni et al., 2010, Ott et al., 2006), 
supporting the link between atherosclerosis and an inflammatory/infective pathophysiology (Ott et 
al., 2006, Wick et al., 2004, Epstein et al., 2000). The low grade inflammation associated with CAD 
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is acknowledged in day to day clinical practice, with a AHA/CDC consensus report (Pearson et al., 
2003) recommending measurement of C-reactive protein (CRP) in asymptomatic subjects at 
intermediate risk for future coronary events (10-year risk of 10–20%) and in selected patients after 
an ACS (Pearson et al., 2003). In fact, the JUPITER trial indicated that statin therapy may reduce 
numbers of adverse cardiovascular events in subjects with normal LDL range, but high CRP 
concentrations (Ridker et al., 2001). Further evidence for the importance of inflammation in 
cardiovascular disease is seen from the ruptured plaque histology with abundance of macrophages, a 
thin fibrous cap and smooth muscle cell loss due to apoptosis (van der Wal et al., 1994). 
The innate immune system plays a major role in the initiation and propagation of atherosclerosis, 
with monocytes/macrophages being the key players in this process (Oude Nijhuis et al., 2007). 
Monocyte involvement in the development of atherosclerotic plaques was reported in the 1970s with 
monocyte accumulation demonstrated in porcine atherosclerotic lesions (Kottke and Subbiah, 1978). 
Three indirectly related processes, which involve monocytes, have been identified in atherosclerosis 
(Figure 1). Monocytes have been shown to play a role: 
(1) During the long-term process of initiation and formation of an atherosclerotic plaque, presumed 
to be accelerated by different risk factors, including smoking, hypertension, hyperglycaemia and 
critically hyperlipidaemia.  
(2) During the acute inflammatory phase that follow destabilization, rupture of the atherosclerotic 
plaque and acute thrombus formation in ACS. 
(3) During healing, where they reside in the myocardial tissue in the hypoxic phase during an acute 
coronary event and may promote myofibroblast accumulation, angiogenesis, and myocardial healing 
and remodelling, thus showing a protagonist or antagonist influence in post-ACS recovery. 
In the present review, we critically examine these three roles of monocytes and evaluate data on the 
modulation of monocyte function indicating future direction of novel therapeutic interventions. 
Several characteristic features of monocytes are important in explaining this multitude of actions, 
namely, varying subpopulations; high plasticity and trafficking capacity; existence of multiple 
reservoirs and hematopoietic maturation sites.  
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 Monocyte diversity in animal models and humans 
Monocytes account for 3-8% of peripheral blood leukocytes. They are  mononuclear cells often 
characterised by typical kidney-like shaped nuclei, but they are more accurately described by their 
expression of various surface receptors (Shalhoub et al., 2011). They are the main component of the 
innate immune system that is responsible for counteracting exogenous bacterial, viral and fungal 
infections mainly by phagocytosis (Libby, 2002). However, they are also involved in endogenous 
inflammatory processes. Monocytes contribute to atherogenesis through promoting leukocyte 
recruitment to plaques, and their roles are also mediated by activation of downstream signalling 
pathways, such as nuclear factor κB (NFκB) pathway (de Winther et al., 2005). Indeed, monocytes 
have been directly implicated in a number of chronic inflammatory conditions including 
glomerulonephritis, rheumatoid arthritis, lung fibrosis and atherosclerosis (Katschke et al., 2001, 
Duffield, 2010). 
Cell surface receptor expression allows discrimination between monocyte subpopulations and was 
first described in murine models. Palframan et al. and Geissmann et al., using CX3CR1 knockout 
mice, demonstrated that peripheral blood monocytes differ in CX3CR1, CCR2, and CD62L 
expression (Palframan et al., 2001, Geissmann et al., 2003). Monocytes expressing CCR2, CD62L, 
and low levels of CX3CR1 appeared to be preferentially recruited to inflamed sites by virtue of their 
recognition of CCL2 (monocyte chemoattractant protein-1, MCP-1). Conversely, the CX3CR1high 
monocytes could migrate into non-inflamed sites (Geissmann et al., 2003) or migrate later during the 
recovery period after an acute inflammation (Nahrendorf et al., 2007). 
In humans, “classical” monocytes, which represent 80-85% of the total population of circulating 
blood monocytes, can be identified by high expression of CD14 and lack of CD16 expression (also 
referred as Mon 1). They are considered inflammatory mediators and represent the predominant 
subpopulation identified in atherosclerotic plaques (Gerrity et al., 1979). These monocytes also 
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express CCR2, CD62L, and CD64 (Wong et al., 2011). The migration of this subpopulation depends 
strongly on MCP-1secreted by resident macrophages (Swirski et al., 2007). 
Another human monocyte subset is defined as the CD14+CD16++ cells and it is referred to as ‘non-
classical’ monocytes or Mon 3 population. They express high levels of CX3CR1 but do not express 
CCR2 or CD62L (Ancuta et al., 2003, Ancuta et al., 2006). This subtype depends on fractalkine (or 
CX3CL1, a soluble chemokine-like domain) for attraction and recruitment to endothelial surfaces. 
Fractalkine is expressed on activated endothelial cells as a transmembrane-anchored adhesion 
receptor thus attracting and arresting monocytes from the circulation into the atherosclerotic plaque. 
Indeed, CX3CR1 knockout mice, fed on a high fat diet showed a significant reduction in monocyte 
recruitment to the vascular wall and reduced atherosclerotic plaque formation. In fact genetic 
deletions of CCL2, CX3CL1, or their cognate receptors, CCR2 and CX3CR1, markedly reduced 
atherosclerotic lesion size in murine models of atherosclerosis (Saederup et al., 2008). When the three 
chemokine receptors CCR5, CCR2 and CX3CR1 were blocked the maximal reduction in the 
atherosclerotic plaque formation was evident, suggesting that all monocyte subpopulations are 
involved in atherogenesis (Combadiere et al., 2008).  Table 1 summarises characteristics of different 
monocyte subsets in humans and mice. 
Differences between monocyte subpopulation functions have been exemplified in an elegant in vivo 
mouse study by Auffray et al. who postulated that non-classical/resident’ monocytes constantly patrol 
healthy tissues through long range crawling along the endothelium (Auffray et al., 2007). During 
acute inflammation these monocytes utilize CX3CR1 and the integrin lymphocyte function-
associated antigen-1 (LFA-1) to “home” on the inflamed tissues on an “as required basis”. In humans 
Cros et al. indicated that CD14low (i.e., CD14+CD16++) ‘non-classical’ monocytes also have similar 
patrolling properties and are involved in the innate local surveillance of tissues and the pathogenesis 
of autoimmune diseases (Cros et al., 2010). 
More recently, a third human monocyte subpopulation has been identified as ‘intermediate’ 
CD14++CD16+ (also called Mon 2) cells (Shantsila et al., 2011). They are reported to be a 
predominant type of monocytes expressing Tie-2 (an angiopoietin receptor), which has been 
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implicated in angiogenesis. The presence of the three distinct monocyte subsets was recently 
confirmed by gene microarray analysis (Wong et al., 2011, Shantsila et al., 2011). The ‘intermediate’ 
subset has the highest expression of major histocompatibility complex class II molecules, 
whereas‘non-classical’CD14+CD16++ monocytes are characterised by high expression of 
cytoskeletal rearrangement genes, inflammatory cytokines, and CD294 (Wong et al., 2011). 
The varying nomenclature utilised to describe monocytes poses a problem in unified interpretation 
of animal and human data. As most of the current knowledge in the field originates from murine 
models, effort is directed towards establishment of parallels between monocyte subsets across 
species. Scarce information on their functions adds to the complexity of drawing reliable conclusions 
on the physiological and pathological roles of monocyte subsets in humans. For example, features of 
the so-called ‘intermediate’ subsets are increasingly demonstrated and recognised in a wide range of 
pathological conditions. An ‘intermediate’ pattern of the subset may be partly due to some overlap 
with other subsets (particularly with ‘non-classical’ monocytes), when their definition is solely based 
on their CD14 and CD16 expression. More accurate delineation of CD14++CD16+ and 
CD14+CD16++ monocytes can be achieved by additional marker CCR2 (Shantsila et al., 2011), with 
‘intermediate’ monocytes being ‘CD14++CD16+CCR2+’ and ‘non-classical’ monocytes being 
‘CD14+CD16++CCR2–. Of note, CD14++CD16+ monocytes show the highest of all monocyte 
expression of many surface receptors, particularly those involved in reparative processes (e.g., 
CXCR4, Tie2, VEGF receptors type 1& 2). This together with the evidence of specific enrichment 
of this subset in bone marrow indicates that it is unlikely to just represent an ‘intermediate’ state 
between the other two subsets, but rather a unique and distinct monocyte subpopulation. Although it 
is not yet entirely clear whether specific monocyte subsets are predetermined to differentiate into 
particular types of tissue macrophages and dendritic cells, published data suggest existence of 
common features and links between CD14++CD16– (Mon 1) and CD14++CD16+ (Mon 2) 
monocytes and M1&M2 polarized macrophages, respectively. Also in vivo, Ly-6Clo and Ly-6Chi 
monocytes from mice differentiate more readily into M2-like cells and M1-like macrophages 
respectively, but macrophage development also depends on surrounding microenvironment and 
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interaction(s) with other cell types, such as lymphocytes (Geissmann et al., 2010, Gratchev et al., 
2012). Accordingly, the assignment of numerical dominators (i.e., Mon 1, Mon 2, and Mon 3) for 
human monocyte subsets may be appropriate until more data are available on the-relationships 
between the subsets. 
  
 
Table 1: Comparison of different monocyte subpopulations phenotype and function 
Characteristic Inflammatory/ Classical 
Newly described  
intermediate 
population 
Resident. /Non classical 
Human 
CD14++CD16-CCR2+ 
CX3CR1lo; CD62L+ 
CD115+ (Mon 1) 
CD14+CD16+CCR2+, 
CX3CR1hi, CD62L-, 
CD115+ (Mon 2) 
CD14+CD16++CCR2- 
VCAMhi CCR2lo CD64low 
(Mon 3) 
Mice 
Ly6-Chi, CCR2+, 
CXCR1lo, CD62L+, 
CD115+, CD11-, MHC 
class II -ve  
No distinct model is 
available, however has 
characteristics of Ly6-
Chi models  
Ly6Clow, CX3CR1hi, 
CD62L-, CD115, MHC- class 
II +ve 
Recruitment 
Early in acute 
inflammation 
Early in Acute 
inflammation 
Late in acute inflammation 
Reservoirs Spleen None Known Unknown 
Function 
Acute 
Accumulate in injured 
myocardium and perform 
inflammatory and 
proteolytic function 
? Inflammation  
Assumed role in granulation 
tissue formation and 
angiogenesis, later 
mobilization 
Chronic 
Accumulate in 
atherosclerotic plaque in 
response to activated 
endothelium.  
Given high expression 
of CD163 and CD204 
scavenger receptors then 
accumulation in 
atherosclerotic plaque is 
possible 
Accumulate in atherosclerotic 
plaque via CCR5 and 
CX3CR1 
MHC: Major histocompatibility complex; VCAM: vascular cell adhesion molecules.   
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 Monocyte trafficking and developmental plasticity 
High trafficking ability is another characteristic feature of monocytes. A hallmark of monocyte 
trafficking is their capacity to traverse from the circulation into areas of injury/inflammation, aiming 
for resolution of infection and contribution to the restoration of the tissue integrity via differentiation 
of different types of tissue macrophages and dendritic cells. However, presumably ‘reparative’ 
properties of the monocytes may fail and lead to a disease state, with atherosclerosis being an 
example. Indeed, monocytes are precursors of lipid-laden ‘foam’ cell macrophages, which are a 
critical component of atherosclerotic plaques. Even mature monocyte-derived macrophages do not 
lose their mobility entirely, under certain circumstances (which are not entirely understood) 
monocyte/macrophages, including ‘foam cells’ can migrate from the vascular wall back into the 
circulation (Gratchev et al., 2012). In several studies monocyte migration from atherosclerotic 
plaques led to plaque regression under experimental conditions (Feig et al., 2009, Llodra et al., 2004). 
In a mouse model, statin therapy augmented the egression of the plaque macrophages via removing 
the inhibitory effect on CCR7 and independently of lipid levels (Feig et al., 2011), possibly 
representing an additional pleiotropic effect of statins. 
Monocytes are also characterised by an extremely high developmental plasticity, being able to 
differentiate under appropriate stimulation into different cell types ranging from epithelial, 
endothelial, cartilage cells to functional fibroblasts, cardiomyocytes and neuronal cells. Most of this 
work has been done under experimental conditions and the in vivo and (more importantly) clinical 
relevance is only beginning to emerge (as discussed below). 
There has also been a recent shift from a long-term paradigm that the bone marrow is the sole source 
of circulating monocytes. At least in mouse models of myocardial infarction the spleen can serve as 
a reservoir of monocytes, which could be promptly released upon demand Swirski et al. have shown 
that Ly-6Chi monocytes (the murine equivalent of ‘classical’ human monocytes) accumulated in the 
infarcted myocardium in numbers that exceeded their availability in the circulation, suggesting a 
different source of monocyte supply may exist, with the spleen identified as an important ‘storage’ 
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reservoir (Swirski et al., 2009). The group revealed that hematopoietic and progenitor cells can 
migrate from the bone marrow to the spleen, where they undergo maturation, followed by release of 
Ly-6Chi monocytes that infiltrate atherosclerotic plaques producing inflammatory cytokines, and 
proteases, and leading to ‘foam’ cell formation (Robbins et al., 2012). These results indicate the 
existence of extramedullary monocyte sources in mice, whilst differential functional characteristic of 
bone marrow and plaque monocytes are still be investigated and also explored in humans (Robbins 
et al., 2012).  
 
 Endothelial activation and monocyte recruitment 
Activation of the endothelium is the first step in the initiation of monocyte recruitment from 
peripheral blood. Multiple factors may lead to endothelial damage and activation, including oxidative 
stress, bacterial and viral infections, long-term hyperglycaemia, as well as increased plasma levels of 
both native and oxidised LDL (Quinn et al., 2011). The endothelium normally releases nitric oxide 
(which is vasodilatory); however, the presence of oxidised LDL hampers its activity (Vidal et al., 
1998). Platelets are also involved in the activation of the endothelium, by producing platelet factor 4 
and P-selectin which attract monocytes to the endothelium by forming monocyte-platelet aggregates 
(Vorchheimer and Becker, 2006). 
Upon stimulation, endothelial cells over-express chemokines (e.g. CCL5 and CCL2), as well as toll 
like receptors (TLRs) and adhesion molecules (Crola Da Silva et al., 2009). Blood monocytes “roll” 
onto the endothelial surface and are recruited to the activated/damaged endothelium. The expression 
of adhesion molecules, such P- and E-selectins, VCAM-1 and ICAM-1 facilitates an initial adhesion 
followed by the firm attachment of activated monocytes expressing reciprocal ligands such as Mac-
1 and VLA-4 onto endothelial cells (Huo and Ley, 2001). Monocytes from patients with 
hypercholesterolaemia are more prone to native LDL-mediated changes of adhesion molecule 
expression compared to monocytes from controls (Serrano et al., 2009). Simvastatin is capable of 
inhibiting these LDL mediated effects (Serrano et al., 2009). 
11 
The monocytes transmigrate across the endothelium via diapedesis to the subendothelial space. None 
the less junction adhesion molecules (JAM)-A and -C have been shown to be involved in the control 
of vascular permeability and thus leukocyte transmigration across endothelial cell surfaces (Weber 
et al., 2007). The process also relies on activation of the NFκB pathway to activate matrix 
metalloproteinases (MMPs) which assist monocytes in breaching the endothelium (Tobar et al., 
2010).  
 
 Monocytes in the stable atherosclerotic process 
Given monocyte plasticity, monocytes are able to cross from the blood into the subendothelial space 
where, monocytes differentiate to macrophages promoted by factors such as macrophage colony 
stimulating factor. The macrophages ingest oxidised LDL via scavenger receptors (SR), such as 
CD36, forming ‘foam’ cells (Collot-Teixeira et al., 2007). Lipid-laden macrophages undergo a 
process of apoptosis/necrosis which perpetuates the formation of further ‘foam’ cells. This, in 
conjunction with smooth muscle migration and proliferation across the intima leads to the formation 
of lipid-rich atherosclerotic core covered by a fibrous cap. The lipid laden macrophages also release 
cytokines, growth factors, MMP, reactive oxygen species (ROS) and tissue factor, all perpetuating 
the inflammatory response, and vascular remodelling (Badimon et al., 2011). This also activates and 
attracts platelets, thus increasing plaque susceptibility to thrombus formation.  
Interestingly, lipid laden macrophages are also involved in the reverse transport pathway of lipid 
metabolism that circulates lipids to the liver via the ABCA1 transporters. In atherosclerosis the 
activity of this pathway is impaired especially in the presence of statin therapy, suggesting that these 
highly effective anti-atherosclerotic agents may also pose some (rather minor) pro-atherogenic 
properties (Wong et al., 2008). The cholesterol level and state of macrophage maturity appear to 
determine the effect of statin on the efficiency of the ABCA1 export pathway. Of note, 
supplementation of human macrophages with cholesterol reverses the statin-mediated down-
regulation of the ABC transporter expression and vice-versa, indicating that statin beneficial effects 
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on plaque regression may be more prominent in subjects with more severe hypercholesterolaemia 
(Wong et al., 2008).  
It is not only the monocyte-to-macrophage axis of monocyte differentiation that contributes to 
atherosclerosis formation, but monocyte-derived dendritic cells also playing a role. Dendritic cells 
are antigen presenting cells that prime the T cell response to “self” and “foreign” antigens, inducing 
self-tolerance (Bobryshev, 2010). These cells are also implicated into acute and chronic inflammatory 
responses, and contribute to memory T cell-mediated immune response. Hence DC are the sentinel 
of the adaptive immune system. DC are present within atherosclerotic plaques being selectively 
enriched in rupture prone areas of the atherosclerotic lesions (Bobryshev and Lord, 1995, Yilmaz et 
al., 2004). In an in vitro model, adhesion of DC to injured carotid arteries was mediated by platelets 
via Mac-1 and platelet JAM-C (Langer et al., 2007). Intraplaque accumulation of DC led to 
atherosclerosis progression due to DC induced lymphocyte proliferation.  
In addition to presenting “atherosclerotic-relevant” antigens to lymphocytes, DC produce cytokines 
that create a local inflammatory microenvironment, which favours propagation of the atherosclerotic 
lesions. Indeed, in an in vitro model, plaque DC produced IL-12 which upregulated the expression of 
CCR5 on surface of T cells resulting in further attraction and activation of T cells (Zhang et al., 2006). 
DC may also have a role in foam cell formation, even though classically this was attributed to 
macrophages. In fact therapeutic manipulation of DC function by various clinically available agents 
(such as statins, ezetemibe, and diltiazem) resulted in atherosclerotic plaque regression (Feig and 
Feig, 2012).  
 
 Monocyte activation and the role of toll like receptors 
Toll-like receptors (TLRs) are the most characterised members of the pattern recognition receptor 
family. At least 13 different TLRs have been identified in mammals. Activation of TLRs leads to 
downstream activation of NFκB-signalling pathway with pro-inflammatory consequences (Faure et 
al., 2001). TLR4 is required not only for the bacterial endotoxin-induced inflammatory responses, 
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but also for non-bacterial ligands, such as fatty acids and heat shock proteins (HSPs) (Lee et al., 2001, 
Vabulas et al., 2002, Asehnoune et al., 2004). The main TLRs implicated in the atherosclerotic 
process are TLR2 and TLR4 (Poltorak et al., 1998). Expression of both receptors is increased in LDL 
receptor deficient (LDLR−/−) and apolipoprotein E deficient (ApoE−/−) mice (Edfeldt et al., 2002). 
Whilst the biological role of TLR4 over-expression is likely to be protective against infection-related 
factors, chronic stimulation of the pathway by host ligands results into self-perpetuating 
inflammatory milieu inside the vascular wall, facilitating leukocyte accumulation and plaque 
formation and growth (Xu et al., 2001). 
TLR4 signalling is involved in atherosclerotic plaque destabilization. Lipopolysaccharides (LPS) 
induce the macrophage expression of MMP- 9 via TLR4, whilst MMP- 9 has been shown to degrade 
collagen fibrous caps, thus predisposing to plaque rupture (Grenier and Grignon, 2006). TLR4 was 
also increased systematically in patients following myocardial infarction (MI) and locally at site of 
plaque rupture, yet suggesting that monocyte TLR4 has a role in plaque destabilization and rupture 
(Ishikawa et al., 2008). TLR4 was increased in both stable and unstable angina, with a congruent 
increase in TLR2 in the unstable state only (Ashida et al., 2005). This was recently echoed in the 
Atherosclerosis Risk in Communities (ARIC) study where monocyte TLR2 expression was 
associated with larger plaques, and TLR4 was associated with smaller ones (Matijevic et al., 2011). 
Recently our group demonstrated that TLR4 expression on surface of monocytes is unchanged in 
ACS patients, however with the increase in monocyte mobilization and attraction to areas of infarct 
led to a relative (but not true) increase in detection of TLR4 on surface of Mon 1 and Mon 2 (Tapp 
et al., 2013) .  
Inhibition of TLR4 attenuates the inflammatory response in a mouse model of MI, as shown by a 
significant decrease in infarct size and expression of inflammatory mediators (Chong et al., 2004, 
Oyama et al., 2004, Kaczorowski et al., 2007). A new benzisothiazole derivative inhibitor of TLR4 
signal transduction, suppressed LPS-induced up-regulation of cytokines, adhesion molecules and 
pro-coagulant activity in human vascular endothelial cells and peripheral mononuclear cells, 
suggesting a potential for management of atherosclerosis (Nakamura et al., 2007). Several agents 
14 
blocking TLR2 and TLR4 showed promising anti-inflammatory properties (Yang et al., 2009). They 
demonstrated that valsartan was able to inhibit TLR4 expression concomitant with a reduction in 
mouse myocardial injury, a smaller infarct size, and lower levels of myocardial enzymes post 
infarction. 
 
 Activation of the NFκB pathway 
NFκB is one of the major transcription factors mediating inflammatory responses of monocytes and 
macrophages. Its activation leads to the production of proinflammatory and prothrombotic molecules, 
such as cytokines, MMPs, tissue factor (TF) and IκB, which exerts a negative feedback loop on NFκB 
activation (Palombella et al., 1994, De Rycke et al., 2005, D'Acquisto et al., 2002). Monocyte 
stimulation leads to activation of the NFκB which was linked to inflammation associated with 
atherosclerosis (D'Acquisto et al., 2002). Thus, measurement of NFκB levels could be used as a 
surrogate for the functional assessment of monocyte inflammatory activity (Monaco and Paleolog, 
2004).  
In non-stimulated monocytes, NFκB is sequestered within the cytosol by an inhibitory protein (i.e., 
IκB; inhibitor of NFκB) that prevents its translocation to the nuclei. Upon stimulation IκB is 
phosphorylated by IκB kinase (IKK), undergoes secondary ubiquitination and is degraded by the 
proteasome (Monaco and Paleolog, 2004). The IKK complex is a phosphorylating enzyme with 
several subunits, IKKα, IKKγ and IKKβ. The β subunit is the most active and is involved in 
transcriptional activation of the pathway by phosphorylating IκB. The degradation of IκB thus allows 
NFκB to translocate into the nuclei where it can act as a transcription factor (Monaco and Paleolog, 
2004, Kollander et al., 2010). Several mechanisms lead to the activation of the NFκB pathway during 
the atherosclerotic process (Table 2).  
Excessive NFκB activation is associated with negative ventricular remodelling (Hamid et al., 2011). 
Myocardial tissues from patients with heart failure had increased expression of NFκB-regulated 
genes. This exacerbated ventricular remodelling with increased pro-inflammatory, pro-fibrotic and 
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pro-apoptotic effects (Hamid et al., 2011). Also, using gene transfer of IκBα Squadrito et al. (2003) 
have demonstrated that repression of NFκB transcription in models of ischaemia-reperfusion injury 
resulted in reduction in leukocyte recruitment to the myocardium, cardiomyocyte death and infarct 
size . Accordingly inhibition of NFκB may become an attractive pharmaceutical target and promising 
data on a well-tolerated pharmacological NFκB inhibitor, BAY 11-7082 have been recently presented 
(Kim et al., 2010). The latter reduces inflammation in a rat model of ischaemia-reperfusion injury 
leading to a significant reduction in the infarct size. 
 
Table 2: NFκB activation in atherosclerosis 
Stage of 
atherogenesis NFκB role Study Results 
Initiation of 
Atherogenesis 
Contributing to the 
environment leading 
to LDL oxidation  
Hajra et al. (2000) 
Mouse model LPS stimulation or high fat 
diet lead to  NFκB activation and 
overexpression of NFκB genes 
Ivandic et al. (1999), 
Han et al. (2001) 
Transgenic mice model 
Role in 
monocyte 
migration 
across 
endothelium 
NFκB controls 
transcription of MMPs 
(crucial enzymes in 
degradation of ECM) 
Han et al. (2001)  
In vitro model of fibroblast cells- activation 
of NFκB signalling in fibroblasts induces 
mt1-MMP gene expression.  
Bond et al. (1998) 
In vitro model-  Activation of NFκB binding 
by inflammatory cytokines was therefore 
necessary but not sufficient for synergistic 
upregulation 
Foam cell 
formation 
Induction of monocyte 
to macrophage 
differentiation via 
MCSF 
Smooth muscle 
proliferation 
Brach et al. (1991)  
In vitro- induction of MCSF (through TNF) 
is dependent on NFκB. 
Hoshi et al. (2000) 
In vitro- PD98059, an inhibitor of ERK, 
suppressed NFκB transcriptional activity 
and SMC proliferation 
Selzman et al. (1999)  In vitro- NFκB inhibited VSMC 
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ERK: extracellular signal regulated kinase; LPS: lipopolysaccharide; LDL: low density lipoprotein; MMP: 
matrix metalloproteinases; MCSF: monocytes colony stimulating factor; SMC: smooth muscle cells; VSMC: 
vascular smooth muscle cells   
 
 Monocytes in the acute coronary syndromes 
Acute coronary syndromes (ACS) refer to a clinical spectrum ranging from those for ST-segment 
elevation myocardial infarction (STEMI) to non–ST-segment elevation myocardial infarction 
(NSTEMI) or unstable angina (Alpert et al., 2000, Hamm et al., 2011, Underwood, 2009). ACS is 
almost always associated with rupture of an atherosclerotic plaque and partial or complete thrombosis 
of the infarct-related related artery. Most cases of ACS occur from disruption of a previously non 
occlusive but unstable (vulnerable) plaque (O'Connor et al., 2010, Chughtai et al., 2011). The 
characteristic features of a vulnerable plaque include a thin fibrous cap, a higher predominance of 
macrophages in the cap, smaller collagen content, and a large, lipid-rich necrotic core with overlying 
thrombus and platelet aggregates (Galis et al., 1994).  
Monocytes promote destabilization of the fibrous cap leading to the plaque rupture. This is mainly 
orchestrated by MMPs (Newby et al., 2009, Medbury et al., 2008). Activated macrophages produce 
a wide range of lytic enzymes, including MMPs (e.g. MMP-1, -2, -3, -8, -9, and -14) (Newby, 2007). 
Increased expression and activity of MMPs has been noted in vulnerable plaque regions while 
elevated serum MMPs have been demonstrated in patients with ACS (Momiyama et al., 2010).  
Plaque rupture could lead to downstream occlusion of coronary flow to the myocardium, the principle 
mechanism of STEMI. Monocytes have a role in thrombus propagation contributing to the 
coagulation cascade during the acute event. Patients with ACS show features of procoagulant 
monocyte activation with exposure of tissue factor (Altieri et al., 1988). Monocyte-platelet 
aggregates, and markers of monocyte and platelet activation involved in regulation of their function 
Zuckerbraun et al. 
(2003) 
In vitro- Gene transfer of IkappaB alpha 
super-repressor inhibited development of 
intimal hyperplasia in vivo and SMC 
proliferation  
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are also increased in ACS patients, persisting even after one month of the acute event (Tapp et al., 
2011). Also, microparticles derived from monocytes are abundant in ACS and support faster fibrin 
formation (Aleman et al., 2011).  
Monocyte adherence to extracellular matrix and extravasation to the injured tissue induces the 
expression of a multitude of cytokines including TNF-α, IL1 and IL6 [potent inflammatory 
cytokines]; platelet derived endothelial cell growth factor [a potent chemoattractant and mitogen for 
fibroblasts]; TGFα and β [which contributes to fibrosis, by stimulating extracellular matrix release, 
primarily collagen, from myocardial fibroblasts]; M-CSF [cytokine necessary for macrophage 
survival],and insulin-like growth factor (Lambert et al., 2008, Frangogiannis et al., 2003). 
Monocytes are also thought to participate in tissue injury. Downstream occlusion of blood supply to 
the myocardium (ischaemia) followed by pharmacological or interventional revascularization therapy 
(reperfusion) results in the ischaemia-reperfusion cascade. During hypoxia, ROS leakage from 
mitochondria is increased (Madamanchi and Runge, 2007). ROS-modified biomolecules formed 
during ischaemia stimulate infiltration of inflammatory cells, including monocytes, thus mediating 
an acute inflammatory response leading to cell injury and necrosis. Recently, a new model of ‘innate 
autoimmunity’ for ischaemia/reperfusion injury has been introduced, which integrates mechanisms 
of both intrinsic ischaemic cell injury and initiation of an extrinsic innate immune response (Zhang 
and Carroll, 2007). This hypothesis that the intrinsic changes associated with cell injury are 
augmented by a second wave of the innate immune system involvement largely represented by 
monocytes (e.g., mediated by the complement system, IgM and their receptors) helps to explain the 
continued loss of myocytes despite reperfusion and, in some in vitro studies, despite elimination of 
inflammatory cells (Haegert, 1979). 
Within the subintimal space, monocytes mature into DC and macrophages, each with its separate 
polarity, and inflammatory functions that have further effect on tissue necrosis (Geissmann et al., 
2010). Macrophages are currently considered to be comprised of two types: the classically activated 
(pro-inflammatory M1 type), and the alternatively activated M2 acting as anti-inflammatory cells 
(Lambert et al., 2008). M1 macrophages promote inflammation and extracellular matrix destruction. 
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IL-1β secretion from  M1  induces MMP- 9 and TGFβ secretion and stimulates fibroblast proliferation 
(Lambert et al., 2008). Macrophage phagocytosis of dying cells also triggers TGFβ production 
(Singer and Clark, 1999). Of interest, in murine models, monocyte tissue residence time was found 
only to be around 20 hours, with persistently high rates of recruitment to infarcted myocardium days 
after the acute event, and disproportionally slower rate of  exiting from infarcted tissues at  a 
maximum rate of 13%/day (Leuschner et al., 2012). 
A mouse model of MI has demonstrated substantial functional differences between monocyte subsets 
in the course of the infarction. For instance, mice Ly-6Chi monocytes (considered to be equivalent to 
CD14++CD16–CCR2+ human cells) are mobilised early after MI onset and show distinct phagocytic 
properties. In contrast Ly-6Clo monocytes (considered to be the equivalent of human 
CD14+CD16++CCR2– cells) showed anti-inflammatory properties and were critical for myocardial 
healing and reverse remodelling in MI, promoting myofibroblast accumulation, angiogenesis and the 
deposition of collagen (Nahrendorf et al., 2007). The production of these subsets seemed to follow a 
biphasic mode, with an early release of Ly-6Chi followed by a later production of Ly-6Clo (Nahrendorf 
et al., 2007). 
At the other end of the monocyte differentiation spectrum, levels of circulating DC (both 
plasmacytoid as well as myeloid DC) have been found to be significantly reduced in patients 
following an acute coronary syndrome, compared to healthy controls (Fukui et al., 2012). It is thought 
that this is due to increased recruitment of DC to the infarcted tissue. This hypothesis was supported 
with immunohistochemistry findings indicating an increase in the DC and T-cell infiltration of peri-
infarct zone (Kretzschmar et al., 2012).  
 
 Cardiac Remodelling 
An important structural event after myocardial infarction (MI) is left ventricular (LV) remodelling, 
which generally can be defined as changes within the cellular and extracellular constituents of the 
myocardial wall leading to changes in myocardial geometry subsequently leading to changes in LV 
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volumes. The rate and extent of this post-MI remodelling process have been established to be 
independent predictors of morbidity and mortality. Thus, identifying those patients at the greatest 
risk for developing post-MI remodelling and the basic mechanisms that contribute to post-MI 
remodelling holds great diagnostic/ therapeutic relevance. The factors that contribute to post-MI 
remodelling are multifactorial and include both cellular and extracellular processes. It is now 
becoming recognized that changes within the myocardial extracellular matrix (ECM) contribute to 
post-MI remodelling. Disruption within the fibrillar ECM network will cause a loss of normal 
structural support and continuity, resulting in myocyte fascicles being subjected to abnormal stress 
and strain patterns during the cardiac cycle, which in turn cause changes in myocardial geometry and 
function. Hence cardiac remodelling post-MI is defined by the degree of the residual impairment of 
LV contractility (e.g. ejection fraction) and geometry of LV after completion of the process of 
myocardial scar formation (e.g. LV end-systolic and end-diastolic volumes at 6 months after MI 
onset).  
The matrix metalloproteinases (MMPs) constitute of a large family of proteolytic enzymes 
responsible for ECM degradation and remodelling under normal and pathological conditions. An 
important control point for MMP activation is binding to an endogenous family of inhibitors, the 
tissue inhibitors of MMPs (TIMPs). A clear cause-and-effect relationship between MMPs and the 
post-MI remodelling process has been demonstrated through the use of various animal models. In 
general, these preclinical studies have demonstrated that an imbalance between MMPs and TIMPs 
occurs in the post-MI myocardium and that increased MMP proteolytic activity facilitates post-MI 
remodelling and eventually LV dilation. Moreover, these preclinical studies have demonstrated that 
a specific temporal pattern of MMP/TIMP expression occurs after MI that is causally related to the 
degree of post-MI remodelling.  
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Figure 1: LV remodelling on myocyte level (adapted from Konstam et al., 2011) 
 
Cardiac remodelling plays a key role in the pathophysiology of LV dysfunction. The process of post-
MI myocardial recovery depends on numerous factors, with multiple theories at the cellular and 
molecular level. Release of ROS, phagocytosis, fibroblast accumulation and angiogenesis have all 
been suggested to be involved and these relate to monocyte activity (Cavalera and Frangogiannis, 
2014) . Inflammation plays an important role in cardiac healing (Frantz et al., 2009, Christia and 
Frangogiannis, 2013). 
Cardiac remodelling can be assessed by transthoracic 2D and 3D echocardiography, using LV 
ejection fraction, volumes and mass as surrogate parameters. Using echocardiography, negative left 
ventricular remodelling is defined as an increase of 20% in the end diastolic volumes at 6 months 
follow up (Verma A, 2008, Konstam MA, 2011). 
 
  Monocytes and cardiac remodelling 
Despite advances in medical and interventional therapy for ACS, many patients still develop heart 
failure. The process of post-MI myocardial recovery depends on numerous factors at the cellular and 
molecular levels. After the initial tissue damage induced by hypoxia, an acute inflammatory response 
ensues with recruitment of leukocytes to the infarcted areas (Nahrendorf et al., 2007). Subsequent 
release of ROS, phagocytosis, fibroblast accumulation, angiogenesis and, tissue formation occurs, 
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ultimately leading to cardiac remodelling and recovery modulated by the activity of these recruited 
cells. The role of inflammation is important. For example, an increase of the pro-inflammatory 
cytokine TNF-α with a corresponding decrease of anti-inflammatory cytokine IL10 is associated with 
adverse/reverse ventricular remodelling (Grieve et al., 2004). Together, leukocytes degrade 
extracellular matrix constituents and macromolecules released by the injured cells and aid clearance 
of dead cardiomyocytes and their debris.  
Historically, monocytosis has been associated with left ventricular dysfunction post MI, with 
recruited monocytes releasing multiple cytokines, such as IL-1α and β, IL-6, TNF-α which are 
negatively associated with myocardial healing and development of heart failure (Jonsson et al., 2011). 
The balance between removing dead myocytes and prompt initiation of regeneration may determine 
patients’ outcomes.  
Monocyte injection and their cardiac recruitment through MCP-1, IGF-1 secretion, in enhanced 
remodelling with improved post-MI cardiac contractility in mice (Apostolakis et al., 2010). 
Monocytes are also involved in myocardial fibrosis and post-infarction scar formation, whilst their 
release of angiogenic factors (e.g., VEGF) promotes angiogenesis in and around the healing tissue. 
Of note, prolonged Ly-6Chi monocytosis early after MI onset could impair myocardial healing in a 
murine model (Bouchentouf et al., 2010, Panizzi et al., 2010). On the other hand, depletion of Ly6Chi 
monocytes early post infarct led to increased areas of debris and necrotic tissue with impaired 
ventricular healing (Nahrendorf et al., 2007). This accords with results of previous murine study 
where post infarct macrophage depletion led to ventricular dilatation and myocardial wall thinning 
with concurrent decrease in neovascualisation, myofibroblast and collagen depositions (van 
Amerongen et al., 2007). Recently, depletion of DC led to a similar result, with sustained expression 
of inflammatory cytokines such as IL-1β, TNF-α, IL18, and MMP- 9, as well as a decrease in IL-10 
within the infarcted area in a mouse model. Interestingly, there was an increase in Ly6Chi monocytes 
in DC depleted mice (Anzai et al., 2012). It could be postulated that this is due to interruption of DC 
induced “negative feedback” on differentiation signalling that controls monocyte 
subpopulations/macrophage interaction. Hence depleting DC may lead to uncontrolled monocyte 
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differentiation and disruption of this phagocytic system thus illustrating the intricate balance and 
cross talk between it different components.  
However our knowledge of the effect of monocytes on cardiac remodelling and clinical outcome in 
humans is still limited. Although similarities exist in MI pathophysiology between species, the inter-
species differences between monocyte subsets are substantial (including the fact that monocytes 
account for 50% of murine leukocytes versus a much smaller proportion in humans). This may make 
extrapolation of animal data to humans challenging from a clinical and pharmaceutical perspective 
(Shantsila et al., 2010).  
The effect of monocytes on ventricular healing in humans has been investigated in one small study, 
where numbers of CD14+CD16– monocytes were negatively associated with myocardial salvage 
following STEMI and poor clinical outcome (Tsujioka et al., 2009). CD16+ monocytes (analysed as 
a mixture or ‘intermediate’ and ‘non-classical’ monocytes) had no effect on ventricular remodelling, 
which contrasted with previous animal data (Nahrendorf et al., 2007). In a recent study where levels 
of the three human monocyte subsets in STEMI were analysed separately a prominent (over 2.5-fold) 
up-regulation of the CD14++CD16+CCR2+ (Mon 2) - described elsewhere in the literature as 
intermediate monocytes) subset in acute STEMI was observed with no changes in 
CD14+CD16++CCR2– (Mon 3) cells (Tapp et al., 2011). This was accompanied by a significant 
change in phenotype of the ‘intermediate’ subset (increase in CD14 and CCR2 expression, and a 
reduction in CD16 expression). These observations of distinctive changes related to this subset 
together with existing evidence of their pro-reparative and pro-angiogenic phenotype and anti-
inflammatory properties are suggestive of their possible specific roles in cardiac recovery, but 
sufficiently powered data in this respect are lacking.   
Interest in the ‘intermediate’ monocytes has been echoed into a number of clinical studies that 
indicated that their high levels have been associated with poor clinical outcome both in terms of 
future MI in stable coronary artery disease (the HOM SWEET HOMe study) (Rogacev et al., 2012); 
and lower left ventricular ejection fraction in patients post STEMI (Tapp et al., 2012); or as recurrence 
of coronary events in patients with chronic kidney disease and in stroke patients (Rogacev et al., 
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2011, Heine et al., 2008). The biological roles of this subset are complex and expression of receptors 
with putative role in angiogenesis and repair (e.g.,  VEGF receptor 2, CD163, and CXCR4, which 
was found to be relevant to STEMI, are highest in this subset (Shantsila et al., 2013). One may 
speculate that the intermediate monocyte subset may play a role in myocardial reparation post MI. 
However the cause of such associations remains unclear and the exact function of the intermediate 
monocytes is still under investigation. Currently our knowledge only extends to very limited 
functional studies and a number of descriptive surface and genetic markers (to mention a few: CCR5, 
VEGF receptor 2, HLA-DR, ENG, CLEC10A, ACE, GFRA2) (Wong et al., 2011, Zawada et al., 
2011). It is still unclear whether this subpopulation is a separate and independent entity from Mon 1 
and Mon 2, and hence have their own differentiating pathway, or if they are an intermediate “stop” 
for classical monocytes as they shift towards a non-classical monocytes phenotype.  
Of importance, ‘classical’ monocytes are featured by a distinct proinflammatory phenotype and their 
high counts are associated with poor myocardial recovery and worse outcome after MI (van der Laan 
et al., 2012). Although inflammatory stress associated with these cells is usually mentioned in the 
context of their potentially detrimental effects, the role of these cells is by far more complex and 
includes a number of potentially beneficial properties, including: phagocytic activity and regulation 
of extracellular matrix turnover. An appropriate balance in numbers and functional activity as well 
as in timing in relation to MI onset is probably the key in relation to the role of the cells in acute 
coronary catastrophes. However this perspective is based on numerical quantification and presence 
of monocytes as opposed to assessment of function, not to mention that the role of the ‘intermediate’ 
and ‘non-classical’ monocytes is still to be deciphered. 
The role of progenitor cells in wound healing and cardiac remodelling is currently the object of 
intense scientific interest. Infusion of mesenchymal cells into the mouse myocardium 48 hours after 
MI induction reduced overall myocardial macrophage/monocyte levels. This included pro-
inflammatory M1-type macrophages, whilst alternatively activated M2-type macrophages were 
significantly increased both in the circulation and the heart (Dayan et al., 2011). Delivery of the 
mesenchymal cells: reduced cardiac expression of IL-1b; reduced expression of IL-6; increased anti-
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inflammatory IL-10 expression without changes in angiogenesis in the infarct area; and improved 
cardiac systolic function (Dayan et al., 2011). This could suggest that mesenchymal cells may 
regulate the switch in monocyte/macrophage phenotype towards M2 polarisation and favourable 
remodelling post infarction.  
Of interest, Kuwana et al. described CD14+monocyte-derived mesenchymal progenitors, that can 
differentiate into a variety of mesenchymal cell types as well as having phagocytic function, thus 
providing a possible cellular source for tissue regeneration including wound healing and potentially 
heart remodelling (Kuwana et al., 2003). Also, monocyte-derived progenitor cells have been 
implicated in cardiac allograft vasculopathy likely due to their ability to differentiate into smooth 
muscle cells and promote intimal hyperplasia (Salama et al., 2011). However it is important to note 
that this group of patients routinely receive anti-rejection medication and it remains to be seen 
whether this has an effect on the abundance of monocyte-derived progenitor cell (Salama et al., 2011).  
To address the potential role for inflammation in tissue damage post-MI, steroid therapy was used in 
the 70’s and 80’s in acute MI, but has not produced the anticipated beneficial effect, and failed to 
show an improvement in clinical outcome post STEMI (Bush et al., 1980, Peters et al., 1978). This 
may be partly due to creating an imbalance between the different monocyte subpopulations 
eradicating both the inflammatory as well as the reparative subtypes, altering the downstream 
differentiation of monocytes or potentially disturbing the cross talk between dendritic cells, 
monocytes and macrophages. Hence targeting specific subpopulations at appropriate phases of 
cardiac healing/remodelling is a theoretical alternative to improve outcome of inflammatory events 
post-MI (Figure 2).  
Interestingly successful stem cell therapy in STEMI has been based on intracoronary administration 
of bone marrow mononuclear cells, which include a large proportion of monocytes (Table 3). 
However none of the studies used purified monocyte-derived progenitor cells but rather utilized a 
total pool of mononuclear progenitors.  
Perhaps delivery or modulation of specific monocyte subpopulations, at different stages of healing 
will form the basis of future regenerative cell therapy after MI. Indeed Leor et al. have shown that 
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administration of activated human macrophages to the ischaemic myocardium in rats accelerated 
vascularisation and repair of the infarcted myocardium with improved cardiac remodelling and 
systolic function (Leor et al., 2006).  
 
Table 3: Summary of clinical trials using bone marrow mononuclear cells in acute coronary 
syndrome patients with summary of trial findings 
Study Methodology Study 
Period 
Study 
Population 
(Intervention / 
control group) 
Results 
BALANCE 
study 
(Yousef et 
al., 2009) 
 
BMNC in the culprit 
lesion/vessel 
3, 12 and 
60 months 
60 (30/30) 
 
Compared to control group, 
patients treated with BMNC 
exhibited: Improved contractility 
of infracted area; Reduced 
mortality; Improved exercise 
REPAIR-
AMI trial 
(Schachinger 
et al., 2006) 
 
Bone marrow 
progenitor cells 
infusion into culprit 
vessel 3-7 days post 
AMI 
12 months 204 
 
In patients vs. placebo: BM PC 
administration was a significant 
predictor of a favourable outcome; 
Cumulative endpoints of death, 
recurrence of MI or 
revascularisation or 
hospitalization for heart failure 
significantly reduced.  
BOOST 
study 
(Meyer et al., 
2009) 
 
BMNC intracoronary 4 
days post AMI 
6 and 8 
months 
60 (30/30) 
 
Increased global EF in 
intervention group (6% at 
6months).  
Effect between intervention group 
and control group lost at 18 
months; However improved EF 
retained amongst transmural 
infarct group.  
Janssens et 
al., (2006) 
 
Bone marrow stem 
cells intracoronary 24 
hours post AMI 
4 months 67 (33/34) No improvement in ejection 
fraction 
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ASTAMI 
(Beitnes et 
al., 2009) 
 
BMNC intracoronary 3 years 100 (50/50) 
 
The results indicate that 
intracoronary BMNC treatment in 
AMI is safe in the long term; A 
small improvement in exercise 
time in the BMNC group was 
found, but no effects of treatment 
on global LV systolic function. 
Traverse et 
al., (2010)  
 
Bone marrow MNC 
intracoronary at day 3-
10 
6 months 40 (30/10) No difference in EF between 
groups; BMNC group had 
improved remodelling with 
significantly lower LVEDV. 
BMNC- bone marrow mononuclear cells; LV- left ventricle; LVEDV- left ventricular end diastolic volume; 
AMI- acute myocardial infarction; EF- ejection fraction; PC- progenitor cells  
27 
 
Figure 2: The triple role of monocytes at different stages of the atherosclerotic process 
The three panels depict the functions of monocytes). Monocytes patrolling in the circulation are activated by different factors. They traffic to 
the damaged/activated endothelium. The dysfunctional endothelium over-express monocyte chemotactic protein-1 ligand and adhesion 
molecules (VCAM-1, ICAM-1) on its surface. After rolling and attachment to the endothelium the monocytes cross the endothelial surface 
(diapedesis). In the subendothelial space monocytes differentiate to macrophages via macrophage colony stimulating factor. The macrophages 
ingest oxidised LDL via scavenger receptors, especially CD36, forming ‘foam’ cells. These undergo a process of apoptosis/necrosis which 
perpetuates the formation of further lipid laden macrophages. The middle panel depicts events during an ACS with plaque rupture, thinning 
of the fibrous cap on plaque surface and monocyte platelet aggregates. Panel three illustrates cardiac repair, acutely with attraction of 
monocytes CD14++CD16–CCR2+ (Mon 1) and later in the phase two of remodelling where CD14+CD16++CCR2– (Mon 3) (and potentially 
CD14++CD16+CCR2+ (Mon 2) cells) alters the extracellular matrix remodelling by myofibroblast deposition and angiogenesis, leading to 
thinning of the infarcted cells. [ICAM-1: Intercellular adhesion molecule-1; VCAM: Vascular cell adhesion molecule. 
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 Where are we now? 
No doubt monocytes play an important role in the pathophysiology of SCD and its 
complication. Blood monocytes are easier to detect and characterise, compared to tissue 
macrophages. As medical practice moves into the XXI century with more emphasis on the 
prediction and prophylaxis of future acute events monocyte numbers and functions may 
become a very attractive biomarker. However the key monocyte parameters with a potential 
to become prognostic markers and treatment targets are still to be defined and validated. 
Indeed, there are still gaps in our knowledge of how monocytes differentiate into specific type 
of macrophages/dendritic cells in coronary plaques and later within infarcted tissue, and their 
role in regulating post-infarct reparative processes. The preferential differentiation of certain 
monocyte populations into particular macrophage types and other cells (e.g. myofibroblasts) 
has been suggested but needs further evidence.  
The understanding of the function of intermediate monocytes is still in its early days. This 
venture will be blighted with practical difficulties: namely the isolation of the small amounts 
of intermediate monocytes from whole blood, then maintaining cell viability (without 
differentiation) to allow characterisation of their function and downstream inflammatory 
pathway activation. A multitude of murine or other animal models could be utilised but 
ultimately development of new high resolution molecular in-vivo imaging techniques to tag 
and track monocytes is needed. This will provide valuable information on mechanisms and 
magnitude of mobilisation of individual monocyte subsets to the myocardium, their 
differentiation and may shed further light on intimate aspects of monocyte activities which 
may prove to be new therapeutic targets. The role of the microenvironment and local factors 
in driving monocyte differentiation both in the sub-endothelial space and in the infarcted tissue 
also need to be further elucidated. Furthermore, detailed exploration of monocyte action via 
interaction and in coordination with other cells, such as lymphocytes and platelets, and in 
relation to different progenitor and stem cells is deserved.  
The expression of chemokine receptors on the surface of infarcted cardiomyocytes is essential 
to be studied, even on animal models e.g. porcine hearts (the most closely related species 
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anatomically and physiologically to human hearts). If therapeutic agents could modulate the 
expression of MCP-1, fractalkine or CCR5, then monocytes subpopulations could be attracted 
to infarcted tissues earlier leading to concurrent removal of debris, angiogenesis, fibroblast 
deposition and better myocardial recovery.   
 
 Unanswered questions in the field of monocyte research 
Multiple essential roles are played by monocytes during the various stages of atherosclerosis, 
from its initiation to the progression and development of its complications - and later on, 
during myocardial healing and remodelling. These different roles can provide a fertile ground 
for pharmacological modulation of atherogenesis, stabilization of the atherosclerotic plaque 
or more importantly in myocardial healing and post infarction remodelling. 
Monocyte-mediated pathways are not limited to the cardiovascular system and inhibition of 
any of the surrounding milieu of cellular mechanisms could actually alter this finely tuned 
balance in other inflammatory systems leading to deleterious side effects. Hence, direct 
targeting of specific monocyte subpopulations at different sites and stages of MI would seem 
to be the best option. In fact, stem cell therapy relying largely on monocyte subpopulations 
renders an attractive potential. Given that most of our current knowledge in the field comes 
from murine models, further clinical studies are clearly required to improve our understanding 
of monocyte pathophysiology in human cardiac damage post-ACS and the subsequent 
remodelling and recovery of the myocardium. 
Whichever way we appraise our current knowledge about origin and progression of 
atherosclerosis, we are drawn to the same common origin: monocytes, their subpopulations, 
their function and their differentiation. With multiple therapeutic agents targeting “the clot” 
during ACS, an alternate and most attractive target for therapy lies in inflammation (Libby, 
2013) and particularly specific monocytes subpopulations with their diverse phenotypes and 
sentinel role in both the innate and adaptive immune system.  
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The exact role of CD14++CD16+CCR2+ (Mon2) cells remains unclear, more data is required. 
However as they are associated in humans with low ejection fraction after recovery from 
STEMI, it could be postulated that they have a role in debris removal early in the healing 
process. None the less their surface expression of Tie-2 is suggestive of a role in angiogenesis 
and reparation.  
  
CD14++CD16–CCR2+ and 
possibly CD14++CD16+CCR2+ 
monocytes: reduce or abrogate to 
reduce inflammatory effect and 
remove myocytes from infracted 
and peri-infarct areas.  
CD14++CD16+CCR2+ 
monocytes and possibly 
CD14++CD16+CCR2+ 
monocytes: improve 
angiogenesis, myofibroblast 
deposition  
PHASE I 
PHASE II 
Figure 3: Hypothesised principles of pharmaceutical targeting of monocyte subpopulations in the healing 
myocardium.  
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Chapter 2 
Monocyte subsets in ST elevation myocardial 
infarction 
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2.1  Introduction 
Ischaemic heart disease remains the most prevalent cause of death in the western world and 
the UK; coronary artery disease and heart failure are devastating pathologies for NHS 
resources and for patients’ morbidity, mortality and quality of life. Over the last 30 years 
management of coronary artery disease saw the introduction of invasive percutaneous 
coronary intervention (PCI) for the management of acute myocardial infarction with reduction 
in the acute mortality rate following a myocardial infarction. Indeed PCI has now superseded 
thrombolysis therapy as the gold standard for managing myocardial infarction with reduction 
in infarct area, post infarct complications and mortality rates (Steg et al., 2012). PCI success 
is not only attributed to the mechanical restoration of coronary flow but also to concomitant 
use of antiplatelet therapy. However other avenues of clinical intervention, other than 
thrombus management, are now needed to continue improving patients’ outcome on both 
clinical and subclinical measures.  
Hence, the identification of an association between leucocytosis and development of adverse 
cardiac outcomes opened a new era in cardiovascular research (Horne et al., 2006). Thereafter 
there was rapid unravelling of subset-specific involvement of monocytes in murine models of 
atherosclerosis, their role in progression of coronary artery disease, finally leading to plaque 
rupture and myocardial infarction. Concurrently there was an adjunct enthusiasm in translating 
the findings from murine models to humans. This led to the characterisation of three different 
monocyte subsets in humans, in an attempt to translate murine model work.  
This diversity of monocyte functions has been partly attributed to the existence of different 
monocyte subsets with specific phenotypic and functional properties (Geissmann et al., 2003, 
Auffray C, 2009, Cros et al., 2010, Zawada et al., 2011). Specific monocyte subsets have been 
shown to be differentially involved in the pathogenesis and outcomes of a range of diseases 
including heart failure (Wrigley et al., 2013), cerebrovascular accidents (Urra et al., 2009), 
and renal disease. Indicating the broad inflammatory effect of monocytes.  
With the identification and reliable characterisation of three distinct monocyte subsets, the last 
few years were marked by a number of papers thoroughly describing the surface markers, 
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cytokine and integrin markers expression of the three monocytes subpopulations in humans 
(Zawada et al., 2011).    
Mon 1 is characterised by high expression of CD14, IL6 receptor, CD64, CCR2 and CD163, 
but low expression of VCAM receptor and CD204 and absent CD16. Mon 2 is characterised 
by maximal expression of ICAM receptor, Tie2, CXCR4, CD163, VEGF receptor 1, KDR, 
ferritin, ApoB and CD115. Compared with Mon 1, Mon 2 have up-regulated CD16, VCAM1 
receptor and CD204. In contrast, Mon 3 had maximal expression of CD16, VCAM1 receptor 
and CD204, but diminished levels of CD14, IL-6 receptor, CD64, CCR2 and CD163. On the 
basis of these findings, Mon1 appear to correspond to Ly-6Chi mouse monocytes and Mon 3 
to Ly-6Clo monocytes (Shantsila et al., 2011). However, it is not clear whether any mouse 
monocyte subset may correspond to the human Mon 2.  
It is now clearly described that there are two phases of monocyte subset recruitment to an 
infarcted myocardium post coronary artery ligation in murine models. The spleen is an 
important source of monocytes which can be mobilized in response to generalised 
inflammatory stimuli such as during myocardial infarction. These monocytes have a possible 
role in orchestrating post infarct healing by meeting the increased demand on macrophages, 
through supply of their progenitor monocytes, in order to aid “mopping up” of infarcted/ dead 
tissue.  
The phenotypic and functional characteristics of monocyte subsets, especially that of Mon 2, 
remains undetermined. 
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2.2  Aims and Hypothesis 
The aim of this study was to compare differences in frequency between the three human 
monocyte subsets in patients with CAD and healthy subjects defined according to 
contemporary nomenclature of the three monocyte subsets utilising CD16, CD14 and CCR2 
surface markers.  
The phenotypic and numerical comparison was performed in different health and clinical 
states (healthy controls, ST elevation myocardial infarction (STEMI), and stable coronary 
artery disease patients).  
Total monocyte counts and their subset variations were also investigated longitudinally in 
prospectively recruited, consecutive STEMI patients to establish the characteristics of 
monocyte subpopulations in a large sample size. This chapter addresses the hypothesis that 
monocyte subpopulations are higher, acutely compared to the recovery phase 14 days post- 
STEMI.    
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2.3   Methods 
2.3.1 Patient Recruitment 
2.3.1.1 ST elevation myocardial infarction patients  
Patients with STEMI admitted to Heartlands Hospital, Queen Elizabeth Hospital and Sandwell 
and West Birmingham Hospitals (SWBH) NHS Trust. Patients who met the study criteria 
were recruited between March 2011 and December 2012. Details of patients recruited are 
included in the appendix I.  
 
2.3.1.2 Exclusion criteria  
Exclusion criteria included: myocardial infarction in the preceding 6 months, sepsis on 
admission; pre-diagnosed haemodynamically significant valvular heart disease; ongoing 
malignant process with a prognosis of less than one year; as well as active inflammatory 
conditions requiring immune-suppressants (e.g. rheumatoid arthritis, psoriasis, systemic lupus 
erythematosus). 
 
2.3.1.3 Control Subjects 
Data from control subjects were utilised to compare counts in a cross sectional study with the 
main STEMI population patients. These included both patients with stable coronary artery 
disease as well as healthy individuals. More details on healthy control recruitment are included 
in appendix II  
 
2.3.2 Statistical methods 
2.3.2.1 Power Calculation 
Power calculations were based on the results by Larose et al. who have shown that 20% of 
ACS patients have cardiovascular events during one year (Larose et al., 2010). This was 
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performed by resident statistician prior to the study commencing. Briefly, in order to achieve 
80% statistical power to detect the difference in the MACE (with p<0.05) in count of the 
monocyte subsets, at least 35 MACE events were needed. MACE in this project includes: 
death, new diagnosis of heart failure and recurrent ACS. Thus, at least 175 patients were to be 
recruited. More details are available in appendix III.  
 
2.3.2.2 Statistical analysis 
Normality testing was undertaken using Shapori and Wilkes test with normality distribution 
curves. Data are expressed as mean ± standard deviation (SD) for normally distributed data; 
or median with first and third quartiles (Q1-Q3) for non-normally distributed data. Statistical 
significance of differences between monocyte subsets in different health states was 
determined by one way analysis of variance (ANOVA) with Tukey’s post-hoc test for 
normally distributed parameters and Kruskall and Wallis for non-parametric data with Dunns 
post-hoc test. A p-value (two tailed) of <0.05 was considered statistically significant. SPSS 
21 (SPSS, Inc, Chicago, Illinois, USA) A value of p<0.05 and GraphPad Prism 4.0 software 
(La Jolla, CA, USA) statistical software was used to perform the statistical analyses. 
Monocytes counts were interrogated between day 1 and day 14 post infarct using paired t-test 
for parametric data and Wilcoxon rank test for non-parametric data.  
 
2.3.3 Measuring monocyte subset counts 
2.3.3.1 Sample collection: 
Patients who consented for study after fulfilling inclusion criteria, phlebotomy was carried out 
via routine aseptic venesection at the point of recruitment into the study after attaining full 
consent. Venesection was attained at a single puncture with a 22 gauge wide bore sterile needle 
(to reduce risk of red blood cell haemolysis) into EDTA-containing tubes after the patients 
rested for 20 minutes (Chong et al., 2004). The venous samples collected were stored in the 
dark and transported from the recruitment site to the Centre for cardiovascular sciences 
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laboratory within an hour after which processing was initiated. Details for each analysis and 
sample preparation is included in the relevant chapters (Monocyte counts and phenotypic 
characterisation- chapter 2, section 2.3.3.2; Phagocytosis- chapter 3, section 3.3.3.; IKKβ- 
chapter 4, section 4.3.2). Patient serum was stored at -70 ᴼC after centrifugation as described 
in chapter 4, section 4.3.3 and 4.3.4.  
Coronary artery samples were aspirated from the guide catheter after the culprit vessel was 
stented and where applicable and aspiration catheter was utilised. Samples from the coronary 
arteries were stored and transferred in similar technique to venous samples.  
In order to define monocyte subset counts in health, disease and over time, flow cytometric 
analysis of the fluorescence-labelled antibodies directed against specific cell surface receptors 
was undertaken.  Flow cytometric analysis was performed using the BD FACS Calibur flow 
cytometer (Becton Dickinson, Oxford, UK). VentuirOne, Version 3.1 software (Applied 
Cytometry, Sheffield, UK) was employed for data analysis. Flow cytometric analysis was 
performed by a single operator to minimize analytical error, (table 4 and 5 for reproducibility 
values) (Chughtai et al., 2011). The analyses were performed on whole blood samples 
obtained by Dr A Ghattas.  
 
2.3.3.2 Immunophenotypic characterisation of monocyte subtypes and absolute 
count quantification 
A mastermix, which includes mouse anti-human monoclonal fluorochrome-conjugated 
antibodies anti-CD16-Alexa Fluor 488 (clone DJ130c, AbD Serotec, Oxford, UK), anti-
CD14-PE (clone MфP9, BD), anti-CD42a-PerCP (clone Beb1, BD) and anti-CCR2-APC 
(clone 48607, R&D) CD14 2.5 µl, CD16 2.5 µl, CD42a 5 µl and CCR2 2.5 µl fluorochrome 
labelled antibodies, was prepared. Mastermix (12.5 µl) was mixed with 50µl of fresh EDTA 
anticoagulated whole blood in BD TruCount tubes (BD) containing 50,000  fluorescent count 
beads using an electronic micropipette. The TruCount tube was gently mixed on the vortex 
for 3 seconds. The tube was then incubated for 15 minutes in the dark at room temperature, 
shaking with a horizontal shaker (set at 500 units). Lysis was then performed by adding 450 
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µl pre-diluted BD FACS Lyse solution and the sample was then incubated for a further 15 
minutes after being mixed gently on the vortex. Before analysing the sample through the flow 
cytometer, the sample was diluted with 1.5 ml of PBS solution, gently mixed again and then 
immediately analysed using the flow cytometer. Monocytes were selected using gating 
strategies and using forward and side scatter to exclude natural killer lymphocytes, and 
granulocytes. Granulocytes were excluded by CD14 expression versus side scatter (Figure 4, 
panel b). CD16+CD14- natural killer lymphocytes were excluded from CD16+ monocytes 
based on ungated CD14 versus CD16 expression (Figure 4, panel c). Mon 1 were identified 
as CD14++CD16- cells (Figure 4, panel e). The CD16+ cells (Figure 4, panel e) were 
separated into Mon 2 and Mon 3 based on their expression of CCR2. Absolute counts of 
monocyte subsets (cells/µl) were obtained by calculating the number of monocytes 
proportional to the number of count beads according to the manufacturer’s recommendations. 
Definitions of CD14, CD16 and CCR2 positivity were made using appropriate isotype 
controls (Ziegler-Heitbrock et al., 2010).  
The methodology developed differentiates between monocyte subpopulations according to 
surface expression of CD14, CD16 and CCR2. Three populations are recognized namely: a 
CD14++CD16-CCR2+ (Mon 1), CD14+CD16+CCR2+ (Mon 2) and CD14+CD16++CCR2- 
(Mon 3) subsets. Data was collected on 10,000 total cell events.  
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Figure 4: Absolute count gate from a recruited patient: A FSC/SSC plot (forward and side 
scatter plot) of a whole blood sample. All monocytes are gated within the circled area. Other 
leukocyte populations detected e.g granulocytes with higher side scatter are later removed. B, 
shows individual monocyte subpopulations to delineate different surface expression of CD14 
and CD16 (X and Y axis respectively) to differentiate between Mon 1 and Mon 3. C, shows 
differentiation of the CD16+ subpopulations according to CCR2 expression, with CCR2 
positive populations being Mon 2 (Shantsila et al., 2011) 
 
This is a robust and reproducible protocol, for discriminating between different monocyte 
subpopulations based on surface expression of CD14 CD16 and CCR2 with good 
reproducibility has been developed (Shantsila et al., 2011). The coefficient of variation for the 
intra-assay reproducibility of the assay was: Mon 1: 5%, Mon 2: 6.5%, Mon 3: 6.6% Table 4). 
This was based on samples collected from healthy volunteers (N=2), each repeated six times. 
The mean and standard deviation are reported below. Inter-assay variability was from 2.5%- 
5.3 (table 5) 
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Table 4: Intra-assay variability of flow cytometry for measurement and quantification 
of monocyte 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total monocyte count, Mon 1, Mon 2 and Mon 3 as well as total MPA (monocyte platelet 
aggregates). Mean and standard deviation are reported. CV: coefficient of variation (%). 
 
 
Table 5: Inter-assay variability of flow cytometry for measurement and quantification 
of monocyte 
 Total 
monocyte 
count 
(cells/µl) 
 
Mon 1 
(cells/µl) 
 
 
Mon 2 
(cells/µl) 
 
 
Mon 3 
(cells/µl) 
 
    
 
 
 
Subject 1 
Sample 1 362.84 314.42 30.26 18.16 
Sample 2 338.35 304.25 34.17 20.48 
Sample 3 384.69 319.99 37.52 17.35 
Sample 4 313.41 317.63 33.52 19.14 
Sample 5 356.2 288.54 35.66 17.33 
Sample 6 345.25 297.51 36.24 18.65 
Mean ± SD 350 ± 24.1 307 ± 12 35 ± 2.6 18.5 ± 1.2 
CV % 6.9 4.1 7.4 6.4 
 
 
 
Subject 2 
Sample 1 455.4 317.18 106.67 26.69 
Sample 2 412.67 298.87 100.18 26.24 
Sample 3 468 338.96 116.78 28.25 
Sample 4 479.65 352.78 117.88 24.58 
Sample 5 438.67 299.21 118.62 28.62 
Sample 6 468.87 319.62 112.62 29.66 
Mean ± SD 454 ± 25 321 ± 22 112 ± 7.3 27 ± 1.8 
CV % 5.4 6.7 11.3 6.7 
Intra-assay CV average 
(%) 
6.2 5.4 6.5 6.6 
 Total 
monocytes 
(per µl) 
Mon 1 
(per µl) 
Mon 2 
(per µl) 
Mon 3 
(per µl) 
Total 
MPA 
(per µl) 
Day  1 446 213 151 82.74 48 
Day  2 470 236 167 89 51 
Day  3 469 258 168 79 49 
Day  4 457 247 152 76 52 
Day  5 469 228 149 89 45 
Day  6 468 239 163 85 50 
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Total monocyte count, Mon 1, Mon 2 and Mon 3 as well as total MPA (monocyte platelet 
aggregates). Mean and standard deviation are reported. CV: coefficient of variation (%). 
 
2.3.4 Ethical consideration 
This study was performed in accordance with the Helsinki declaration. Ethical approval was 
granted by the Coventry Research Ethics Committee (reference number 09/H1210/11) and 
approval was obtained from the Research & Development departments at SWBH NHS Trust 
and Heart of England NHS Foundation Trust. All participants provided written informed 
consent.  
 
2.4   Results 
2.4.1 Absolute monocyte subpopulation count variation between 
peripheral versus coronary artery sampling 
This investigation of monocytosis in STEMI, with its various subpopulations, on clinical 
outcome and ventricular remodelling, is based on systemic peripheral blood analysis. To 
demonstrate the relevance of this for the site of infarct, a study was undertaken to compare the 
absolute monocyte subpopulation count between the peripheral blood samples, and those 
obtained directly from affected coronary artery. Blood samples were thus attained directly 
from the occluded coronary artery in STEMI patients undergoing thrombus aspiration during 
percutaneous coronary intervention. These samples were obtained peri-intervention. The 
monocyte subpopulation counts in blood taken from the occluded artery were compared to 
counts obtained from samples taken peripheral from the antecubital fossa post-procedure.  
Day  7 453 229 161 84 48 
Day  8 479 239 169 80 49 
Day  9 468 241 159 84 50 
Day  10 478 221 151 82 48 
Mean ± SD 
466 ±  11 
235.1 ± 
13 159 ±  8 83 ± 4 49 ± 2 
Inter-assay 
CV% 
2.3 5.5 4.9 4.9 4.0 
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There was no statistical difference between monocytes counts of the three subsets between the 
two sites. The results are illustrated in (Figure 5). 
 
Figure 5: Monocyte subpopulation counts are not different between coronary artery 
circulation and peripheral venous samples: A total of ten STEMI patients were recruited 
with blood samples acquired simultaneously from the coronary artery post thrombus 
aspiration during percutaneous coronary intervention as well as peripherally from the brachial 
vein. The samples were analysed by flow cytometry for total monocyte counts, Mon 1, Mon 
2, and Mon 3 counts. Statistical significance was tested using a paired t-test. 
 
2.4.2 Time-delay of patient recruitment and effects on monocyte counts 
It is logistically impossible to recruit patients at the same time with the same time gap between 
treatment and recruitment. Hence the effect of time delay between recruitment and sample 
analysis was investigated to direct time of recruitment, within the first 24 hours. Here blood 
samples were attained from seven consecutive STEMI patients. Blood samples were obtained 
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at 3 hours, 6 hours, 12 hours and 24 hours after the performance of coronary revascularisation. 
Using paired t-test the differences between different time points were investigated.  
  
Table 5: Effect of temporal variation on monocyte count 
Samples were obtained and analysed for monocyte subset at 4 different time points after 
patients received percutaneous coronary intervention (PCI). Data are expressed as median 
with interquartile range in parenthesis for non-normally distributed data and as mean plus 
standard deviation for normally distributed data. Statistical significance was tested using 
paired t-test. There was no statistical difference in the different monocyte subsets between the 
four different sampling time points. Normally distributes data are described as mean ± SD, 
non-normally distributed data are presented as median (with range). 
 
 
2.4.3 Patient Results 
2.4.3.1 Monocyte subset counts in stable artery disease and healthy individuals 
All three patient groups (i.e. STEMI, stable coronary artery disease and healthy individuals) 
were matched for age and gender (one way Anova with post Tukey post hoc, p= 0.42 and 0.84 
respectively). Given the exclusion and recruitment criteria (chapter 2, section 2.3.1 and 
appendix I), there were no inherent differences between STEMI patients, or stable coronary 
artery disease patients.  
Patients were recruited as described in (chapter 2, section 2.3.1 and appendix I). Total 
monocyte count, Mon 1 and Mon 2 monocytes were significantly increased in patients with 
STEMI compared with patients with stable coronary artery disease (SCD) and control groups 
 3 hours post 
PCI 
6 hours post 
PCI 
12 hours post 
PCI 
24 hours post 
PCI 
pValue 
Total 
monocytes, 
(cells/µl) 
682 (592 – 769) 678 (624 – 752) 628 (618 – 736) 647 (575 – 694) 0.52 
Mon 1 
(cells/µl) 
556 (468 – 639) 543 (469 – 617) 529 (479 – 592) 521 (438 – 585) 0.75 
Mon 2 
(cells/µl) 
107 ± 40 103 ± 49 102 ± 43 96 ± 40 0.97 
Mon 3 
(cells/µl) 
30 ± 23 39 ± 26 31 ± 19 32 ± 23 0.89 
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(table 7). There was no significant difference between stable coronary artery disease and 
healthy controls (p = 0.52) (Figure 6). 
Table 6: Total monocyte count and monocyte subset counts differ according to health 
and disease 
 
 
 
 
 
 
ST elevation myocardial infarction (STEMI), healthy controls and stable coronary artery 
disease (CAD) blood samples were analysed by flow cytometry for total monocyte, Mon 1, 
Mon 2, Mon3. Statistical significance was tested using ANOVA with Tukey post- hoc test for 
normally distributed parameters and Kruskall and Wallis for non-parametric data with Dunns post-hoc 
test, where (*) represents significant difference between STEMI and controls and (†) represents 
STEMI versus CAD. Normally distributed data are described as mean ± SD, non-normally distributed 
data are presented as median (with range). 
 
Monocyte subsets STEMI (n=40) Stable CAD 
(n=20) 
 Healthy 
controls (n=40) 
p- Value 
 Total monocytes 
(cells/µl) 
842 (595 – 1109)*† 439 ± 148 353 ± 92 <0.0001 
 Mon 1 (cells/µl) 646 ± 258*† 341 ± 102 281 (237 – 338) <0.0001 
 Mon 2 (cells/µl) 191 ± 143 *† 66 ± 53 30 (16 – 75) 0.02 
 Mon 3 (cells/µl) 58 ± 38 46 (7.2 – 10.6) 9 (4 – 30) <0.0001 
 Mon 1 proportion 
(%) 
89 (72 – 93) 70 ± 17* 81 (67 – 86) 0.007 
 Mon 2 proportion 
(%) 
21 ± 13* 13 ± 10 8 (5 – 18) 0.01 
 Mon 3 proportion 
(%) 
7 ± 3 9 ( 7 – 11) 3 (1.2 – 8) 0.50 
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Figure 6: Monocyte subpopulations counts in different health states: A- Total monocyte 
counts were significantly higher in STEMI patients compared to stable coronary artery disease 
and healthy controls. B- Mon 1 and C- Mon 2 counts also had a similar pattern of phenotypic 
variation. Mon 3 counts were only higher in STEMI patients compared to healthy controls. 
Whole blood was obtained from 10 STEMI patient both directly from the coronary circulation 
during PCI and later peripherally form venous puncture.  
 
2.4.3.2 Recruited STEMI patients’ demographics 
In total, 209 STEMI patients who met inclusion criteria were recruited from March 2011- Dec 
2012. The average age of the recruited patients was 61 ± 11 (mean ±SD) years with 
predominance of males being recruited accounting for 75% of subjects. This reflects the 
background epidemiology of ischaemic heart disease. There was a relatively short delay in 
patients presenting to hospital after the onset of symptoms with an average time of hospital 
admission post onset of symptoms of 4.7 ± 2.6h. In this patient population group there was a 
high prevalence of risk factors contributing to developing ischaemic heart disease (table 8) 
46 
including: smoking, hypertension, hypercholesterolaemia, history of previous myocardial 
infarction, as well as past medical history of chronic stable angina.  
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Table 7: Recruited patients demographics, past medical history and drug history 
 
A total of 209 patients were recruited. ACE inhibitor- angiotensin converting enzyme 
inhibitor; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; 
COPD: chronic obstructive airway disease; CVA: cerebrovascular accident PCI: percutaneous 
coronary intervention; WCC: white cell count. Data are expressed as mean ± standard 
deviation (SD) for normally distributed data; or median with (interquartile range) for non-
normally distributed data 
 
          
N=209 
 
 
 
Demographics 
Age 61 ± 11 
Sex 
Time from symptoms onset to 
presentation to hospital (hours) 
Time from hospital presentation to 
recruitment to study (hours) 
 
75% males 
 
4.7 ± 2.6 
 
16 ± 5 
 
  
                                    Peak Troponin (ng/ml) 7065 (4521 – 14461) 
Peak Creatinine kinase (mg/ml) 
Total WCC (mmol/L) 
1466 ( 894 – 1698) 
11 (8.2 – 13.1) 
Biochemical profile at 
recruitment  
Estimated GFR (ml/min/1.73m2) 
Total Cholesterol (mmol/L) 
Body surface area  
 
74 ± 16 
4.9 (4.3 – 5.3) 
1.9 (1.8 – 2.0) 
   
Diabetes 23 
Hypertension 53 
Smoking  56 
Hypercholesterolaemia 43 
Past medical history at 
the point of recruitment 
(%) 
History of angina 5 
Previous myocardial infarction 
Obesity 
COPD 
CVA 
CABG  
Previous PCI 
LAD 
Inferior STEMI  
15 
15 
14 
8 
4 
9 
41 
38 
   
 
Aspirin 36 
Clopidogrel 3 
Statin therapy 34 
Calcium channel blocker 21 
Drug history at 
recruitment (%) 
Beta blocker 
Loop diuretic 
Thiazide diuretic 
ACE inhibitor 
Nitrates 
18 
15 
9 
41 
7 
48 
2.4.3.3 Monocyte subpopulation correlations with patients’ demographics 
Using Pearson’s correlation analysis, total monocyte counts as well as Mon 1 correlated 
significantly with peak troponin (R = 0.19, p= 0.03). Both counts also correlated significantly 
with classical cardiovascular risk including myocardial infarction and history of PCI (table 9).  
 
Table 8: Correlation of monocyte subpopulations with recruited patients’ past medical 
history and biochemical markers 
 
eGFR: estimated glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; WCC: white cell count’ (Pearson’s correlation was performed for all 
analytes). 
 
2.4.3.4 Total monocyte and monocyte subset counts in recruited STEMI patients 
in a longitudinal study 
There was a significant increase in the total monocyte counts as well as the three monocyte 
subset counts between the first 24 hours post infarction and at phase 2 (days 14- day 28 post 
index event). Interestingly there was no change in the proportion of Mon 1 and Mon 2 
subpopulations between the two sampling time points. However, there was a significant 
increase in the proportion of Mon 3 at phase 2 with no significant increase in the total Mon 3 
count. This is in keeping with the potential angiogenic and fibrotic reparative role of Mon 3 
hence the increase in proportion during the recovery phase post infarction.  
  Total 
Monocyte 
count 
Mon 1 Mon 2 Mon 3 
  R p - 
Value 
R p - 
Value 
R p – 
Value 
R p - 
Value 
Age  0.07 0.31 0.06 0.38 0.06 0.39 -0.02 0.78 
Peak troponin 0.19* 0.03 0.17* 0.04 0.14 0.11 -0.03 0.74 
CK troponin 0.13 0.07 0.08 0.26 0.16 0.02 0.03 0.73 
Total WCC 0.04 0.56 0.07 0.35 -0.05 0.5 0.04 0.57 
eGFR 0.06 0.40 0.04 0.54 0.04 0.56 0.07 0.34 
Total cholesterol 
-0.03 0.63 -0.04 0.59 0.02 0.74 -0.09 0.19 
MI 0.18* 0.01 0.15* 0.03 0.12 0.08 0.10 0.14 
PCI 0.15* 0.03 0.12 0.09 0.1 0.16 0.12 0.08 
Hypertension  0.06 0.44 0.09 0.18 -0.07 0.33 0.03 0.64 
Diabetes mellitus 0.07 0.33 0.08 0.28 -0.02 0.82 0.09 0.21 
Smoking  0.00 0.95 -0.04 0.61 0.05 0.44 0.03 0.66 
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A concurrent significant decrease in the total number of monocyte platelet aggregates was also 
demonstrated at second sampling phase (day 14- day 28 post infarction) compared to 
recruitment during the index event. This may reflect the effect of therapeutic interventions that 
patients received on admission, including coronary intervention as well as antiplatelet therapy. 
 
Table 9: Monocyte counts in STEMI patients at Day 1and second phase (day 14-28 days 
post infarct) 
Normality testing was by Shapiro Wilk test and distribution curves. Dependent t-test was used 
as data were normally distributed. There was significant differences between total monocyte 
count and all three subsets. All cell counts were higher in the first 24 hours post infarction 
compared to day 14.   
  
Monocytes Median 
Florescence 
intensity at day 1 
± Standard 
deviation 
 
N= 208 
Median 
Florescence 
intensity at phase 
2 ± Standard 
deviation 
 
N= 151 
Parametric 
analysis 
(paired t-test) 
 
 
 
pValue 
Total monocyte count 
(cells/µl) 
Mon 1 (cells/µl) 
Mon 2 (cells/µl)  ⃰
Mon 3 (cells/µl)  ⃰
852 ± 294 
634  ± 240 
157 ± 113 
61 ± 40 
564 ± 288 
399 ± 147 
93 ± 72 
51 ± 35 
P< 0.01 
P< 0.01 
P< 0.01 
0.005 
Mon 1 proportion (%) 
Mon 2 proportion (%) 
Mon 3 proportion (%) 
73 ± 14 
18 ± 11 
8 ± 6 
78 ± 68 
17 ± 12 
10 ± 8 
0.35 
0.17 
0.001 
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2.5   Discussion 
This study was designed to understand the effect of STEMI on monocyte counts. Given the 
fact that ST elevation myocardial infarction is an acute occlusion of a coronary artery, there 
was a need to determine the difference, if any, in monocyte counts obtained centrally from a 
coronary circulation versus peripherally from a large calibre vein. In a small pilot study of 10 
STEMI patients, no statistically significant differences were observed in monocyte counts 
analysed from blood obtained from the culprit coronary artery and the counts acquired from 
the peripheral circulation. This provides validity to the use of systemic blood samples for 
investigating monocyte counts in this work.  
The rapid and persistent increase in monocyte counts acutely is in keeping with results by 
Dutta et al. where the increase in monocyte counts occurred within 24 hours of infarction with 
rapid transit time of macrophage and monocyte counts (Dutta et al., 2015). In another study 
there was a peak of monocyte and macrophage counts within 24 hours of infarction with a 
trough 2 days post infarction (Heidt et al., 2014). Its worthy of note that both these studies 
were using murine models. In contrast a small series in humans indicated that monocyte counts 
continue to rise up and reached a peak to day 3 post myocardial infarction (Tsujioka et al., 
2009). Elsewhere, Tapp et al. reported an increase in Mon 1 and Mon 2 counts up to three 
days post ACS (Tapp et al., 2012). All together these findings could suggest the rapid 
production rate, transition time of monocytes through the arterial-venous system eventually 
reaching the coronary circulation and finally the rapid differentiation rate to macrophages and 
dendritic cells in the target tissue during the acute phase.  The discrepancy in these time frames 
will ultimately require a study based on hourly monitoring of monocyte count in a number of 
subjects post myocardial infarction (not healthy individuals). In the early hours post infarction, 
it is difficult to exactly postulate the time frame during which monocyte counts start to 
increase, or indeed are at the highest. Such a study will ethically be difficult to implement as 
it is likely to impinge on patients’ comfort during the peri-acute phase of the myocardial 
infarction. Also the time delay from symptoms onset, and hence acute coronary occlusion, to 
presentation to hospital will pose a time lag during which monocyte counts cannot be studied.  
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In recruiting STEMI patients it is logistically impossible to unify the time between having PCI 
and patients recruitment in this study. Hence, I investigated the effect of time delay between 
receiving treatment and recruitment time. This is of paramount importance given the dynamic 
differentiation and prompt physiological response to the acute inflammatory state posed by 
the myocardial infarction. Hence monocyte counts were measured at 3,6, 12, and 24 hours 
post PCI. The data shown here, in a group of 7 patients, confirmed that there was no significant 
change in monocyte counts acquired.   
Our group has published previously on the effect of effect of exercise and diurnal variation on 
monocyte subpopulation. This suggested a diurnal variation in Mon 2 expression with highest 
Mon 2 counts expressed at 6:00 PM and lowest counts at 6:00 AM. There was no diurnal 
difference in total monocyte count or in Mon 1 and Mon 3 counts. We also demonstrated that 
a delay of up to 2 hours prior to sample analysis after venepuncture did not significantly affect 
counts of monocyte subsets. By 4 hours, the numbers of Mon 2 and Mon 3 significantly 
increased (p=0.005 and p=0.02, respectively). Studying the effect of these different 
physiological states and diurnal variation not only helps to unify the methodology utilized but 
also limits confounding factors that could significantly alter results. 
Establishing the differences between monocyte counts in different health states in a cross 
sectional study, was essential in confirming the acute variation of monocyte and monocyte 
platelet aggregate counts in the STEMI study population. A significant increase in all 
monocyte subset counts in STEMI patients was observed compared to healthy individuals and 
stable coronary artery disease patients.  These results concur with an earlier observational 
series by Tapp et al., who also described the dynamics of alterations of surface marker 
expression of the three monocyte subsets acutely after an infarction (Tapp et al., 2012). There 
was a prominent increase in Mon 2 but no changes in Mon 3 acutely post infarct. Significant 
increases in Mon 2 CD14 and CCR2 expression, and reduction in CD16 expression were also 
described by Shantsila et al. reported that the expression of IL-6R and VCAM-1 are reduced 
on circulating monocyte subsets in STEMI patients (Shantsila et al., 2013). These changes are 
hypothesized to represent a regulatory feed-back mechanism aimed at rebalancing the marked 
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inflammation which is typically present following acute MI or indeed to aid selective homing 
of monocytes with high receptor expression to damaged myocardium.  
In stable coronary artery disease subjects, there were previous reports from small case series 
indicating an increase in CD16+ve percentages (likely to correspond to Mon 2 and Mon 3 
here) in patients with symptomatic coronary artery disease compared to healthy controls even 
after adjusting for common risk factors including smoking and hypertension (Berg et al., 
2012). In another study of stable coronary artery disease patients, the number of cardiovascular 
risk factors independently predicted elevated CD14++CD16+ monocytes (likely to represent 
Mon 1 and Mon 2) (Woollard and Geissmann, 2010). Interestingly inflammatory monocytes 
were not associated with stable atherosclerotic plaque assessed angiographically (Imanishi et 
al., 2010). However there was an association in patients with unstable angina, and thus 
unstable vulnerable atherosclerotic plaques (Imanishi et al., 2010). 
This study is the largest study prospectively recruiting consecutive STEMI patients. The 
distribution of the three different monocyte subsets has been described in STEMI patients both 
acutely and 2 weeks after the index event of the myocardial infarction. Confirming previous 
findings, there was statistically significant higher counts of all three monocyte subsets at 24 
hours post infarction when compared to counts 14 days post-STEMI. This acute increase in 
counts could be explained by the acute augmentation in expression of CCR2 on the surface of 
the myocytes (Hilgendorf et al., 2014, Dutta et al., 2015) as a response to the acute hypoxic 
state induced by the myocardial infarction as well as release of multiple inflammatory 
cytokines, e.g. TNF-α. The rapid mobilization of monocytes from the bone marrow as well as 
spleen is required acutely to replenish the supply of the rapidly consumed macrophages post-
STEMI (Swirski et al., 2009). It is now recognized that there are resident macrophages within 
the myocardial tissue even in stable healthy state (Heidt et al., 2014). These are thought to be 
essential in maintaining healthy myocyte microenvironment. Acutely the increase in 
macrophage exit leads to an increase demand on monocytes mobilization and hence the higher 
counts measured in the hypoxic infarcted state (Heidt et al., 2014).  
There is a multitude of observational studies describing surface makers and 
cytokine/chemokine associations of monocyte subpopulations in different pathologies 
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(Shantsila et al., 2011, Tapp et al., 2012, Zawada et al., 2011). However, there is a paucity of 
data describing the functional characteristics of these subsets. Indeed the effect of the above 
described increase in monocytes subpopulations, in the peripheral and central circulation, on 
patients’ clinical outcome as well as the general function of the cardiac muscle post infarction, 
is yet to be determined.  These unaddressed areas are the focus of the remaining studies of this 
thesis.  
One limitation of my study design is that the glucose levels were not documented in STEMI 
patients at the point of admission. It is has been previously described that admission glucose 
levels in heart failure patients are an independent predictor of outcome, regardless of whether 
the patients have a history of pre-diagnosed diabetes mellitus or not. Monocyte counts 
association with glucose levels and clinical outcome remains to be an area requiring further 
investigation.  
 
2.6   Conclusion 
In the largest study recruiting STEMI patients and investigating numerical distribution of the 
newly characterised three monocyte subpopulation counts, there was a significant increase in 
inflammatory subset counts which were higher in the acute phase as well compared to counts 
14 days post infarcts. 
This work confirms with greater statistical power findings from pilot data and sets the path for 
the need to investigate the function of these subsets in the acute physiological state of STEMI. 
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Chapter 3 
Monocyte subset chemotaxis and phagocytic activity 
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3.1   Introduction 
Typically monocyte-derived macrophages have been associated with phagocytic function. 
With the avid interest in the role of macrophages and their precursors in the healing and 
recovery post infarction, it is hypothesised that the phagocytic activity of both monocytes and 
macrophages can account for their reparative process via removal of the infarcted hypoxic 
tissue damage hence influencing ventricular remodelling. A number of murine models have 
investigated the phagocytic activity of monocytes and macrophages. It was shown that the 
early influx of LyC6hi monocytes early post infarction are associated with poor outcome and 
adverse cardiac remodelling.  
The behaviour of monocyte subpopulations is the centre of extensive research in a multitude 
of acute and chronic pathological conditions, including chronic kidney disease, 
cerebrovascular events, liver fibrosis, and patients who sustained an acute coronary syndrome 
or who have stable coronary artery disease. In fact peripheral monocytosis has been associated 
with poor outcome in atherosclerosis and coronary artery disease (Rogacev et al., 2012), as 
well as chronic kidney disease (Rogacev et al., 2011). The precise functions of these 
monocytes subsets remain ill defined, with limited gene-expression (Wong et al., 2011) and 
surface marker profiling (both angiogenic and scavenger) (Zawada et al., 2011, Shantsila et 
al., 2013). To date there has been no characterisation of the phagocytic activity of the different 
monocyte subpopulations and very few papers assess the functional characteristics of these 
subpopulations in healthy participants and under various normal physiological conditions 
(Shantsila et al., 2012). 
Here we characterise the phagocytic capacity of the three defined monocyte-subpopulations 
in a novel flow cytometry assay. In doing this we assess further the phagocytic capabilities of 
monocytes in healthy individuals and investigate the effect of various physiological and 
disease states on phagocytic function of monocyte subpopulations. 
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3.2   Aims and Hypothesis 
The aim of this chapter is to describe a flow cytometric method for measuring the phagocytic 
activity of the three different human monocyte subpopulations: Mon 1, Mon 2 and Mon 3. I 
will discuss the validation experiments carried out for the phagocytosis protocol; consider the 
effect of time delay in sample preparation on the phagocytic activity; investigate any effect of 
circadian rhythm variation on phagocytic activity of monocytes; and examine the effect of 
exercise. The beneficial effect of exercise in reducing mortality from cardiovascular disease 
in individuals with coronary artery disease, as well as reducing the generalised inflammatory 
state associated with ageing has been intensely studied. I hypothesis that exercise reduces the 
phagocytic activity of monocytes. 
The difference in the phagocytic activity of the three monocyte subsets healthy controls, 
patients with stable coronary artery disease, STEMI and healthy controls will be investigated.  
These experiments have been designed to test the hypothesis that the phagocytic activity of 
monocytes in STEMI patients is significantly higher compared to patients with stable coronary 
artery disease or healthy individuals.  
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3.3   Methods 
3.3.1 Study subjects 
Healthy controls, stable coronary artery disease patients, and STEMI patients were recruited 
as discussed in appendix I and section 2.3.1 of chapter 2. Briefly healthy individuals were 
consented for participation and recruited in City Hospital, Birmingham, UK. Stable coronary 
artery disease patients were recruited from City Hospital, Birmingham, UK or from 
Birmingham Heartlands Hospital. The inclusion criteria for STEMI patients are described in 
Chapter 2. All patients underwent primary coronary angioplasty as the default 
revascularisation strategy, and were initiated post-procedure on standard post-STEMI 
cardiovascular therapies as described in Chapter 2. Patients were recruited within 24 hours of 
admission. Further details on recruitment of study subjects are also included in appendix I.  
The exercise studies were performed by 12 healthy subject (age 32±5, males, 60%). These 
subject had no significant past medical history and were not on any regular medication. They 
were recruited from Centre of Cardiovascular Sciences. Subjects were asked not to partake in 
aggressive physical activity in the 24 hours pre exercise experiment.  
3.3.2 Flow cytometry 
Flow cytometric analysis was performed using the BD FACSCalibur flow cytometer (Becton 
Dickinson, Oxford, UK [BD]) as published previously (Shantsila et al., 2011).  
3.3.3 Phagocytosis Assay 
Whole blood (6ml) was collected into a lithium-heparinised bottle and stored on ice en route 
for sample preparation and analysis. All sample processing was undertaken within one hour 
of collection. The phagocytosis assay utilises pHrodo E. coli BioParticles (Invitrogen). These 
neutralized E. coli contain a fluorochrome that is inactive at neutral pH. However upon 
phagocytosis of the bacteria, within the acidified phagosome the acidic environment activates 
the fluorochrome which is detected by flow cytometry.  
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For each blood sample to be analysed, 100 µl of whole heparinised blood was mixed with 20 
µl of pHrodo™ BioParticles®.  A control, lacking bioparticles was prepared in parallel, with 
20µL of PBS. The samples were mixed gently by vortexing and incubated at 37ºC for 10 
minutes. Following incubation, monocyte sub-populations were labelled with an excess of 
fluorochrome-conjugated monoclonal antibodies: anti-CD16-Alexa Fluor 488 (clone DJ130c, 
AbD Serotec, Oxford, UK), anti-CD14-APC (clone MфP9, BD) were added to both the 
sample and control. The tubes were mixed gently and placed in the incubator again for a 
further 10 minutes. Red blood cell lysis was then performed with a 100 µl of lysis buffer 
(Component A- enclosed with pHrodo E.Coli BioParticles Phagocytosis Kit for Flow 
Cytometry (Invitrogen, California, UK)). The tubes were incubated at room temperature for 
five minutes, thereafter 1 mL of buffer B was added to the tubes. These were mixed and 
incubated again at room temperature for 5 minutes. The samples were then centrifuged at 500 
g for 5 minutes at room temperature. The supernatant was decanted and the cell pellet 
resuspended with 1mL of PBS. The samples were then washed again and the cell pellet finally 
resuspended in 300µls of PBS, gently mixed and analysed on the flow cytometer.  In order to 
discriminate the three monocyte subpopulations (Mon 1-3), a multi-step flow cytometric 
method was developed previously (Figure 4; Shantsila et al., (2011)). Initially (Figure 4 a), 
light scatter characteristics were used to differentiate monocytes from other leukocytes 
(granulocytes and lymphocytes). This gated population was then analysed based on CD14 
versus CD16 staining to identify Mon 1, 2 and 3 (Figure 4 b). Further sub-analysis was then 
undertaken to assess the phagocytic activity (pHrodo fluorescence) of these monocyte 
subpopulations (Figure 7). 
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Figure 7: Flow cytometry gating for monocyte subset phagocytosis assay: Whole 
heparinised blood was incubated with E. coli pHrodo bioparticles and, after incubation, 
monocytes were stained with fluorescent anti-CD14 and anti-CD16 mAbs prior to lysis of red 
cells, fixation and flow cytometric analysis.  A- Utilising forward scatter and side scatter to 
differentiate between monocytes, granulocytes and lymphocytes in whole blood. B- 
Discrimination between Mon 1 Mon 2 and Mon 3 monocyte subsets according CD14 and 
CD16 surface expression. C- Frequency histogram to show the relative phagocytic activity of 
the three monocyte subsets combined. Region M1 highlights positive fluorescence indicative 
of phagocytosis of E. coli pHrodo bioparticles. 
 
 
The coefficient of variation of the phagocytosis assay was 5.4%, 7.1% and 1.4% for Mon 1, 
Mon 2 and Mon 3 respectively (table 11). These results were produced after analysing whole 
blood from three healthy individuals. 
Table 10: Inter assay variability of the monocyte subset phagocytic assay 
Parameter Subject 1 Subject 2 Subject 3 CV% 
Phagocytic activity of Mon 1 
(MFI) 
155.38 139.49 147.22 5.4 
Phagocytic activity of Mon 2 
(MFI) 
155.38 137.00 138.24 7.1 
Phagocytic activity of Mon 3 
(MFI) 
56.23 54.74 55.73 1.4 
CV, coefficient of variation. Phagocytic activity of Mon 1, Mon 2, and Mon 3 were highly 
reproducible.  
 
A B C 
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3.3.4 Analysis of monocyte CD14 and CD16 surface expression 
For the analysis of cell surface antigen expression by the three monocyte subsets, 100µl of 
whole blood was incubated with mouse anti-human monoclonal fluorochrome-conjugated 
antibodies for 15 minutes in the dark. Subsequently red blood cells were lysed with 2ml of 
BD lysing solution® for 10 min, followed by washing in PBS and immediate analysis by flow 
cytometry. The three monocyte subsets were defined as CD14++CD16– monocytes (Mon 1), 
CD14++CD16+ monocytes (Mon 2) and CD14+CD16++ monocytes (Mon 3) in accordance 
with contemporary guidelines (Ziegler-Heitbrock et al., 2010) using anti-CD16-Alexa Fluor 
488 (clone DJ130c, AbDSerotec, Oxford, UK) and anti-CD14-PerCP-Cy5.5 (clone M5E2, 
BD) antibodies.  
 
3.3.5 Effects of physical exercise on phagocytic activity of monocyte 
subsets 
Treadmill exercise was performed using Case 16 exercise testing system (Marquette Medical 
Systems Inc, Milwaukee, WI, USA) according to Bruce protocol with the volunteers 
exercising to exhaustion, as previously described (Watson et al., 2010). Venous blood samples 
were taken immediately pre-exercise, 15 minutes, 60 minutes and 24 hours post-exercise (four 
samples in total). The choice of time points for the post-exercise sampling was based on 
preliminary results from two volunteers with samples obtained at 15 minutes, 30 minutes, 1 
hour, 2 hours, 4 hours, 6 hours and 24 hours. These time frames were determined from a 
previous paper from the laboratory investigating the effect of exercise on monocyte counts 
(Shantsila et al., 2012). All participants were asked to abstain from other strenuous physical 
activity for the period of the study.  
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3.3.6 Diurnal variation 
Diurnal variations in monocyte subsets phagocytic activity were assessed in 6 healthy 
volunteers (age 36 ± 8.7 years, 5 male). Blood samples were taken at 6 hourly intervals, 
starting at 6 a.m. and finishing 6 a.m. on the following day (5 samples in total). 
  
3.3.7 CD14+ monocyte chemotaxis 
In a cross over study design, 100µl of patient plasma (5 patients having sustained STEMI, 5 
had STEMI and developed a MACE event, 5 stable coronary artery disease) was added to a 
2.5x105 of CD14+ cells isolated from healthy control subjects. These were placed in separate 
well inserts of an 8 well plate in triplicate. Control treatments were isolated monocytes with 
no patient serum, and isolated monocytes stimulated with 500ng/ml of LPS. The wells were 
placed in 8 well plate coated with 100µl of 100ng/ml of MCP1. The cell migration was then 
analysed using Cell-IQ® MLF (CM Technologies- Midland, ON, Canada). The samples were 
examined with 10x objective using a green filter cube and the number of migrating cells was 
recorded. The rate of migration was recorded hourly for a maximum of 9 hours. 
 
3.3.8 Statistical analysis 
Data distribution was assessed for normality by the Kolmogorov method (Wayne, 1990). Data 
are expressed as mean± SD for normally distributed parameters and median (interquartile 
range) for non-normally distributed parameters. Statistical significance of the difference in 
phagocytic activity between different monocyte subsets in health, disease and exercise was 
determined by repeated measures ANOVA with Tukey post-hoc analysis. The Friedman test 
was utilized for non-normally distributed parameters. A value of p<0.05 was considered 
statistically significant. Statistical analysis was performed with SPSS18.0 software and 
GraphPad Prism 4.0 software (La Jolla, CA, USA).   
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3.4   Results 
3.4.1 Characteristics of recruited subjects 
Healthy individuals recruited into the exercise programme were age 35.3±7.62 years (60% 
male). Healthy controls were recruited for the cross sectional study were age and gender 
matched to a group of STEMI and stable coronary artery disease patients. There were no 
differences between both groups in past medical history or medication at time of recruitment 
(Chapter 2, section 2.3.1 and appendix I).   
3.4.2 Chemotaxis of isolated monocytes 
In order to understand whether factors present in plasma may influence monocyte function, 
plasma from patients was incubated with primary monocytes from healthy donors and their 
migration to MCP1 was measured by cell IQ. There was no significant difference in monocyte 
migration to MCP1 between plasma from different patient groups (Figure8). The variance 
within group accounted for 15 %of the migrated cell number. There appeared to be a trend of 
increased rate of monocyte cells mobility in the MACE patients compared to SCD and STEMI 
patients who did not suffer from MACE with higher counts attained at the end of 9 hours. 
However, migration of monocyte subsets with no serum, and those stimulated with LPS also 
appeared to have a higher mobility rate compared to SCD and STEMI patients with no MACE. 
The total count of migrated CD14+ve cells incubated with MACE patients serum, isolated 
monocytes with no serum and isolated monocytes stimulated with LPS were higher at the end 
of 9 hours compared to counts from SCD and STEMI patients. It is very plausible that the 
serum of recruited patients had an inhibitory mechanism that controls the rate of monocytes 
chemotaxis and migration acutely. Isolated cells with LPS and those that are serum free lack 
this inhibitory effect and hence the rate of chemotaxis is higher. It appears that patients who 
suffered a MACE event loose this inhibitory effect and hence are able to migrate at a higher 
rate.  
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Figure 8: Monocyte migration to MCP-1 is affected by plasma from patients post-
STEMI: CD14++ monocytes (2.5x105) were isolated from 30ml of venous blood from healthy 
individuals. Isolated cells were then incubated with 100µl of recruited patients’ plasmas from 
MACE patients (n=5) STEMI patients (n=5, with uncomplicated recovery); stable coronary 
artery disease (n= 5, SCD). As controls each plate included isolated monocytes with no serum 
added, and isolated monocytes stimulated with LPS at 500ng/ml. The base of the well was 
coated with 100ng/ml of MCP-1 as the chemoattractant for subsets. The mobility of 
monocytes were measured using Cell-IQ® MLF. Data are expressed as the mean SD as error 
bars included in the SCD and isolated monocyte patients. One way Anova with Tukey post 
hoc analysis was utilised to test the differences between the different subject groups. There 
was a significant difference between MACE patients compared to stable coronary artery 
disease patients (SCD), and those who had STEMI but no MACE (p<0.001). 
 
3.4.3 Surface CD14 expression and effect on phagocytosis 
Given the high surface expression of CD14 (an LPS receptor) on both Mon 1 and Mon 2 and 
the phagocytosis E-coli bioparticles simulating a Gram negative organism (i.e. LPS-bearing), 
the requirement for CD14 in phagocytic activity was examined. CD14 expression was 
analysed versus E. coli uptake (i.e. MFI from phagocytosis assays). There was a negative 
correlation between the cell surface CD14 surface expression on Mon 1 cells and E. coli 
phagocytosis (r= -0.68, p=0.007), with a stronger negative correlation that was significant with 
Mon 2 (r= -0.64, p= 0.04). These data suggest that CD14 levels per se do not explain the 
different levels of phagocytosis noted within the subpopulations of monocytes.  Interestingly 
there appeared to be a positive correlation between Mon 3 and E. coli (noting that Mon 3 are 
only weakly positive for CD14) (Figure 9).   
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Figure 9: Mon 1 and Mon 2 subsets phagocytosis of E. coli correlates inversely with CD14 
expression: CD14 surface expression levels against uptake of E.coli bioparticles as mean 
fluorescent intensity (MFI). Statistical analysis was performed using simple correlation 
analysis. 
 
Given the inherent differences in monocyte subset functions assessed in the phagocytosis 
assay, it was of interest to identify the possible effect of physiology and pathology on this 
function. 
 
3.4.4 Effect of exercise on phagocytic activity 
The effects of exercise on the dynamics of phagocytic activity of monocytes was assessed in 
12 healthy volunteers (age 35.3 ± 7.62 years, 8 male). To address the effect of exercise on 
monocyte subset function, healthy subjects were subjected to an incremental treadmill 
exercise for 14 minutes (Bruce protocol), equivalent to 12.9 mets (Shantsila et al., 2012, 
Hamm et al., 2011, Watson et al., 2010). At various time points post-exercise, blood samples 
were harvested and phagocytic activity assessed in comparison to baseline (pre-exercise) 
levels.  The phagocytic activity of Mon 1 and Mon 3 was increased significantly at 24 hours 
post-exercise compared to baseline (pre-exercise) levels and 15 minutes post exercise (Table 
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11 and Figure ) (p= 0.003 and p= 0.006 for Mon 1 and Mon 3 respectively). There was no 
significant change in the phagocytic activity of Mon 2 at any time point following exercise.  
Table 11: Phagocytic activity of monocyte subsets is affected by exercise 
 Baseline 
(pre-
exercise) 
15 minutes 
post 
60 minutes 
post 
24 hours 
post 
p Value 
Phagocytic 
activity of 
Mon 1 (MFI) 
95 [65-115] 81 [61-118] 107 [73-139] 179 [73-195] 0.003 
Phagocytic 
activity of 
Mon 2 (MFI) 
84 [66-98] 78 [60-99] 85 [64-103] 65 [47-127] 0.71 
Phagocytic 
activity of 
Mon 3 (MFI) 
18 [12-28] 23 [12-32] 24 [16-44] 44 [22-50] 0.006 
MFI, median fluorescence intensity; non-normally distributed data are presented as median [with 
interquartile range]. 
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Figure 10: Phagocytic activity is increased in Mon 1 and Mon 3 after exercise: Healthy 
individuals (n=12) were exercised according to Bruce protocol until exhaustion. Phagocytic 
activity was measured as median fluorescence intensity (MFI) E. coli bioparticle uptake. 
Effect of time after exercise was determined by ANOVA. 
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3.4.5 Effect of circadian rhythm on phagocytic activity 
This was important in delineating the logistics of patient recruitment during the longitudinal 
study of recruiting STEMI patients, six patients were recruited to investigate if diurnal 
variation had any effect on phagocytic activity. The maximum phagocytic activity of all the 
three monocyte subsets was at 12:00. This was not statistically different form phagocytic 
activity at 18:00. Even though it was logistically impossible to recruit patients at the same 
time of the day, most patients were recruited till early afternoon in order to reduce the effect 
of circadian rhythm on the results.  
Table 12: Effect of diurnal variation on monocyte subsets phagocytic activity 
 06:00 12:00 18:00 00:00 06:00 p 
Value 
Phagocytic 
activity of 
Mon 1 
(MFI) 
126±24.4 161±10.9 137±16.5 94±17.9† 105±29.7 <0.00
5 
Phagocytic 
activity of 
Mon 2 
(MFI) 
117±24.4 161±7.54 127±7.56 88±16.4† 113±9.73 <0.00
5 
Phagocytic 
activity of 
Mon 3 
(MFI) 
38.7±8.29 58.4±13.6 57.5±5.95 33.6±6.80 52.5±36.8 0.21 
MFI, median fluorescence intensity, Normally distributed data are described as mean ± SD 
 
3.4.6 Phagocytic activity of monocyte subsets in different health states 
In a cross sectional study, a total of 40 STEMI patients, 20 patients with stable coronary artery 
disease (SCD) and 40 healthy individuals were recruited to investigate the effect of disease on 
monocyte subset phagocytic activity. Patients were matched for age, gender, and clinical 
charactersitics (Chapter 2, section 2.3.1 and appendix I) Phagocytic uptake of E. coli 
bioparticles by the three different monocyte subsets were significantly higher in STEMI 
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patients compared to stable coronary artery disease patients and healthy controls (p values of 
<0.0001, 0.004 and <0.0001 for Mon 1, Mon 2, and Mon 3 respectively- Table 13 and Figure 
11). There were no significant differences in phagocytic activity between stable coronary 
artery disease patients and healthy individuals (Table 13). 
Table 13: Phagocytic activity of the three different monocyte subsets varies with health 
states 
Monocyte subsets STEMI (n=40) Stable coronary 
disease (n=20) 
Healthy 
controls 
(n=40) 
pValue 
Phagocytic activity 
of Mon 1 (MFI) 
114 (97 – 129)  96 (73 – 114)  78 (55 – 102) <0.0001 
Phagocytic activity 
of Mon 2 (MFI) 
106 (84 – 121) 85 (66 – 107)  66 (47 – 97) 0.004 
Phagocytic activity 
of Mon 3 (MFI) 
52 (29 – 78) 34 (18 – 49) 39 (26 – 56) <0.0001 
CAD, coronary artery disease; MFI, median fluorescence intensity. Phagocytic activity of 
monocytes in peripheral blood was determined as E. coli pHrodo uptake. 
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Figure 11: Phagocytic activity of the three monocyte subsets in in STEMI and healthy 
controls: Mon 1, Mon 2, and Mon 3 counts were assessed 24 hours post infarction (N=40) 
and compared with age- and gender-matched healthy controls (N=40). Phagocytic activity of 
Mon 1, Mon 2, and Mon 3 were significantly higher in STEMI subjects compared to healthy 
controls (Mann- Whitney U test was performed as data were non-parametric, p=0.02, p=0.007, 
p=0.02 for Mon 1, Mon 2 and Mon 3 respectively).  
 
There was a significant increase in the phagocytic activity in all monocyte subpopulations 
from STEMI patients compared to those from healthy participants (Figure 11). Four-fold 
higher phagocytic activity was observed in Mon 1 compared to Mon 3 irrespective of health 
or disease.  
 
3.3.7 Phagocytic activity in STEMI patients  
The demographics of recruited STEMI patients are outlined in appendix I and Chapter 2, 
section 2.3.1.  
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The phagocytic activity of monocyte subsets in these STEMI patients (N= 209), did not 
change significantly when compared to the phagocytic activity at follow up 14 days post index 
event. This applied to all three monocyte subsets (p =0.36, 0.59, and 0.52 for Mon 1, Mon 2 
and Mon 3 respectively), (table 15).  
 
Table 14: Phagocytic activity of the three monocyte subsets is not affected over time after 
infarct :  
Median fluorescence intensity, MFI. Data are expressed median with (interquartile range) for 
non-normally distributed data 
  
Monocyte subsets Within the first 24 hours 
post infarct (n=209) 
At phase 2 post-infarct 
(n=149) 
pValue 
Phagocytic activity 
of Mon 1 (MFI) 
119 (101 – 146) 115 (95 – 140) 0.36 
Phagocytic activity 
of Mon 2 (MFI) 
119 (92 – 145) 113 (91 – 143) 0.59 
Phagocytic activity 
of Mon 3 (MFI) 
41 (29 – 55) 42 (26 – 57) 0.52 
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3.5   Discussion 
It is well described that during infarction there is an increase in surface expression of MCP-1 
as a ligand for CCR2 hence leading to monocyte chemotaxis to the area of infarction (Tacke, 
2007). Hence in order to investigate the function of monocyte after infarction the mobility of 
CD14+ monocyte subsets (Mon 1 and Mon 2) was investigated. Plasma from patients who 
had an adverse cardiac event on follow up (MACE) induced a higher rate of monocyte 
migration than from healthy controls, with higher cell numbers migrating to MCP-1 after 9 
hours, compared to other patient population groups. There was also a trend for higher cell 
density and faster migration rates by isolated monocytes with no cross over plasma, and in 
those stimulated with LPS. It is possible that the plasma of patients who have sustained a 
STEMI, with no MACE, or those with stable coronary artery disease to have a suppressive 
chemokine/cytokine in the microenvironment that impairs the mobility of monocytes to 
infarcted tissue in an attempt to reduce monocyte chemotaxis acutely. Patients who sustain 
MACE might lose this inhibitory braking mechanism hence the higher count rates that are 
equivalent to LPS stimulated cells and control cells without patient’s plasma. Here a 
reproducible, rapid flow cytometry-based technique was validated to assess phagocytic 
activity of monocyte subsets. As discussed in chapter 2, flow cytometry has been utilised to 
differentiate their identification based on cell surface expression of CD14 and CD16. The 
same immunophenotyping methodology was used to assess the phagocytic activity of these 
subpopulations (Figure 7). The methodology is highly reproducible (Table 11) and can be 
carried out on whole blood samples, processed within 2 hours of sample collection.  
Mon 1 the classically described monocyte subset, is inflammatory in nature and here they 
exhibited a high phagocytic activity when compared to the ‘non-classical’ Mon 3 subset (table 
14). This was evident in both the healthy subjects as well as patients following STEMI.  
However, for the first time, it has been shown that monocyte subset 2 (CD14++, CD16+) 
exhibits equivalent, high phagocytic activity to Mon 1 (Tables 13 and 14). With a high 
phagocytic activity, the likelihood of Mon 2 having reparative angiogenic role, comparable to 
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the well described Mon 3 subpopulation is debatable. Mon 3 subset has significantly lower 
phagocytic activity compared to Mon 1 and Mon 2 (Figure 11).   
The beneficial effect of exercise in reducing mortality from cardiovascular disease in 
individuals with coronary artery disease, as well as reducing the generalised inflammatory 
state associated with ageing has been intensely studied (Woods et al., 2012). The increase in 
phagocytic activity of Mon 1 and Mon 3 24 hours post-exercise is reported for the first time. 
We have demonstrated previously that the total number of monocytes increased 15 minutes 
post-exercise but did not significantly change post exercise (Shantsila et al., 2012). Previously 
Woods et al., in an animal model, illustrated that moderate exercise had a stimulatory effect 
on the phagocytosis and chemotaxis of monocytes, whilst rats exposed to progressive training 
over 6 weeks showed a decrease in macrophage phagocytic activity (Woods et al., 2003). It 
might be that the increase in phagocytic activity is due to a generalised inflammatory response 
induced by the moderate exercise that our healthy individuals participated in during the study 
irrespective of monocyte numbers. This effect might be lost in persistent progressive training, 
partly explaining the overall beneficial effect of persistent (even mild) exercise observed and 
utilised in cardiac rehabilitation programmes worldwide (Timmerman et al., 2008). An 
increase in reactive oxygen species release post exercise, as well as other inflammatory 
markers has been previously reported (Nahrendorf and Swirski, 2015). In healthy individuals 
endurance exercise was associated with release of troponin but no detectable cardiac 
inflammatory increase in late gadolinium enhancement or fibrotic changes on cardiac 
magnetic resonance (Woods et al., 2003). Understanding the effect of phagocytosis on 
conventional cardiovascular risk factors could provide an additional venue for risk factor 
modification amongst STEMI patients (Walsh et al., 2011).  
Within 24 hours of STEMI, the phagocytic activity of all three monocyte subsets was 
increased. Others have shown an increase in surface expression levels of scavenger receptors 
(e.g. CD163 and CXCR4) on Mon 2 with ejection lower fraction 6 weeks post STEMI 
(Shantsila et al., 2013). Having a high phagocytic activity would partly contribute to the effect 
of Mon 2 observed in predicting cardiovascular death and acute coronary syndromes in 
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patients with stable coronary artery disease (Rogacev et al., 2012). Studying this in 
conjunction with matrix metalloproteinase activity might shed might provide further 
understanding of the phagocytic effect of Mon 2. After STEMI cardiomyocytes die as a result 
of hypoxic injury. These dead apoptotic cells could attract monocytes and macrophages to 
phagocytose the dead cells to allow healing to initiate (Devitt and Marshall, 2011). 
Overzealous phagocytic activity early post infarct could account for the association of high 
counts of Mon 1 and a large size myocardial infarct and negative ventricular remodelling 
(Tsujioka et al., 2009, van der Laan et al., 2012). However this could excessive phagocytic 
activity could also be explained by reduced efferocytosis.  
Enhancing clearance will likely decrease secondary necrosis and inflammation, leading to 
reduced macrophage content in infarcted tissue and potentially reducing the development of 
autoimmune T-cells and circulating auto-antibodies (Tang et al., 2012). As humans we 
preferentially enhance phagocytic clearance of apoptotic cells over blocking macrophage 
apoptosis, because as has been established recently, a resting steady state of macrophages are 
required for healthy myocyte structure. It might be likely that blocking apoptosis of the 
phagocytes may contribute to increased cellularity and autocrine and paracrine inflammation 
due to non-clearance of the phagosome. Oxidative stress and hypoxia have also been reported 
as in vitro inhibitors of clearance and may play a role in post MI repair (Zhang et al., 2014). 
Aberrant calcium signalling has also been recently implicated in efferocytosis. Both 
extracellular and intracellular sources of Ca2+ have long been implicated in phagocytic 
signalling, particularly during uptake of opsonized particles (Hackam et al., 1997). Changes 
in extracellular Ca2+ concentration, a feature of infarcted myocardium, can directly affect the 
conformation and therefore capacity of phagocytic receptors to bind targets for engulfment. 
Aberrant calcium signalling has been recently implicated in efferocytosis as well.  
The data presented here suggest that the phagocytic activity of CD14+ monocytes are not 
CD14-dependent, despite these also being abundantly present on the surface of E. coli. Thus 
the detected results are reflective of the functional activity of monocytes and not merely a 
measurement of E. coli uptake. Phagocytosis of apoptotic polymorphonuclear cells was also 
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recently shown to be independent of CD14 with CD16+ve monocytes (both Mon 2 and Mon 
3) having a higher phagocytic activity of apoptotic cells (Mikolajczyk et al., 2009). However 
Lingnau et al., describe that monocytes have both CD14-dependent and CD14-independent 
phagocytic activity either of which could be enhanced by the effect of surrounding cytokines 
including IL-10 and IFN-gamma (Lingnau et al., 2007). 
With more data coming to light describing the transition of surface expression of CD16 on 
surface of monocytes and their function, it remains unclear whether Mon 2 is a separate entity 
of monocyte differentiation with their own differentiation end products (i.e. macrophages and 
dendritic cells); or whether they are a transient state observed between Mon 1 and Mon 3. 
Immunohistochemistry studies ought to be considered to address this question.  
Recently the phagocytic activity of monocytes has been shown to be independent of their 
downstream differentiated macrophages (Lund et al., 2002). There is a need to investigate the 
effect of the phagocytic activity of monocytes both on ventricular remodelling and on clinical 
outcome. Such new information may support the potential for phagocytic activity to be utilised 
as therapeutic target in improving patient outcome post infarction.  
 
3.6   Conclusion 
For the first time a flow cytometry-based technique to assess the phagocytic activity of the 
three monocytes subpopulations in whole blood has been described. Mon 2 appears to have a 
high phagocytic activity that is not statistically different from Mon 1 in healthy individuals or 
in patients with STEMI. This suggests that they might have predominantly an inflammatory 
role. The phagocytic activity was not dependent on CD14 surface expression. Moderate 
interrupted exercise appears to cause an increase in natural phagocytic activity. This paper 
provides a stepping stone in describing phagocytic activity of the three monocyte subsets that 
could be used on wide scale in clinical studies and clinical practice.  
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Chapter 4 
NFκB pathway activation in monocyte subsets 
in relation to STEMI 
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4.1   Introduction 
During myocardial infarction the acute hypoxic state associated with the infarction leads to 
overexpression of CCR2 and hence chemotaxis of monocytes.  
The NFκB pathway is also thought to be activated in monocytes during hypoxia. NFκB is one 
of the major transcription factors mediating inflammatory responses of monocytes and 
macrophages. Its activation leads to the production of proinflammatory and prothrombotic 
molecules, such as cytokines, MMPs, TF and IkB. Excessive activation of NFκB has been 
linked to inflammation associated with atherosclerosis (Kutuk et al., 2003). Thus, 
measurement of NFκB levels could be used as a surrogate for the functional assessment of 
monocyte inflammatory activity. 
In non-stimulated monocytes, NFκB is sequestered within the cytosol by an inhibitory protein 
(i.e., IκB; inhibitor of NFκB) that masks the nuclear localization signal present within the 
NFκB protein sequence. Upon stimulation IκB is phosphorylated by IKKβ, undergoes 
secondary ubiquitination and is degraded by the proteasome (Verma et al., 2004). The IκB 
kinase (IKK) complex is a phosphorylating enzyme with several subunits IKKα, IKKγ and 
IKKβ. The β subunit is the most active and is facilitates transcriptional activation by NFκB 
through phosphorylating IκB. The degradation of IκB thus allows NFκB to translocate into 
the nuclei where it can act as a transcription factor (Haden et al., 2004) (Figure 12).  
Excessive NFκB activation has been associated with negative ventricular remodelling (Gupta 
et al., 2005).  Myocardial tissues from patients with heart failure of various aetiologies exhibit 
activation of NFκB and increased expression of NFκB-regulated genes. Also, using gene 
transfer of IκB-α, Squadrito et al. demonstrated that repression of NFκB transcription in 
models of ischaemia-reperfusion injury reduced leukocyte recruitment to the myocardium, 
cardiomyocyte death and infarct size (Squadrito et al., 2003). A well-tolerated 
pharmacological NFκB inhibitor, BAY 11-7082, reduced inflammation in a rat model of 
ischaemia-reperfusion injury leading to a significant reduction in the infarct size.  
NFκB is activated in the heart during acute ischaemia and reperfusion and during unstable 
angina. Blocking NFκB activity reduces ischaemia–reperfusion injury in experimental studies 
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with short times of observation. Wong et al., 2008 showed that NFκB was activated in 
cardiomyocytes in failing hearts of patients with ischaemic heart disease, while similarly an 
increased NFκB expression was present in the fibrotic areas in patients with dilated 
cardiomyopathy. Later studies have confirmed that NFκB and its target genes are activated in 
cardiomyocytes of patients with failing hearts of various aetiologies and that the same is the 
case in mouse and rat models of heart failure (Gupta et al., 2005). 
The outstanding technical problem with the measurement of NFκB is that the resting cytosolic 
form and the activated nuclear form cannot be distinguished by flow cytometry. Active nuclear 
NFκB is normally detected in cell lysates with an electrophoretic mobility shift assay, Western 
blot assays or by detecting its binding to a consensus sequence promoter oligonucleotides. 
There are no data on monocyte subset NFκB activity in STEMI. Therefore, here a method to 
measure the cytosolic IKKβ as a surrogate for NFκB activation has been optimized. 
TNF-α is the most widely studied pro-inflammatory cytokine in cardiac pathophysiology. In 
murine models, TNF-α promotes progressive left ventricular dysfunction and remodelling in 
animal models. Serum TNF-α has been shown to be elevated in patients with heart failure and 
correlates with mortality. TNF-α stimulates NFκB as well as being a downstream product of 
the pathway stimulation. To further validate that IKKβ was a surrogate marker for NFkB 
activation, TNF-α secretion by monocytes was analysed after LPS activation. Furthermore, 
TNF-α, MMP- 9 and IKKβ activity were analysed in plasma from STEMI patients to 
investigate their interrelationship. 
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Figure 12: NFκB inflammatory pathway. Activation of the canonical NFκB pathway leads 
to downstream production of nuclearTNF-α and IKKβ. Its hypothesised that IKKβ is secreted 
back into the cytosol with a positive feedback loop on the NFκB pathway. Uprtream, 
activation of the NFκB  pathway occurs by LPS and TNF-α. Upon stimulation IκB is 
phosphorylated by IKKβ, undergoes secondary ubiquitination and is degraded by the 
proteasome (Verma et al., 2004). The IκB kinase (IKK) complex is a phosphorylating enzyme 
with several subunits IKKα, IKKγ and IKKβ. The β subunit is the most active and is facilitates 
transcriptional activation by NFκB through phosphorylating IκB. The degradation of IκB thus 
allows NFκB to translocate into the nuclei where it can act as a transcription factor. 
 
4.2   Aims and Hypothesis 
In this study the aim to validate a flow cytometry based assay for the measurement of IKKβ 
activity as a surrogate for NFκB pathway activation. The aim is to utilize this method to 
describe IKKβ activity of different monocyte subsets in different health states in a cross-
sectional study and also in STEMI patients over 6 months, as a longitudinal study.  
The aim is to describe the relationship between monocyte subsets, TNF-α and MMP- 9 levels.  
The hypothesis is that IKKβ levels will be higher in STEMI patients compared to other health 
states with decrease in the level of IKKβ activity in STEMI patients during the follow up 
period at the second phase. As a consequence of NFκB activation, I hypothesis that there will 
be an increase in TNF-α and MMP-9 levels in STEMI patients.  
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4.3   Methods 
4.3.1 Patient recruitment 
STEMI patients, subjects with stable coronary artery disease and healthy individuals were 
recruited into the study as discussed in chapter 2, section 2.3.1  
4.3.2 Assessment of NFκB pathway 
A flow cytometry based technique for measuring NFκB activation indirectly was developed 
by determining intracellular IKKβ levels in monocyte subsets. Blood was obtained from two 
healthy individuals (age 30 ± 2). 
4.3.2.1  Flow cytometry assessment of IKKβ levels 
Whole blood in EDTA (100µl) was added to 5 µl of CD16-AF 488 and 2.5µl CD14 PerCP-
CY5.5. The sample was then mixed gently on the vortex and incubated in the dark for 15 
minutes. Red cell lysis was then carried out by adding 2.0 ml of ‘PharmLyse’ solution, gently 
mixed and then incubated for 10 minutes in the dark. The sample was centrifuged for 5 minutes 
at 500g and the supernatant was removed by a disposable pipette. To stain the cells, 2ml of 
‘Staining Buffer’ was added to the tube, and the sample was centrifuged again for 5 minutes 
at 500g and the supernatant removed. After adding 500µl of ‘Fixation and Permeation’ 
solution [neutral pH-buffered saline (Dulbecco's Phosphate-Buffered Saline) that contains 4% 
w/v paraformaldehyde- BD], the sample was mixed and incubated for 20 minutes in the dark. 
The sample was spun again for 5 minutes at 500g and the supernatant removed. Washing was 
performed by adding 2 ml of ‘Perm-Wash’, incubating the cells afterwards for 10 minutes and 
then spinning for 5 minutes at 500g. Finally the supernatant was removed again and 10µl of 
anti-IKKβ-APC antibody was added to the sample and left to incubate for 30 minutes in the 
dark. A final washing step was repeated again with 2 ml of ‘Perm-Wash’ [BD Perm/Wash 
buffer: consists of 100 ml of concentrated stock solution (10X) containing both Fetal Bovine 
Serum (FBS) and saponin], spinning for 5 minutes at 500g. After removing the supernatant, 
50µl of 4% PBS (Sigma E8008) was added, mixed with the sample and then run through the 
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flow cytometer. This is a very reproducible assay with my interassay variability of 6.3% and 
intra-assay of 4.9% (Figure 13).  
 
 
Figure 13: Flow cytometric discrimination between the IKKβ expression of three 
different monocyte subsets: Monocyte subsets are distinguished according to CD14, CD16 
and CCR2 cell surface expression (panel C) after gating for total monocytes (panel A), and 
eliminating granulocytes (panel B). IKKβ expression of the different monocyte subsets (Mon 
1, Mon 2 and Mon 3 in panels D-F respectively) is detected by APC binding. 
 
4.3.2.2 Cell sorting and monocyte isolation 
Whole blood (30ml) was collected into EDTA from a healthy volunteer. Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient centrifugation. 
Blood was diluted 1:1 with 0.5 mM EDTA in PBS pH 7.1-7.7 (2-8 oC) (Sigma, E8008), 
carefully and slowly layered over the Ficoll-Hypaque in a 15 ml conical tube, with 1 volume 
of Ficoll-Hypaque used for 2 volumes of diluted blood. The tubes were then centrifuged for 
25 min at 1000 g with no break on deceleration (Hettich centrifuge). The upper layer is 
removed leaving the mononuclear cell layer undisturbed at the interphase. The interphase cells 
(consisting of lymphocytes and monocytes) are transferred to a new 15 ml conical tube. Ice 
cold PBS was added to form 15 ml total volume and then centrifuged for 10 min at 1900 at 
4C using the Eppendorf centrifuge. The supernatant was removed carefully and cells 
resuspended to a total volume of 15 ml with ice cold PBS.  The cells were washed twice with 
ice cold PBS at 4oC for 10 min at 430 g and repeated as necessary until the solution is clear.  
A B C 
E F D 
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Monocyte subsets were further isolated by magnetic sorting of the PBMC fraction using 
VarioMACS (Miltenyi Biotec, Düsseldorf, Germany) and direct labelling of CD14+ 
monocyte subpopulations using microbead-conjugated antibodies, using commercial 
monocyte Isolation Kit II (Miltenyi biotec 130-091-153). Per 3ml of collected whole blood, 
10µl of FcR blocking reagent was added with 10µl of Biotin-Antibody Cocktail. The cells 
were mixed by pipetting and incubated for 10 minutes at 4-8 oC.  Then 30µl of MACS buffer 
were added for every 3ml of blood along with 20µl of anti-biotin microbeads. The mixture 
was mixed well and incubated for 15 minutes at 4-8 oC. After washing the cells for 10 minutes 
at 270 g, the supernatant was removed and the cells resuspended in 500µl of MACS buffer. 
The LS column was in the meantime prepared by rinsing with 3ml of buffer and the cell 
suspension applied. This was washed 3 times with 3mls of buffer on each occasion. The eluent 
was collected in the same falcon tube containing the isolated CD14+ cells (Figure 14).  
 
Figure 14: Cell sorting protocol for isolation of monocyte subsets from whole blood 
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Monocyte subsets obtained by cell sorting were suspended at a density of 1x106 cells⁄ml, in 
culture medium consisting of RPMI-1640, fetal bovine serum supplemented with 2 mM L-
glutamine, 100µg/ml gentamycin and 100µg/ml penicillin. Cell suspensions were incubated, 
at 37°C, in a 5% CO2 humidified atmosphere, in the presence or absence of 1µg/ml 
lipopolysaccharide (LPS) endotoxin (Escherichia coli 0127:B8). Cells were harvested and 
incubated CD16-Alexa Fluor 488 (clone DJ130c, AbD Serotec, Oxford, UK) and CD14-
PerCP-Cy5.5 (clone M5E2, BD) for 15 min. After adding 500µl of ‘Fixation and Permeation’ 
solution [neutral pH-buffered saline (Dulbecco's Phosphate-Buffered Saline) that contains 4% 
w/v paraformaldehyde], the sample was mixed and incubated for 20 minutes in the dark. The 
sample was spun again for 5 minutes at 500g and the supernatant removed. Washing was 
performed by adding 2 ml of ‘Perm-Wash’ [BD Perm/Wash buffer: consists of 100 ml of 
concentrated stock solution (10X) containing both foetal bovine serum (FBS) and saponin].  
The cells were incubated afterwards for 10 minutes and spun for 5 minutes at 500g. Finally 
the supernatant was removed again and 10µl of ‘IKKbeta-APC’ antibody added to the sample 
and incubated for 30 minutes in the dark. A final washing step was repeated again with 2 ml 
of ‘Perm-Wash’, spun for 5 minutes at 500g. After removing the supernatant, 50µl of 4% 
PFA/PBS (Sigma E8008) was added, mixed with the sample and analysed by flow cytometry. 
 
4.3.2.3 Detection of NFκB protein after pathway activation 
NFκB nuclear binding was assessed by using an ELISA based NFκB TransAM transactivation 
kit (Active Motif, Carlsbad, Calif) according to manufacturer’s instructions. Nuclear extract 
was prepared from 2.5x105 isolated CD14+ that had been incubated with 50µl of STEMI 
patients’ plasma. Nuclear protein (75µg/well) were loaded in 96-well plates pre-coated with 
consensus oligonucleotides, and the active- NFκB that bound to the oligonucleotide was 
detected HRP-conjugated secondary antibody. The absorbance was read using a plate reader 
at 450nm, and absorbance was expressed as the direct activity of NFκB. 
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4.3.2.4 Localisation of IKKβ in LPS stimulated CD14+ve monocytes 
Isolated cells (2.5x105, 200 µl) in RPMi were added to microscope slides. The cells were left 
to adhere for one hour at room temperature in a dark, moist box. Then fixation 
permeabilisation agent was added for 15 minutes at room temperature.  After wash with 
permeabilisation buffer twice by dipping slides in 50mls of buffer, the slides were left to dry 
prior to staining with IKKβ antibody. Slides were incubated for 30 minutes in a dark humid 
environment at room temperature. The slides were then washed once again with perm wash 
and allowed to dry for few seconds. Slides were mounted with a drop of mounting agent and 
fixed with a cover slip. A Leica Microsystems TCS SP5II system was used with a 63x 
objective lens (HCX PLAPO 63x/1.4-0.6 oil CS) and with 488nm laser to excite the anti-IKKβ 
fluorophore-conjugated antibody.  
 
4.3.3 Measurement of MMP- 9 concentration using ELISA 
MMP- 9 levels were measured in plasma using an enzyme-linked immunosorbent assay 
(ELISA) (R&D systems- USA). The capture antibody was diluted with PBS. One hundred µl 
of the diluted capture antibody was used to coat a 96 well microplate. The plate was then left 
at room temperature overnight. The plate was washed three time with washing buffer. The 
plates were then blocked with 300 µl of reagent diluent and the plate is incubated for 1 hour. 
The plates were washed afterwards three times and left to dry. 100µl of patient plasma is then 
added in triplicate to the plates and left to incubate in room temperature for two hours. The 
plate was washed and aspirated three times and then 100 µl of detection antibody was placed 
to each well and incubated for further two hours. After 10 minutes of incubation at room 
temperature in a light-protected environment the reaction was stopped using 0.5M sulphuric 
acid and the plate was read immediately using a microplate reader at an absorbance of 450 
nm. Data were analysed using GraphPad Prism (GraphPad Software, California, USA) and 
unknown sample concentrations were calculated against the calibration curve generated from 
the plate standards. The intra-assay coefficient of variation was 4.1–6.9% and inter-assay 
coefficient of variation of 5.8–6.3%. 
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4.3.4 Measurement of TNF-α concentration using ELISA 
TNF-α levels were measured using a quantitative enzyme immunoassay technique (Peprotech, 
Rocky Hill, NJ, USA). Respective monoclonal antibodies specific for TNF-α were pre-coated 
onto a microplate. Standards and samples were pipetted into the wells and any TNF-α present 
was bound by the immobilized antibody. A polyclonal antibody specific for TNF-α conjugated 
to peroxidase was added to the wells. Following a wash to remove any unbound antibody- 
enzyme reagent, ABTS substrate solution was added to the wells and left to develop for 20 
minutes before the reaction was stopped with 0.5M sulphuric acid. The absorbance was read 
using a microplate reader at 430 nm. The concentration of TNF-α in plasma was analysed 
using GraphPad Prism (GraphPad Software, California, USA) against the calibration curve 
generated from the known standards. 
 
4.4   Results 
4.4.1 In vitro proof of concept studies of NFκB activation pathway 
A novel flow cytometry based methodology was developed for the detection and 
quantification of IKKβ subunit activity upon NFkB pathway activation. A number of 
experiments were designed to validate the flow cytometry methodology. 
4.4.1.1 IKKβ expression in whole blood after LPS stimulation 
The first step was to confirm that primary monocyte activation elicited an increase in IKKβ 
expression. LPS was selected to activate monocytes as it elicits robust and reliable of NFkB 
activity in monocytes.  Here whole blood was stimulated with different LPS concentrations 
for up to 3 hours. There was an increase in IKKβ level of CD14+ve cells stimulated cells both 
with prolonged incubation time and in response to higher LPS concentrations (Figure 15). 
However at 20µg/ml concentration of LPS the detectable IKKβ was reduced suggesting that 
such high concentrations of LPS lead to cell toxicity and death. 
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Figure 15: IKKβ levels increase in monocytes in whole blood stimulated with LPS: Blood 
was venesected from two healthy individuals (age: 28±3). Whole blood was venesected from 
two healthy volunteers. The blood was stimulated with increasing concentrations of LPS and 
allowed to incubate for different times. Red blood cells were lysed and stained IKKβ 
antibodies. Samples were run in duplicates. There was an increase in IKKβ levels in response 
to longer incubation with increasing concertation of LPS. A concentration of 20µg/ml led to 
a decrease in IKKβ levels probably due to cell toxicity at higher concentrations. Data are 
presented as mean with (SD- error bars).  
 
4.4.1.2 IKKβ activity in isolated CD14+ cells after LPS stimulation 
As a proof of concept, an in vitro study was carried out to determine the time frame for IKKβ 
transcription and detection in the cytosol. Whole blood was obtained from two healthy 
volunteers (one male and one female; age 28±3). Isolated monocytes were stimulated with 
four different concentrations of LPS and incubated for 24 hours. The supernatant from the 
cultured monocytes were removed and cells stained for IKKβ antibody and analysed by flow 
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cytometry at 0, 3, 12 and 24 hours after incubation with LPS. (Figure 16). The higher 
concentrations of LPS (500ng/ml and 1µg/ml) led to highest levels of IKKβ levels at 12 hours 
and 24 hours. Mean fluorescence intensity for IKKβ antibody was higher at 1µg/ml of LPS 
stimulation compared to 500ng/ml. The maximum detected median fluorescent intensity of 
IKKβ was higher at 24 hours than three hours post LPS stimulation.  
 
 
Figure 16: LPS increases IKKβ in monocyte populations after 24h:The response of (A) 
purified monocyte subpopulation 1 (CD14+veCD16-ve CCR2+ve) and (B) monocyte 
subpopulation 2 (CD14+veCD16+ve CCR2+ve) measured as the IKKβ mean fluorescence 
intensity (MFI) after stimulation with LPS (100ng/ml, 500ngml, 1ug/ml LPS) for 1, 2, 3, 12 
and 24 hours (n-=1) At each time point there was a control sample with no LPS added. A 
group of samples (0 hour) was also analysed immediately after LPS stimulation. 
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4.4.1.3 IKKβ activity in isolated CD14+ cells after LPS stimulation with NFκB 
inhibition 
To confirm that the increase in IKKβ level was due to NFκB activation, monocytes were 
isolated from the whole blood of a third healthy subject (age 36) with the addition of SN50 (a 
peptide that inhibits translocation of the NF-κB active complex into the nucleus). There was 
an increase in IKKβ levels with increasing concentrations of LPS and with prolonged 
incubation periods. However there was no change in IKKβ in the presence of the highest LPS 
concentration and SN50 (Figure 17). 
 
Figure 17: IKKβ levels upon LPS stimulation as well as incubation with SN50: Monocytes 
(2.5x105) isolated from one healthy individual were stimulated with different concentration of 
LPS (100ng/ml; 500ng/ml; 1ng/ml) as well as with SN50 (NFKB pathway inhibitor) all 
incubated with RPMI. 100 µl of supernatant was removed at different time points (Hr 
0,3,12,24) these were then prepared and stained with IKKβ antibody and analysed on the flow 
cytometer. There was an increase in IKKβ levels with increasing concentrations of LPS and 
with prolonged incubation periods. However there was no change in IKKβ in the presence of 
SN50. Differences between groups was assessed by Anova statistical test.  
 
4.4.1.4 TNF-α secretion by LPS stimulated CD14+ monocytes 
NFκB pathway activation, and hence detection of IKKβ, leads to downstream production of 
various pro inflammatory cytokines, including TNF-α and IL-6. Thus, to confirm that the 
activation of monocytes with LPS was associated with downstream gene expression, 
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transcription and activation, an ELISA for TNF-α was performed on the supernatants from 
isolated monocytes after stimulation with LPS for different time periods (0, 3, 12, 24 hours). 
TNF-α secretion from primary monocytes of different healthy donors increased with longer 
incubation time and with increasing LPS concentrations studied here (Figure 18).  
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Figure 18: TNF-α secretion from LPS stimulated isolated monocytes: Isolated CD14+ve 
monocytes (2.5x105) from one healthy individual were stimulated in the presence and absence 
of LPS (100g/ml; 500ng/ml; 1µg/ml) in RPMI over a period of incubation. TNF-α secretion 
in the supernatant was determined using ELISA. Supernatant was collected at 0, 3, 12 and 24 
hours. The experiment was repeated using monocytes isolated from two healthy individuals 
(A and B plots; age 28±3). Results are presented as means ± SD (as error bars). 
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4.4.1.5 NFκB protein in cross over study 
We utilised the TransAm method, in order to detect NFκB protein as a confirmatory 
experiment using more standard techniques to detect activation. In a plasma cross over study 
100µl of serum from different patient population was incubated with isolated monocyte cell 
(2.5 x105). 
There was a significant increase in NFκB protein after 12 hours of incubation compared to the 
first hour (p=0.02- paired t-test; Figure 19)  
This corresponded to a change in CCR2 levels detected by flow cytometry 
 
Figure 19: Nuclear NFκB is increased in CD14+ monocytes from healthy donors by 
plasma from STEMI patents: Monocytes isolated from whole blood of one healthy 
individual (female; age 33), were incubated with 20 µl plasma from STEMI patients for 12 
hours. Nuclear NFκB was determined using TransAM ELISA. There was a significant 
increase in NFκB protein after 12 hours of incubation compared to the first hour (p= 0.02- 
paired t-test). 
 
 
The level of the corresponding CCR2 levels on surface of isolated monocyte CD14+ cells 
were measured after 1 hour and 12 hours stimulation with LPS in vitro. CCR2 levels were 
significantly higher at one hour of stimulation compared to 12 hours (p <0.001). 
The number of viable analysable cells measured at both time points was not statistically 
different (mean ± SD: 325± 37 at 1 hour compared to 297 ± 48 at 12 hours, p= 0.12) – (Figure 
20).  
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Figure 20: Surface CCR2 expression is decreased after 12 hours of cross over study 
with patients’ plasma: Monocytes isolated from whole blood of one healthy individual 
(female; age 33), were incubated with plasma from STEMI patients for 12 hours. CCR2 
levels were significantly higher at one hour of incubation compared to 12 hours (paired t-
test, p<0.001). 
 
 
Having indicated an increase in NFκB levels are detected in the cross over studies after 12 
hours of incubations, the different levels of NFκB expression were then investigated in 
different patient population groups to establish if there was a difference amongst different 
groups. 
 
4.4.1.6 NFκB protein levels in different patient population groups 
Isolated monocytes (2.5x105) were stimulated with the serum of different groups of recruited 
patients (5 stable coronary artery disease patients; 6 STEMI patients; 6 STEMI patients who 
sustained a MACE; 4 healthy controls all in duplicates. NFκB levels were significantly higher 
in STEMI and patients sustaining a MACE (p= 0.002, Figure 21).  
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Figure 21: NFκB protein levels in different patient population groups after cross over 
study: Isolated CD14+ve cells (2.5x105) cells have been incubated for 12 hours with plasma 
from different patient population groups (6 STEMI patients, 6 MACE patient, 5 stable 
coronary artery disease (SCD), 4 healthy controls in duplicates). NFκB protein levels were 
significantly higher in STEMI patients and MACE patients at 12 hours compared to stable 
coronary artery disease. 
 
 
4.4.1.7 Cytosolic IKKβ visualization 
Finally, we attempted to visualize and localize the IKKβ protein detected using confocal 
microscopy. Monocytes were isolated and slides prepared, as described in methodology. The 
IKKβ protein was found to be cytoplasmic (Figure 22).  
Having validated the methodology in vitro the NFκB activity pathways of different monocyte 
subpopulation were examined in STEMI and CAD.   
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Figure 22: Cytoplasmic staining with IKKβ APC antibody in a proof of concept: This is 
demonstrated witth the pink halo around the nucleus (blue) of isolated cells (panel B). This is 
in comparison to control cell with no LPS stimulation or plasma crossover studies (panel A) 
 
4.4.2 IKKβ activity in different health states 
In order to investigate the ilammatory activity of monocyte subpopulation, IKKβ levels of the 
three different monocytes were measured in three different inflammatory vascular disease 
states represented by three different patient groups: ST elevation myocardial infarction 
patients within 24 hours of the infarct representing a high inflammatory state; patients with 
established stable coronary artery disease representing a chronic inflammatory state; and 
healthy individuals with quiescent inflammatory state. 
The levels of IKKβ were significantly higher in all three monocyte subsets in STEMI patients 
within one day of infarct compared to those with stable coronary artery disease or healthy 
individuals. IKKβ levels were significantly higher in STEMI patients compared to subjects 
with stable coronary artery disease patients and healthy individuals (p=0.002) (Figure 23). 
IKKβ activity was not significantly different amongst stable coronary artery disease and 
healthy individuals (p=0.25) (Figure 23).  
 
A B 
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Figure 23: IKKβ expression is higher in monocyte subsets from STEMI patients: 
Monocyte subsets from 40 STEMI patient, 40 healthy participants and 20 stable coronary 
artery disease patients were compared for cellular IKKβ expression. Results are shown as 
mean ±SD, differences between groups have been analysed by one way anova with post hoc 
Tukey analysis.  
 
 
4.4.3  NFκB pathway activity in STEMI patients 
 
4.4.3.1 Patient demographics 
209 STEMI patients were recruited to examine the effect of time on NFκB activation and 
outcome; the characteristic demographics are summarized in chapter 2, section 2.4.3 
4.4.3.2 IKKβ level of activity in STEMI patients 
There was a statistically significant decrease in the levels of IKKβ activity between day1 and 
follow up, which is consistent with the concept that inflammation reduces post-infarction 
(Table 16).  
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Table 15: IKKβ expression in monocytes from STEMI patients: 
 Index Admission 
(N= 209) 
Two weeks post MI 
(N= 140) 
 
p Value 
IKKβ Mon 1 (MFI) 
 
71 ±26 64 ± 22 0.007 
IKKβ Mon 2 (MFI) 
 
67 ± 23 65 ± 24 0.396 
IKKβ Mon 3 (MFI) 
 
71 ± 23 66 ± 19 0.010 
A paired t-test was used to investigate the difference between IKKβ activity at index event 
and two weeks afterwards. IKKβ levels of Mon 1 and Mon 3 were significantly higher at day 
14 than day 1 
 
4.4.4 Monocyte numbers correlate with circulating TNF-α and MMP- 9 
To investigate the relationship between monocyte subset counts with other markers of 
inflammation, plasma TNF-α and MMP- 9 were examined, as critical factors in tissue 
remodelling and as markers of ongoing inflammatory activity regulated by NFκB pathway 
activation.  
 
4.4.4.1 Patients’ demographics 
Of the 209 STEMI patients recruited, 162 plasma samples were available for measuring TNF-
α and MMP- 9 levels.  
The average age of patients that were recruited with STEMI was 61± 11 (mean ± SD) with 
75% male.  As reflected from general patients characteristic, chapter 2, section 2.4.3, there 
was abundance of classical cardiovascular risk factors amongst recruited patients; with 54% 
suffering from hypertension, 53% were smokers, 46% suffered from hypercholesterolaemia, 
and 17% had history of angina or previous MI. Eighty one percent of patients had either an 
anterior or an inferior infarct (43% and 38% respectively). Consistent with the existing 
vascular disease risk factors of the recruited patients, 38% were on aspirin, 25% were on 
calcium channel blockers for hypertension management, 19% were prescribed β- blocker 
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therapy, whilst 24% regularly took diuretic therapy (both thiazide and loop diuretics, 10% and 
14% respectively (table 17).  
Table 16: STEMI patient demographics 
One hundred and sixty two patients had plasma available for measurement of TNF-α and 
MMP- 9. GFR: glomerular filtration rate; CVA: cerebrovascular accident; CABG: coronary 
artery bypass grafting; PCI; percutaneous coronary intervention; STEMI: ST elevation 
myocardial infarction. Normally distributes data are described as mean ± SD, non-normally 
distributed data are presented as median (with range). 
 
      
N= 162 
 
Demographics Age 61 ± 11 
Gender 
Time from symptoms onset to 
presentation to hospital (hours) 
75% males 
 
4.7 ± 2.6 
  
                              Peak Troponin 2340 (843 – 6397) 
Peak Creatinine Kinase 
Total WCC (mmol/L) 
959 (452 – 2189) 
11 (8 – 13) 
Biochemical profile at 
recruitment  
Estimated GFR 
(ml/min/1.73m2)   
Total Cholesterol (mmol/L) 
Body surface area 
 
77 (63 – 90) 
4.9 (4.3 – 5.3) 
1.9 (1.8 – 2.0) 
 
  
Diabetes 39 (24) 
Hypertension 94 (58) 
Smoking  86 (53) 
Hypercholestrolaemia 75 (46) 
Past medical history at 
the point of recruitment 
History of angina 9 (6) 
Previous myocardial infarction 28 (17) 
[Number and (%)] Obesity 27 (17) 
COPD 21(13) 
CVA 14 (9) 
CABG 9 (6) 
Previous PCI 17 (10) 
Anterior infarct 69 (43) 
 
Inferior STEMI 62 (38) 
 
  
 
Aspirin 62 (38) 
Clopidogrel 4  (2)  
Statin therapy 61 (4) 
Calcium channel blocker 41 (25) 
Drug history at 
recruitment  
[Number and (%)] 
Beta blocker 
Loop diuretic 
Thiazide diuretic 
ACE inhibitor 
Nitrates 
31 (19) 
23 (14) 
15 (10) 
70 (13) 
9 (6) 
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4.4.4.2 Monocyte subset correlation with plasma MMP- 9 
There was a significant correlation between MMP- 9 levels at day 1 post STEMI with total 
monocyte count, Mon 1 and Mon 2 (p<0.001). There was no correlation between MMP- 9 and 
functional studies as assessed by phagocytosis or IKKβ levels. At day 2 there were no 
correlations between monocyte numbers and MMP- 9 (Table 18).  
 
Table 17: MMP- 9 correlation with monocyte subsets and functional parameters 
 MMP- 9 day 1 MMP- 9 day 2 
R2 p Value R2 p Value 
Total Monocyte count  0.43 <0.001 0.01 0.91 
Mon 1 (cells/µl) 0.39 <0.001 0.03 0.77 
Mon 2 (cells/µl) 0.28 <0.001 0.03 0.81 
Mon 3 (cells/µl) 0.02 0.79 -0.19 0.09 
IKKβ Mon 1 (MFI) -0.01 0.87 0.22 0.06 
IKKβ Mon 2 (MFI) -0.01 0.87 0.17 0.15 
IKKβ Mon 3 (MFI) 0.06 0.43 0.17 0.14 
Phagocytosis Mon 1 
(MFI) -0.04 * 0.64 0.10 0.37 
Phagocytosis Mon 2 
(MFI) 0.02 * 0.82 0.17 0.14 
Phagocytosis Mon 3 
(MFI) -0.01 * 0.94 0.01 0.96 
Pearsons correlation was utilized to assess correlation of MMP- 9 with monocyte subsets and 
functional parameters.(* Phagocytosis parameters are non-parametric, hence Spearmans 
correlation was performed). 
 
4.4.4.3 Monocyte subset correlations with TNF-α 
There was a significant correlation between TNF-α at day 1 with total monocyte count, Mon 
1, Mon 2 and Mon 3 (p<0.001). Functionally, IKKβ activity of Mon 1 and Mon 2 (p<0.001 
and 0.006 respectively) were correlated with α. There was no correlation between TNF-α at 
day 14 with monocyte subsets (Table 19).  
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Table 18: TNF-α correlation with monocyte subsets and functional parameters 
 TNF-α day 1 TNF-α day 14 
R2 pValue R2 pValue 
Total Monocyte count  0.64 <0.001 -0.07 0.62 
Mon 1 (cells/µl) 0.60 <0.001 0.03 0.83 
Mon 2 (cells/µl) 0.26 <0.001 -0.17 0.25 
Mon 3 (cells/µl) 0.27 <0.001 -0.14 0.36 
IKKβ Mon 1 (MFI) 0.41 <0.001 -0.19 0.22 
IKKβ Mon 2 (MFI) 0.27 0.006 -0.14 0.36 
IKKβ Mon 3 (MFI) 0.06 0.53 -0.10 0.53 
Phagocytosis Mon 1 
(MFI) 0.05 * 0.58 -0.02 0.91 
Phagocytosis Mon 2 
(MFI) 0.17 * 0.07 -0.02 0.88 
Phagocytosis Mon 3 
(MFI) 0.16 * 0.09 0.22 0.13 
Pearsons correlation was utilized to assess correlation of MMP- 9 with monocyte subsets and functional 
parameters. (*Phagocytosis parameters are non-parametric, hence Spearmans correlation). 
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4.5   Discussion 
In this study a validated flow cytometric based methodology for the assessment of NFκB 
inflammatory pathway activation is presented. This approach uses the measurement of IKKβ 
as a surrogate marker in monocytes in whole blood after transcription and activation of the 
NFKB inflammatory pathway. This has been validated in both in-vitro and in-vivo 
experiments. There is a clear difference in detected IKKβ correlating with TNF-α, in STEMI 
patients compared to steady state of healthy individuals or patients with stable coronary artery 
disease.  
Upon incubation of isolated monocytes with patients’ plasma, there was an increase in the 
level of CCR2 expression in the supernatant of the isolated cells within 1 hour. NFKB protein 
was significantly increased in those samples 12 hours after incubation with patients’ plasma. 
This suggests that an increase in CCR2 expression in response to a stimulant in STEMI 
patients’ microenvironment led to activation of NFKB pathway 12 hours later. Chandrasekar 
and Freeman observed two waves of NF-κB activity in the heart after ischaemia–reperfusion. 
In their experiments, they observed NF-κB activity following 15 min of ischaemia and 15 min 
of reperfusion, which lasted until 1 h of reperfusion. The second wave began at 3 h of 
reperfusion and lasted until 6 h   
In recruited STEMI patients there was a significant correlation between plasma TNF-α and 
total monocyte count, the three monocyte subsets and IKKβ levels of Mon 1 and Mon 2. This 
is in keeping with the in vitro studies that are summarized in figures 17 and 18 where TNF-α 
levels increased after stimulation with LPS and corresponded in an increase IKKβ levels. 
MMP- 9 on the other hand also correlated significantly with total monocyte count, Mon 1 and 
Mon 2, this could support the hypothesis that MMP- 9 is secreted by monocytes in response 
to hypoxia and reperfusion injury.  
The interaction between NFκB pathway activation and TNF-α is complex and intricate: on the 
one hand NFκB pathway activation leads to downstream secretion and release, and on the 
other hand TNF-α is one the stimulants of the canonical NFκB pathway. Hence in the heart, 
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the interaction between TNF-α could lead to a vicious cycle of propagated inflammation and 
concurrently myocyte cell death or indeed uncontrolled apoptosis.   
The literature illustrates that there are two varying roles for NFκB pathway activation. On the 
one hand, the cardioprotective role of NFκB signalling has been described in a number of 
studies. De Moissac et al. reported that Bcl-2 suppresses cell death of ventricular myocytes 
through a mechanism involving IKKβ mediated activation of NFκB pathway (de Moissac et 
al., 1998). Cardiac-specific expression of a similar IkB mutant increased the susceptibility of 
myocytes to apoptosis following acute coronary occlusion in vivo (de Moissac et al., 1998, 
Gordon et al., 2011), whereas p50 null mice displayed enhanced cardiac dysfunction following 
myocardial infarction. This finding is supported by recent evaluation of a natural occurring 
human polymorphism in the p50 gene that is associated with increased functional deterioration 
in patients with heart failure (Gordon et al., 2011).  
The effect of monocyte stimulation of NFκB pathway stimulation on cardiac remodelling post 
infarct as well as clinical outcome in STEMI patients post infarction is discussed in chapters 
5 and 6.  
 
4.6   Conclusion 
Here we describe a prompt, reproducible technique for measuring the activity of NFκB 
pathway. STEMI patients had an increased level of IKKβ at day one compared to phase 2. 
IKKβ was significantly higher in STEMI patients compared to patients with stable coronary 
artery   
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Chapter 5 
Monocyte subsets and their functional assessment in 
determining ventricular remodelling and ventricular 
deformation post STEMI 
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5.1   Introduction 
Post myocardial infarction the healing myocytes undergo complex geometrical changes as 
individual muscle cells and globally as an organ leading to alterations in the overall shape, 
size and function of the left ventricle, as the main pumping chamber of the heart, as well as 
overall of the heart as an organ.  
The occurrence of left ventricular (LV) dilatation after acute myocardial infarction is not 
uncommon. Giannuzzi et al. noted severe LV remodelling 6 months after infarction in 16% of 
the patients (Giannuzzi et al., 2003). The clinical importance of LV remodelling was 
emphasized by White et al., who demonstrated that patients who died during follow-up after 
myocardial infarction had significantly larger LV volumes and lower left ventricular ejection 
fractions (LVEFs) than survivors (Frangogiannis, 2008, White et al., 2014). Furthermore, they 
indicated left ventricular end-systolic volume (LVESV) as the primary predictor of survival 
after myocardial infarction. As a consequence, early identification of patients with LV 
remodelling after acute myocardial infarction is of vital importance to initiate secondary 
prevention medication in an aim to reduce future risk profile.  
Several mechanisms implicated in LV remodelling have been identified, including 
hypertrophy, fibrosis, apoptosis, and activation of proteolysis. These processes lead to changes 
both in the systolic and diastolic functions of the heart. Hence there has been a number of 
definitions for ventricular remodelling post infarction, with increasing in LV diastolic volume, 
reduction in systolic volumes or reduction in ejection fraction. However, over the last years 
LV remodelling post infarction was defined in a number of studies as an increase in left 
ventricular end diastolic volume of 20% as indexed to body surface area (LVEDVI). This is 
the definition utilised in assessing LV remodelling in his study. 
 
5.1.1 Extracellular matrix and heart remodelling  
Previous basic science studies have provided a cause-effect relation between MMP- 9 and 
adverse LV myocardial remodelling after MI. The results from these murine models suggest 
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that the robust increase in plasma MMP- 9 levels observed early after MI likely reflects the 
initiation of an adverse myocardial structural remodelling process that is manifested as LV 
dilation in the later post-MI period.   
 
A landmark paper described in murine models the sequential mobilisation and delivery of 
monocyte/macrophage phases in the immediate period after a myocardial infarction and later 
in the ensuing recovery period. In the initial phase post infarction, Ly-6chigh monocytes give 
rise to early inflammatory macrophages, both ultimately clearing damaged tissue by 
phagocytosis and secreting proteolytic enzymes. In the second phase, Ly-6clow macrophages 
facilitate wound healing and regeneration by promoting myofibroblast accumulation, collagen 
deposition, and angiogenesis. Infiltrated monocytes may also interact with extracellular matrix 
in the damaged myocardium, leading to fibronectin release (Frantz and Nahrendorf, 2014). 
Once in the infarct, monocytes differentiate into macrophages in the presence of M-CSF. 
There are two macrophage subset, M1 and M2. It is yet unclear which monocyte subset 
differentiate into which macrophage subtype (van Amerongen et al., 2007). Macrophages 
promote angiogenesis, fibroblast proliferation, and extracellular matrix deposition. 
Macrophages also play a role in organ regeneration (Godwin et al., 2013). Though MI in adult 
mammals leads to scarring and diminished ventricular function, neonatal mouse hearts can 
regenerate after MI without scarring, but depleting cardiac macrophages impedes this repair 
process. A recent study by Pinto et al. showed that embryonic-derived cardiac macrophages 
promote angiogenesis and healing after myocardial damage (Pinto et al., 2012). Consistent 
with this, salamander limb regeneration also depends on macrophages (Godwin et al., 2013). 
Although inflammation is required for cellular debris removal and new tissue formation after 
ischaemic injury, exaggerated inflammation may impede the healing process, as shown in 
ApoE−/− mice with coronary ligation (Panizzi et al., 2010). Accordingly, blood monocyte 
count after MI positively correlates with left ventricular end-diastolic volume and negatively 
correlates with ejection fraction in patients.  
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5.1.2 Monocytes in heart remodelling  
As the precursor of macrophages and dendritic cells monocytes have been previously reported 
to have an important role in timely “wound” healing post myocardial infarction with early 
phagocytosis of infarcted cells allowing for appropriate scar formation and hence containing 
and limiting the ensuing dilatation of cardiac chambers and volumes thus limiting the chance 
of adverse remodelling. In recent years however, peripheral monocytosis was demonstrated 
to be associated with worse clinical outcome with small series replicating these finding in 
STEMI patients.  
Evidence supporting the hypothesis of monocyte functional diversity in MI in vivo is 
supported by the findings of sequential mobilisation of monocyte subsets, firstly in mouse 
(Nahrendorf et al., 2007)  and more recently in humans (Tsujioka et al., 2009) . As discussed 
in chapter 1, sequential mobilisation of subsets is thought to be due to the orchestrated due to 
expression of subset- specific s. In the mouse model of MI, the Ly-6Chigh monocyte subset 
predominated within the myocardium during phase I after MI (peak level on day 3) and was 
found to exhibit phagocytic, proteolytic and inflammatory activity. In contrast, the Ly-6Clow 
monocyte subset predominated in phase II after MI (peak on day 7) and was implicated in 
myocardial healing and recovery processes, including anti-inflammatory properties, 
promotion of myofibroblast accumulation, angiogenesis and collagen deposition (Nahrendorf 
et al., 2007). In humans, the CD14+CD16- and CD14+CD16+ monocyte subsets peaked in 
the circulation on days 3 and 5 respectively after MI (Tsujioka et al., 2009). Tapp et al. 
indicated that classical monocytes and intermediate monocytes were associated with worse 
reduced EF 6 weeks post infarct (Tapp et al., 2012). Only two studies investigate the role of 
monocyte subsets 
 
5.1.3 Inflammatory markers and heart remodelling  
Tumor necrosis factor-α (TNF-α) is a master cytokine that is produced in significant quantities 
within the infarcted myocardium very soon after MI. TNF-α is secreted primarily by myocytes 
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and macrophages after injury (Kapadia et al., 1997). As discussed in chapter 4, there is an 
intricate relationship between TNF-α and the inflammatory pathway NF-κB. TNF-α binds to 
cell surface receptors and triggers intracellular signalling cascades that can result in activation 
of transcription factors such as NFκB (Mustapha et al., 2000). TNF-α also has direct effects 
on the matrix and collagen framework and is a potential major contributor to cardiac 
remodelling. In addition, TNF-α has direct effects on the matrix and collagen framework and 
is a potential major contributor to cardiac remodelling. TNF-α actives other cytokines such as 
IL-1 and IL-6 and orchestrates the host tissue response to acute injury Here we measure TNF-
α, as an established marker of cardiac remodelling, and investigate its possible role with 
monocyte subsets and ventricular remodelling.  
 
5.1.4 Echocardiogram in assessing heart remodelling 
Transthoracic standard echocardiography (standard echo) is a widely available method; it is 
non-invasive and can be performed bedside. From a cost-benefit point of view, standard echo 
is the preferred method for evaluating left ventricular function. However, an 
echocardiographic examination is highly dependent on the examiners experience and has 
limitations in patients with obesity, obstructive pulmonary disorders or a poor acoustic 
window for other reasons, a limitation of three dimensional echocardiography as well. Given 
its high spatial resolution magnetic resonance imaging (MRI) is considered more sensitive in 
measuring ventricular volumes and ejection fraction.  
Left ventricular (LV) remodelling following acute myocardial infarction (AMI) is a dynamic 
and complex process that develops in the response to myocardial damage. However, the exact 
determinants of this process are not completely understood. The assessment of LV 
remodelling parameters after AMI has therapeutic and prognostic implications as advanced 
LV re-modelling is associated with developing and progression of heart failure. Moreover, 
traditional echocardiographic parameters such as LV volumes and ejection fraction, wall 
motion score index, mitral regurgitation, and left atrial volume have been shown to provide 
prognostic information for LV remodelling.  
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Given the complexity and multidirectional cardiac fibres contractility as well as the multitude 
of molecular and histological changes associated with infarct healing and remodelling not all  
In order to assess of novel parameters, including strain (and strain rate) imaging based on 
speckle tracking imaging. 
(STI) echocardiography or strain determining regional myocardial deformation measured by 
Doppler technique. Deformation studies, have already been correlated with degree of LV 
systolic dysfunction post infarction and with clinical outcome, with better sensitivity even 
than ejection fraction. In earlier technology strain assessment by Doppler is limited to the 
measurement of movement parallel to the ultrasound beam, whereas speckle strain may be 
measured independently of the angle, and measures regional deformation  has thus speckle 
tracking has been found to predict the extent of myocardial injury post infarction as validated 
by CMR.  
 
5.2   Aims and Hypothesis 
The aim of this study was to prospectively identify that the associations of monocyte subsets 
and their functional parameters with systolic and diastolic function parameters. I also 
investigated the impact of monocytosis post STEMI on ventricular remodelling post STEMI 
and on the effect of monocyte subsets. 
  
I hypothesised that the presence of higher counts of monocyte subsets 1 and 2 are associated 
with reduced ejection fraction 6 months after myocardial infarction as well as negative 
ventricular remodelling with a significant increase in end diastolic volumes at 6 months. In 
patients with normal or mildly impaired ejection fraction I hypothesised that high counts of 
monocyte subsets are predictive of reduced subclinical parameters of impaired systolic 
function namely, global and circumferential longitudinal strain.  
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5.3   Methods 
5.3.1 Patient recruitment 
All patients were recruited as summarized in appendix I and chapter 2, section 2.3.1.  
 
5.3.2 Transthoracic echocardiography 
Transthoracic echocardiography uses ultrasound waves to provide detailed imaging of the 
heart. It is non-invasive, portable and rapidly available making it the primary imaging 
modality for the assessment of cardiac anatomy and function. 
 
5.3.2.1 Basic principles 
Ultrasound waves are inaudible mechanical vibrations with a frequency greater than 20,000 
cycles per second (20 KHz) that induces alternate refractions and compressions of the physical 
medium through which they pass. They are generated from the piezoelectric crystals within 
the transducer of the echo machine. An alternating current expands and compresses polarized 
particles within the crystal generating a burst or pulse of ultrasound wave which is transmitted 
(propagates) through tissue (medium) as a straight beam. The acoustic properties of the media 
determine how much of the beam is reflected, refracted (changes the direction of the wave) 
and attenuated (absorption of ultrasound energy) and are the basis of ultrasound imaging. The 
reflected ultrasound energy is received by the piezoelectric crystal in the transducer and 
converted to low amplitude voltage signals. The signal undergoes complex manipulation to 
form an image (Armstrong et al., 2010). 
 
5.3.2.2 Imaging modalities 
Advances in echo technology now allow multiple image displays. A summary of echo 
properties facilitating the study (A, 2009):  
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1. Motion (m) mode - allows a single dimension of anatomy to be graphically presented 
against time. It allows a high repetition frequency of the pulse transmission and receive phase 
of the transducer. The high sampling rate is valuable for evaluation of rapid intra-cardiac 
motion of continuously moving structures.  
2. Two-dimensional imaging (2D) – generated by sweeping of the ultrasound beam made up 
of multiple scan lines across the tomographic plane. Reflected ultrasound signals from each 
scan line are received by the transducer to generate a cross-sectional image depicting structure 
and function in real time. 
3. Doppler imaging- based on the change in frequency of the backscattered signal from small 
moving structures. It is frequently used to assess the velocity, direction and pattern of intra-
cardiac blood flow. 
 
5.3.2.3 Imaging Protocol 
I performed all echocardiograms both at recruitment and at follow up 6 months post infarction. 
These were carried out at the Centre for Cardiovascular Sciences in City Hospital and at   
Birmingham Heartlands Hospital cardiology department depending on the patients’ 
recruitment site. I used second harmonic imaging on a Phillips machine with multi-frequency 
phased-array transducer (1.5 MHz). Patients were positioned in a left decubitus positioning 
with ECG. Standard parameters for chamber quantification, left ventricular systolic and 
diastolic function are outlined in Table 20. All measurements were made in triplicate and 
averaged according to the recommendations of the American Society of Echocardiography 
(Lang et al., 2006). Studies were performed on the same model of the Phillips machine across 
all sites.  
 
Mitral inflow velocities – measured using pulse wave Doppler with the sample volume at the 
tips of the mitral valve during diastole. Measurements include the peak early filling (E-wave) 
and late diastolic filling (A-wave) velocities, the E/A ratio and deceleration time (DT) of early 
filling velocity. Traditionally E/A has been used to assess diastolic function as a marker of the 
109 
LA-LV pressure gradient, however both are effected by increasing age (E velocity and E/A 
ratio decrease and DT and A velocity increase), heart rate and rhythm disturbance. 
 
Colour m-mode propagation velocity (Vp) – measured in an A4C view using a colour m 
mode Doppler through the centre of the LV with measurement of the slope of the first aliasing 
velocity during early filling. It is a marker of LV diastolic function which measures the mitral-
apical flow rate. In the normal ventricle there is rapid early filling of the LV (LV suction) 
driven by the LA-LV pressure gradient. 
 
Isovolumic relaxation time – measured by continuous wave Doppler positioned in the LVOT 
outflow, simultaneously showing the onset of mitral inflow and end of aortic ejection. 
Impairment of myocardial relaxation reduces the LA-LV pressure gradient. The isovolumic 
relaxation period is therefore increased until LV pressure is < LA pressure and the mitral valve 
opens.  
 
Myocardial performance Index (MPI) / Tei index – A Doppler-derived index of combined 
systolic and diastolic myocardial performance. It compares the total systolic time from mitral 
valve closure to mitral valve opening with systolic time involved in actual aortic flow  
 
5.3.2.4 Myocardial deformation 
The echocardiographic measurement of myocardial deformation provides a series of regional 
and global quantitative measures of myocardial function and contractility. Given the 
organization of the cardiac fibre and its complex anatomy. Assessment of this is done by 
deformation indices include strain, strain rate and torsion which provide a more direct 
assessment of intrinsic myocardial contractility than EF or wall motion analysis (Mor-Avi et 
al., 2011). Strain (S) is a measure of deformation (%) and refers to the change in myocardial 
length from an applied force. Strain rate (SR) is the time course of the deformation (s-1) and 
is derived from the difference of two velocities normalized to the distance between them. By 
110 
convention, ventricular contraction shortens longitudinal and circumferential fibres giving a 
negative strain and radial fibres lengthen and thicken giving positive strain. As such, normal 
longitudinal contraction is defined by negative systolic strain followed by biphasic positive 
diastolic strain corresponding to early and late diastolic filling.  
Newer 2D speckle tracking (Doppler independent) semi-automated techniques for assessing 
deformation are accurate, well validated and not effected by 1D methodology limitations 
(Amundsen et al., 2006). Blocks of speckles in a discrete location are tracked from frame to 
frame (simultaneously in multiple regions) and tissue displacement data is derived from which 
strain and strain rates can be calculated. Two dimensional grey scale images from the apical 
four and two chamber views with sector depth and width optimised, were acquired at end-
expiration at a frame rate ≥80 / second. The endocardial border was manually tracked at end-
systole using commercially available software (Q-Lab 9- Philips). The software automatically 
defined the epicardial and mid myocardial line within the region of interest and calculates the 
frame to-frame displacements of the speckle-pattern throughout the cardiac cycle (Figure 24). 
The advantage of speckle tracking include: quantification of deformation indices in any 
direction within the imaging plane and in simultaneous ROIs, less angle dependence and less 
time consuming semi-automated off-line analysis packages (BD, 2011). 
All analysed images were recorded with a frame rate of at least 40 fps for reliable analysis by 
the software. First, the LV end-systolic frame was defined by determining the closure of the 
aortic valve in the apical long-axis view. Then the time interval between R-wave and aortic 
valve was automatically measured and used as a reference for the four- and two-chamber 
views. After defining the mitral annulus and LV apex with three index points in all three apical 
views, the LV endocardial border was automatically traced at end-systole and the created 
region of interest was manually adjusted to the thickness of the myocardium. Segments which 
failed to track by the software were manually adjusted by the operator. Any segments which 
subsequently failed to track were automatically discarded by the software for the calculation 
of global strain (Phillips Q lab 9 manual). Analysis was feasible in 90% of the segments. 
Global longitudinal peak systolic strain for the complete LV was provided by the software 
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using a 17-segment model in a ‘bull’s eye’ plot calculated as the average of longitudinal or 
circumferential peak systolic strain of each view. 
 
Figure 24: An example of speckle tracking of Q-lab and cardiac delineation- A. B Bulls-
eye illustrating areas of reduced deformation (blue coloured segments: The 
echocardiogram is a highly reproducible assessment of cardiac volumes. My inter observer 
coefficient of variation ranged from 4.9-8.8% (Table 19). 
 
 
B 
A 
112 
Table 19: Echocardiogram inter-observer variability  
 Chamber volumes Systolic function Diastolic function RV function 
 ESV EDV LA 
volume 
EF TIE 
index 
SV FS E/A MV 
Dec 
E/E’ 
septal 
E/E’ 
lateral 
TAPSE FAC 
Subject 1              
           Day 1  32 80 18 63 0.1 70 35 1.1 269 8 10 17 25 
           Day 2 33 82 20 59 0.1 68 33 1.3 251 7 9 18 26 
           Day 3 28 75 21 62 0.1 65 32 1.4 268 7 9 18 26 
           Day 4 30 86 22 64 0.1 72 30 1.3 267 7 10 17 27 
           Day 5 33 72 19 60 0.1 76 35 1.2 250 6 10 20 26 
Standard deviation  2.17 5.57 1.58 2.7 0 4.14 2.12 0.11 9.61 0.71 0.55 1.22 0.71 
Coefficient of Variation 
(%) 
 
6.95 
 
7.04 
 
7.95 
 
3.37 
 
0 
 
5.9 
 
6.4 
 
9.05 
 
3.68 
 
10.1 
 
5.70 
 
6.8 
 
2.72 
Subject 2              
           Day 1 48 60 25 51 0.2 65 40 0.9 216 6 9 21 23 
           Day 2 40 66 26 48 0.3 72 37 0.9 189 6 9 22 23 
           Day 3 45 68 28 49 0.3 84 36 0.8 254 6 10 23 26 
           Day 4 49 69 24 47 0.2 78 40 0.8 268 7 9 23 26 
           Day 5 44 75 26 51 0.1 80 39 0.8 248 7 8 24 27 
Standard deviation 3.6 5.4 1.5 1.8 0.0 7.4 1.8 0.05 24 0.55 0.71 1.14 1.87 
Coefficient of variation 
(%) 
 
7.9 
 
8.1 
 
5.7 
 
3.6 
 
0 
 
9.8 
 
4.7 
 
6.5 
 
9.5 
 
8.6 
 
7.9 
 
5 
 
7.5 
Subject 3              
           Day 1 60 100 25 56 0.3 66 28 1 199 6 10 20 29 
           Day 2 58 95 22 60 0.3 79 28 1.1 210 6 11 20 29 
           Day 3  54 90 25 58 0.3 75 30 1.2 222 6 9 19 29 
           Day 4 59 99 26 51 0.25 73 31 1 187 6 10 18 26 
           Day 5 54 95 28 55 0.3 70 29 1.1 224 5 11 18 26 
Standard deviation 2.8 3.9 2.2 3.4 0.02 4.9 1.3 0.08 15.6 0.44 0.84 1 1.64 
Coefficient of variation 
(%) 
 
4.9 
 
4.1 
 
8.6 
 
6.1 
 
7.7 
 
6.8 
 
4.5 
 
7.7 
 
7.5 
 
9.7 
 
13 
 
5.3 
 
5.9 
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Subject 4               
           Day 1 55 90 26 63 0.1 80 35 1.4 170 4 6 21 31 
           Day 2 45 75 28 65 0.1 85 36 1.3 201 4 8 21 29 
           Day 3 49 88 29 61 0.1 76 37 1.3 188 5 7 18 32 
           Day 4 52 86 30 59 0.3 79 34 1.2 166 4 4 18 32 
           Day 5  58 84 27 63 0.3 80 38 1.2 205 4 9 18 31 
Standard deviation 5.1 5.8 1.6 2.3 0 3.2 1.6 0.08 17.6 0.44 0.84 1.64 1.22 
Coefficient of variation 
(%) 
 
9.8 
 
6.9 
 
5.6 
 
3.7 
 
0 
 
4.1 
 
4.4 
 
6.5 
 
9.4 
 
10.6 
 
11.6 
 
8.6 
 
4 
Subject 5              
          Day 1 45 60 27 62 0.2 76 40 1.1 167 8 5 19 32 
          Day 2 46 65 25 66 0.3 66 42 1.3 175 7 6 19 32 
          Day 3 44 66 24 59 0.3 67 45 1.4 184 8 6 17 29 
          Day 4 39 75 26 61 0.2 79 39 1.5 168 5 6 16 30 
          Day 5 40 80 28 68 0.1 70 42 1.4 187 7 6 16 31 
Standard deviation 3.1 8.1 1.6 3.7 0.08 5.7 2.3 0.15 9.1 0.54 0.44 1.51 1.30 
Coefficient of variation 
(%) 
 
7.3 
 
11 
 
6.1 
 
5.9 
 
0 
 
7.9 
 
5.5 
 
11 
 
5.2 
 
7.2 
 
7.7 
 
8.7 
 
4.2 
Average coefficient of 
variation (%) 
 
7.4 
 
7.6 
 
6.8 
 
4.5 
 
1.5 
 
6.9 
 
5.1 
 
8.2 
 
7.1 
 
8.8 
 
8.2 
 
6.9 
 
4.9 
Interobserver variability of the echocardiogram study performed on 5 different subjects on 5 consecutive times.  I was blinded to patient’s recruitment status or past 
medical history. Average of coefficient of variation was between 1.5 – 8.8. Subjects recruited were healthy individuals with no prior cardiac history
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5.3.3 TNF-alpha and MMP- 9 
These were performed by ELISA on recruited patient’s plasma as described in chapter 4 section 
4.3.3 and 4.3.4. 
 
5.3.4 Statistical analysis 
All data in this work were analysed using SPSS version 21 (SPSS Inc., Chicago, Illinois, USA) 
as well as GraphPad Prism version 6. Normality of data distribution for each variable was 
determined using the Kolmogorov-Smirnov test and normality plots. Normally distributed 
variables are presented as mean ± standard deviation and analysed using parametric tests. Any 
non-normally distributed variables were analysed as non-parametric data and were quoted as 
median (interquartile range). Inter-group comparisons were performed using independent t-tests 
(two groups) or a one-way analysis of variance (more than two groups). Non parametric data 
were analysed using a Wilcoxon t-test for independent data and within group analysis was 
performed using Kruskal-Wallis. Within-group comparisons across different time points between 
recruitment and follow up were assessed using paired samples t-test. In case of non-parametric 
measures between-group comparisons across different time points were performed using a 
repeated measures analysis of variance, with the time point. Linear regression analysis was 
performed to determine the relationship between continuous outcome variables. Correlation 
parametric variables were assessed using Pearson’s correlation and any non-parametric variables 
assessed using Spearman’s. Categorical variables were presented as frequency (percentage) and 
analysed using the Pearson and two tailed significance was reported. A Type I error rate below 
5% (p <0.05) was considered statistically significance. In correlation statistics between 
echocardiographic parameters and monocyte counts as well as functional assessment of 
monocytes, the statistical significance is established at p <0.01, in order to reduce the possibility 
of random associations given the number of studied parameters. 
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5.4   Results 
5.4.1 Parameters of echocardiographic study 
A total of 172 patients went on to have the first echocardiogram at recruitment, of those 121 
attended their second echocardiogram at 6 months post infarction with remaining subjects having 
either died or did not attend the invitation or follow up echocardiogram. Using dependent t-test 
for parametric data, or Wilcoxon test for non-parametric data, the echocardiographic parameters 
between the two sampling point were compared (Table 20).  
End systolic indexed volume (ESVI) and end diastolic indexed volume (EDVI) were both 
significantly increased in the second echocardiogram compared to first echocardiographic study, 
p= 0.01 and p <0.001, respectively. 
LV Ejection fraction by Simpson’s biplane was not statistically different between the first and 
second echocardiogram study. The Tei index, fractional shortening, and strove volume with 
higher in the first 24 hours compared to six months post infarction (p = 0.03, p <0.001, and p 
<0.001 respectively).  
As for the diastolic parameters of cardiac function, the deceleration rate and isovolumic relaxation 
time (p=0.62) (IVRT), as well as E/A ratio were prolonged at follow up compared to the post 
infarct study, p <0.001 and 0.02 respectively.   
In deformation studies the global longitudinal strain (GLS) were significantly lower in the first 
24 hours compared to 6 months after infarction, p <0.001.  
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Table 20: Echocardiographic study parameters of recruited patients undergoing both 
echo studies 
 Parameter Within the 
first 24 hours 
post infarct 
(121) 
Six months 
post infarct 
(N= 121) 
p Value 
Chamber 
volumes 
End systolic volume 
/ml (ESV) 
41 (32-54) 42 (33-55) 0.17 
End systolic volume 
index ml/m2 (ESVI) 
21 (16-27) 18 (15-23) 0.01 
End diastolic volume 
/ml (EDV) 
88 (74-102) 84 (65- 110) 0.59 
End diastolic volume 
index ml/m2 (EDVI) 
37 (31-50) 
 
45 (39-53) <0.001 
LA volume /ml 43 (32-53) 46 (36-51) 0.02 
LV systolic 
function  
EF SIMPSON’S 
biplane 
50 (43-56) 50 (43-56) 0.66 
Tie index 0.28 ± 0.14 0.3± 0.16 0.03 
Stroke volume 51 (35-69) 17 (11-56) <0.001 
LV diastolic 
function 
MV E/A 1.2 (0.9-1.5) 0.9 (0.8-1.2) 0.02 
MV deceleration time 210 (164-246) 204 (120-248) 
 
<0.001 
IVRT  98 (69-121) 84 (58-120) 0.02 
EE’ lateral 8.4 (6.6-11.4) 9 (7-11) 0.72 
EE’ septal  11 (8-13) 9 (6-16) 0.08 
RV function 
FAC of RV 33 (27-38) 31 (28-38) 0.02 
TAPSE 19 (17-22) 19 (14-22) 0.47 
Deformation 
study 
parameter 
GLS 
 
-14 (-16 - -11) 
 
-16 (-18 - -13) 
 
<0.001 
 
GCS 
 
-15 (-20- -11) -16 (-21 - -11) 0.31 
Dependent t-test was used for analysing parametric variables. Wilcoxon t-test was used to 
interrogate non-parametric data. The following parameters were significantly higher in the first 
48 hours post recruitment compared to the 6 months follow up study: ESVI, EDVI, LA volume, 
Tei index, stroke volume, fractional shortening, MV deceleration time, IVRT, FAC (Fractional 
area change) of the right ventricle (RV). GLS, global longitudinal strain; GCS global 
circumferential strain. Data are expressed as mean ± SD for normally distributed data or as 
median with (interquartile range) for nonparametric data. 
 
5.4.2 Monocytes correlation with echocardiographic study 
Using linear regression analysis all monocyte subpopulations were negatively associated with EF 
within the first 7 days post admission (R2 = 0.6, 0.7 and 0.3 for Mon 1, Mon 2 and Mon 3 
respectively; p). At 14 days only Mon 2 remained correlated with R of 0.6, p =0.02). 
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At day 1 total monocyte count, Mon 1 and Mon 2 were negatively associated with TEI index as 
another determinant of systolic function (p <0.0001).  
The fractional area change (FAC) of the right ventricle was also associated with total monocyte 
count and Mon 1. IKKβ Mon 1, Mon 2 and Mon 3 were associated with SV. Phagocytic activity 
of Mon 2 was associated with ejection fraction (EF).  
When associating monocyte subset counts and their functional assessment parameters with the 
second echocardiogram 6 months post infarction, there remained to be a negative association 
between total monocyte count, Mon 1, and Mon 2 with ejection fraction (Table25). Higher total 
monocyte count, Mon 1 and were associated with reduced EF (R= -0.42, p<0.001; R= -0.33, 
p<0.001), with a very week correlation and for Mon2.  
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Table 21: Association of monocyte subset counts with different parameters measured on echocardiography at the point of recruitment 
 
Total monocyte count, Mon 1 and Mon 2 had significant negative association with systolic function parameters including EF and TIE index. The former 
two were also associated with fractional area change (FAC) of the right ventricle. ESV- end systolic volume; ESVI- end systolic volume indexed to body 
surface area; EDV- end diastolic volume; EDVI- end diastolic volume indexed to body surface area; LA- left atrium; EF- ejection fraction; SV- stroke 
volume; FS- fractional shortening  
  
 Chamber Volumes Systolic function Diastolic function Right heart 
ESV ESVI EDV EDVI LA 
volume 
EF TEI 
index 
SV FS E/A MV 
Dec 
E/E’ 
septal 
E/E’ 
lateral 
TAPSE FAC 
Total monocyte 
count/ µl 
               
           R  0.181 0.190 0.189 0.200 0.178 -0.429 0.345 -0.191 0.063 0.025 0.048 0.089 0.101 0.032 0.233 
           p Value 0.018 0.019 0.013 0.015 0.019 <0.0001 <0.0001 0.043 0.613 0.789 0538 0.248 0.303 0.730 0.003 
Mon 1/ µl                
           R  0.177 0.179 0.216 0.207 0.151 -0.343 0.304 0.152 0.099 0.002 0.007 0.050 0.055 -0.029 0.212 
           p Value 0.021 0.028 0.005 0.012 0.040 <0.0001 <0.0001 0.068 0.247 0.981 0.927 0.517 0.473 0.698 0.006 
Mon 2/ µl                
           R  0.048 0.112 0.014 0.071 0.202 -0.288 0.205 0.148 0.252 0.079 0.154 0.025 0.074 -0.176 0.071 
           p Value 0.533 0.173 0.854 0.391 0.008 0.0001 0.007 0.046 0.003 0.303 0.046 0.749 0.336 0.022 0.364 
Mon 3/ µl                
           R  0.109 0.130 0.043 0.021 -0.006 0.159 0.094 -0.051 0.093 0.087 0.182 0.062 -0.874 0.141 0.113 
           p Value 0.157 0.114 0.576 0.802 0.942 0.038 0.221 0.541 0.278 0.257 0.018 0.420 0.257 0.065 0.147 
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Table 22: Association of monocyte subset functional parameters with echocardiographic findings  
 
At day 1: IKKβ 1 and IKKβ 2 were negatively associated with TIE index and stoke volume. With IKKβ 3 also positively associated with SV (stroke 
volume). ESV- end systolic volume; ESVI- end systolic volume indexed to body surface area; EDV- end diastolic volume; EDVI- end diastolic volume 
indexed to body surface area; LA- left atrium; EF- ejection fraction; SV- stroke volume; FS- fractional shortening  
  
 
 Chamber volumes Systolic function Diastolic function Right heart 
ESV ESVI EDV EDVI LA 
volume 
EF TIE 
index 
SV FS E/A MV 
Dec 
E/E’ 
septal 
E/E’ 
lateral 
TAPSE FAC 
IKKß 1                
           R -0.089 -0.117 -0.119 -0.157 0.04 0.099 -0.222 0.38 0.15 -0.09 -0.47 0.06 -0.08 0.12 -0.12 
           p Value 0.252 0.159 0.123 0.059 0.61 0.196 0.004 <0.0001 0.10 0.22 0.55 0.47 0.30 0.11 0.15 
IKKß  2 
           R  
 
-0.112 
 
-0.160 
 
-0.121 
 
-0.18 
 
0.05 
 
0.068 
 
-0.238 
 
0.30 
 
0.17 
 
-0.07 
 
-0.08 
 
0.07 
 
-0.09 
 
0.15 
 
-0.15 
           p Value 0.149 0.053 0.118 0.03 0.52 0.377 0.002 0.0003 0.06 0.39 0.29 0.35 0.23 0.06 0.05 
IKKß  3                
           R  0.007 -0.064 0.025 -0.04 0.06 -0.065 -0.118 0.29 0.07 -0.04 0.04 -0.01 -0.08 0.002 -0.15 
           p Value 0.931 0.443 0.751 0.63 0.47 0.404 0.128 0.0006 0.45 0.574 0.63 0.86 0.33 0.98 0.06 
Phagocytosis 1                
           R  0.082 0.106 0.048 0.05 -0.10 -0.102 0.100 -0.03 0.03 0.01 -0.01 0.15 0.04 -0.07 -0.12 
           p Value 0.291 0.206 0.539 0.55 0.22 0.189 0.196 0.73 0.72 0.93 0.94 0.06 0.63 0.40 0.13 
Phagocytosis 2                
           R  0.154 0.161 0.131 0.13 -0.06 -0.154 0.07 0.06 0.01 0.03 -0.05 0.09 0.08 -0.03 -0.13 
           p Value 0.046 0.054 0.091 0.12 0.42 0.007 0.34 0.49 0.90 0.66 0.52 0.27 0.32 0.70 0.10 
Phagocytosis 3                
           R  -0.042 -0.115 -0.041 -0.14 0.03 -0.027 -0.017 -0.001 -0.02 -0.01 -0.07 0.17 0.004 -0.04 0.04 
           p Value 0.59 0.170 0.575 0.099 0.75 0.727 0.826 0.99 0.79 0.93 0.36 0.03 0.99 0.62 0.62 
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Table 23: Relationship between matrix metaloproteinases and TNF-α with echocardiographic study parameters at day 1 after recruitment  
 
There was a week but highly significant negative association between MMP- 9 and TNF-α with EF. ESV- end systolic volume; ESVI- end systolic volume 
indexed to body surface area; EDV- end diastolic volume; EDVI- end diastolic volume indexed to body surface area; LA- left atrium; EF- ejection 
fraction; SV- stroke volume; FS- fractional shortening  
  
. 
 
 
 
 
Chamber volumes Systolic function Diastolic function Right heart 
ESV ESVI EDV EDVI LA 
volume 
EF TIE 
index 
SV FS E/A MV 
Dec 
E/E’ 
septal 
E/E’ 
lateral 
TAPSE FAC 
MMP- 9                
           R  0.15 0.09 0.03 -0.01 0.09 -0.24 .03 0.08 -0.17 0.09 -0.11 0.05 0.05 -0.13 0.11 
           p Value 0.14 0.35 0.71 0.91 0.31 0.004 0.73 0.39 0.09 0.32 0.21 0.59 0.57 0.13 0.20 
TNF-α                 
           R  0.27 0.25 0.27 0.20 0.08 -0.40 0.32 -0.14 -0.16 -0.03 -0.03 0.02 0.04 -0.06 0.12 
           p Value 0.005 0.02 0.005 0.06 0.41 <0.0001 0.001 0.18 0.14 0.78 0.79 0.85 0.58 0.52 0.24 
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Table 24: Relationship of monocyte subset counts with different parameters measured on echocardiography at phase two of sampling 
 
Total monocyte count, Mon 1 and Mon 2 had significant negative association with systolic function parameters including EF and TIE index. ESV- end systolic volume; 
ESVI- end systolic volume indexed to body surface area; EDV- end diastolic volume; EDVI- end diastolic volume indexed to body surface area; LA- left 
atrium; EF- ejection fraction; SV- stroke volume; FS- fractional shortening  
 
T
 Chamber volumes Systolic function Diastolic function Right heart 
ESVI EDV EDVI LA 
volume 
EF TIE 
index 
SV FS E/A MV 
Dec 
E/E’ 
septal 
E/E’ 
lateral 
TAPSE FAC 
Total monocyte count               
           R  0.18 0.17 0.11 0.04 -0.42 0.39 -0.19 0.06 -0.03 0.12 -0.10 0.10 0.03 -0.02 
           p Value 0.03 0.06 0.17 0.66 <0.001 <0.001 0.04 0.63 0.79 0.27 0.26 0.30 0.73 0.87 
Mon 1               
           R  0.15 0.22 0.09 0.09 -0.33 0.31 -0.16 0.02 -0.05 0.21 -0.06 0.07 0.03 -0.04 
           p Value 0.08 0.02 0.26 0.39 <0.001 <0.001 0.09 0.87 0.63 0.06 0.51 0.51 0.78 0.69 
Mon 2               
           R  0.21 0.00 0.12 0.02 0.06 0.42 -0.10 -0.08 -0.04 -0.10 -0.16 0.13 -0.07 -0.13 
           p Value 0.01 0.97 0.14 0.84 <0.001 <0.001 0.32 0.53 0.69 0.36 0.09 0.20 0.43 0.21 
Mon 3               
           R  0.02 0.06 0.01 -0.02 0.04 -0.02 0.03 0.12 -0.01 0.05 -0.06 -0.09 0.13 0.01 
           p Value 0.84 0.54 0.87 0.86 0.62 0.80 0.73 0.32 0.90 0.68 0.53 0.38 0.16 0.32 
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Table 25: Association of monocyte subset functional parameters with echocardiographic findings at phase 2 of sampling 
 
Phagocytic activity of Mon 1 and Mon 2 were negatively associated with EF. IKKβ levels of Mon 1, Mon 2 and Mon 3 were negatively associated with SV. ESV- end 
systolic volume; ESVI- end systolic volume indexed to body surface area; EDV- end diastolic volume; EDVI- end diastolic volume indexed to body 
surface area; LA- left atrium; EF- ejection fraction; SV- stroke volume; FS- fractional shortening 
 Chamber volumes Systolic function Diastolic function Right heart 
ESV ESVI EDV EDVI LA 
volume 
EF TIE 
index 
SV FS E/A MV 
Dec 
E/E’ 
septal 
E/E’ 
lateral 
TAPSE FAC 
IKKβ 1                
           R -0.08 0.09 -0.12 0.03 -0.10 0.16 -0.27 -0.42 0.20 0.09 0.24 -0.09 0.10 0.21 -0.07 
           p Value  0.37 0.31 0.19 0.72 0.31 0.09 0.004 <0.001 0.87 0.33 0.03 0.29 0.31 0.03 0.50 
IKKβ 2 
           R  
 
-0.12 
 
0.04 
 
-0.17 
 
-0.02 
 
-0.16 
 
0.21 
 
-0.27 
 
-0.36 
 
-0.02 
 
0.11 
 
0.17 
 
-0.14 
 
0.06 
 
0.26 
 
-0.09 
           p Value  0.22 0.67 0.07 0.82 0.12 0.02 0.004 <0.001 0.87 0.23 0.14 0.14 0.58 0.005 0.37 
IKKβ 3                
           R  -0.05 0.06 -0.13 -0.02 -0.18 0.09 -0.14 -0.44 -0.07 0.05 0.17 -0.21 0.15 0.11 -0.17 
           p Value 0.58 0.52 0.17 0.81 0.08 0.31 0.14 <0.001 0.59 0.58 0.12 0.02 0.15 0.22 0.91 
Phago 1                
           R  0.15 0.16 0.07 0.12 -0.14 -0.27 0.04 0.02 0.12 -0.11 -0.10 -0.02 -0.16 0.19 -0.11 
           p Value  0.10 0.07 0.48 0.20 0.16 0.004 0.67 0.817 0.36 0.23 0.39 0.58 0.12 0.04 0.27 
Phago 2                
           R  0.25 0.25 0.19 0.23 -0.19 -0.27 0.09 -0.09 0.05 -0.03 -0.05 -0.06 -0.11 0.10 -0.09 
           p Value  0.007 0.006 0.04 0.009 0.06 0.003 0.35 0.35 0.72 0.78 0.69 0.52 0.27 0.29 0.36 
Phago 3                
           R  0.07 0.04 0.04 0.02 -0.02 -0.5 0.08 -0.14 -0.08 -0.05 0.00 -0.01 -0.20 0.17 0.07 
           p Value  0.43 0.67 0.67 0.80 0.85 0.57 0.38 0.14 0.54 0.57 0.97 0.89 0.04 0.06 0.51 
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5.4.3 Monocyte quartiles associations with ejection fraction: 
Higher monocyte count quartiles correlated with lower ejection fraction. Total monocyte count, 
Mon 1, and Mon 2 higher count quartiles were associated negatively with lower EF. Using one-
way Anova testing with 
Tukey post hoc analysis, the number of echocardiograms in each monocyte count quartile were 
statistically different amongst the different quartiles (Figure 25).   
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Figure 25: Monocytes quartiles association with ejection fraction: Higher quartiles of total 
monocyte count, Mon 1 and Mon 2 were associated with lower ejection fraction. (one way anova 
with Tukey post hoc analysis). Differences between groups was postivie at levels of p< 0.05. 
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5.4.4 Monocytes and negative ventricular remodelling 
Negative ventricular remodelling is defined as an increase in end diastolic volume indexed to 
body surface area of ≥20% on the six months echocardiogram compared to first 
echocardiographic study performed 24 hours post infarction.  
 
5.4.4.1 Demographics of patients with negative ventricular remodelling 
In total, 121 patients from the total recruited 209 underwent both echocardiogram studies and 
hence were assessed for ventricular remodelling. Thirty-four patients suffered from negative 
remodelling at the completion of the healing process, i.e. 6 months post infarction. Table 26 
summarizes the clinical characteristics of patients who sustained negative ventricular 
remodelling. Patients who have ‘negative’ LV remodelling were generally well matched to those 
who had a non-remodelled outcome. However, patients who sustained negative remodelling were 
more likely to be on aspirin and ACE inhibitors (p = 0.01, and p = 0.01 respectively). There was 
also a higher percentage of a history of previous myocardial infarction amongst those who 
suffered negative remodelling (p= 0.01). These demographics are summarized in Table 26.  
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Table 26: Patient demographics of those sustaining negative remodelling compared to 
patients with no remodelling 
 
Parameter 
No 
remodelling 
(N= 87) 
Negative 
remodelling 
(N=34) 
p 
Value 
 Age 61 ± 11 64 ± 11 0.10 
Sex  62/85 25/35 0.99 
 Peak Troponin (ng/l) 7520 ± 13665 5627 ± 9511 0.55 
 Peak Creatinine Kinase  1494 ± 1427 1524 ± 1527 0.92 
Patient’s Total WCC (mmol/L) 12 (8.6 – 13) 12 (9 – 13) 0.64 
Demographics Estimated GFR 
(ml/min/1.72m2) 
73 ± 16 74 ± 15 0.91 
(%) Total Cholesterol (mmol/L) 4.8 (4.3 – 
5.2) 
5 (4.7 – 5.3) 0.65 
Time from symptoms onset 
to presentation to hospital 
(hours) 
4.7 ± 2.4 5.2 ± 2.7 0.40 
 
Inferior infarct 33 (39) 12 (34) 0.68 
 
Anterior infarct 41 (48) 11 (31) 0.11 
 
 
Diabetes (%) 
 
19 (22)  
 
10 (32) 
 
0.24 
 
Hypertension (%) 44 (50)  20 (65) 0.21 
 
Smoking (%) 47 (53)  20 (65) 0.30 
 
Hypercholestrolaemia (%) 39 (44) 15 (48) 0.83 
 
Heart failure (%) 11 (13) 3 (8.6) 0.76 
Past History of angina (%) 2 (2.3) 1 (2.9) 0.99 
Medical Previous myocardial 
infarction (%) 
6 (7.1) 10 (29) 0.01 
History [n (%)] Obesity (%) 11 (13) 7 (19) 0.24 
 
Cerebrovascular events (%) 5 (5.7) 3 (6.5) 0.89 
 
Previous CABG (%) 5 (5.7) 3 (10) 0.43 
 
Previous PCI (%) 4 (4.7) 4 (12) 0.23 
 
COPD (%) 
 
8 (9.5) 14 0.52 
 
    
 
Aspirin 31 (36) 20 (65) 0.01 
 
Clopidogrel 2 (2.3) 1 (3.2) 0.99 
 
Statin therapy 29 (33) 14 (45) 0.28 
Drug Calcium channel blocker 22 (25) 8 (26) 0.99 
history at  Beta blocker 13 (15) 9 (29) 0.11 
Recruitment 
(%) 
Loop diuretic  10 (11) 6 (19) 0.36 
 
Thiazide diuretic 8 (9.2) 4 (13) 0.51 
 
ACE inhibitor 31 (36) 20 (65) 0.01 
 Nitrates 
 
6 (6.9) 1 (3.2) 0.67 
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Data are expressed as mean ± standard deviation (SD) for normally distributed data; or median 
with (interquartile range) for non-normally distributed data 
 
 
 
5.4.4.2 Monocyte counts and function in patients with negative remodelling 
At day Patients who suffered from negative remodelling had higher counts of total monocyte 
count, Mon 1 (p= 0.004) and Mon 2 (0.007). Their phagocytic activity were also significantly 
higher for both Mon 1 (p= 0.008) and Mon 2 (p= 0.005) (Table 28). There was no difference in 
the IKKβ activity.  
Table 27: Monocyte count and functional activity in negatively remodeled patients 
 Negative 
remodelling (n= 34) 
No remodelling 
(n= 87) 
p Value 
Total Monocyte 
count (cells/ µl) 
1004 ± 385 821 ± 263 0.004 
Mon 1 (cells/ µl) 752 ± 282 613 ± 225 0.007 
Mon 2 (cells/ µl) 188 ± 134 144 ± 103 0.07 
Mon 3 (cells/ µl) 64 ± 43 63 ± 31 0.87 
IKKβ Mon 1 (MFI) 69 ± 26 73 ± 25 0.39 
IKKβ Mon 2 (MFI) 65 ± 25 68 ± 22 0.57 
IKKβ Mon 3 (MFI) 68 ± 32 73 ± 21 0.36 
Phagocytosis Mon 1 
(MFI) 
139 ± 30 121 ± 32 0.008 
Phagocytosis Mon 2 
(MFI) 
140 ± 49 115 ± 38 0.005 
Phagocytosis Mon 3 
(MFI) 
44 ± 19 42 ± 20 0.73 
Data are expressed as mean ± standard deviation (SD) for normally distributed data 
 
At 14 days (phase 2), there was no significant difference between monocyte counts and any of 
their functional parameters (table 29). 
Table 28: Monocyte count and functional activity in negatively remodeled patient during phase 
2 (day 14)  
 Negative 
remodelling (n= 34) 
No remodelling 
(n= 87) 
p Value  
Total Monocyte 
count (cells/ µl) 
578 ±  573 ± 362 0. 
Mon 1 (cells/ µl) 419 ± 99 404 ± 103 1.0 
Mon 2 (cells/ µl) 101± 44 82 ± 35 0.69 
Mon 3 (cells/ µl) 53 ± 34 49 ± 12 0.26 
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IKKβ Mon 1 
(MFI) 
58 ± 20 64 ± 23 0.67 
IKKβ Mon 2 
(MFI) 
57 ± 20 64 ± 22 0.27 
IKKβ Mon 3 
(MFI) 
65 ± 19 66 ± 19 0.69 
Phagocytosis Mon 
1 (MFI) 
123 ± 29 118 ± 34 0.56 
Phagocytosis Mon 
2 (MFI) 
112 ± 36 120 ± 38 0.32 
Phagocytosis Mon 
3 (MFI) 
43 ± 16 46 ± 12 0..4 
 Data are expressed as mean ± standard deviation (SD) for normally distributed data 
 
 
5.4.4.3 Predictors of negative remodelling 
A univariate and multivariate linear regression model for factors predicting LV remodelling was 
built to determine factors predicting LV remodelling. 
 
 
5.4.4.3.1 Univariate predictors of negative remodelling 
A univariate regression model indicated that amongst patients with negative remodelling having 
a previous history of a myocardial infarction or being a current smoker were both predictive of 
negative remodelling (OR= 1.2, p= 0.03 and OR= 1.41, p=0.04 respectively). MMP- 9 and TNF-
α were also predictive of negative remodelling (OR= 3.58, p=0.02; OR=4.11, p= 0.02 
respectively) (Table 30). 
 
Table 29: Logistic regression model for predictors of negative ventricular remodelling 
 
Patient 
Demographics 
Logistic regression model 
 
OR 95% CI p Value 
Age 1.01 0.88 – 1.16 0.88 
Diabetes Mellitus 1.39 0.57 – 3.39 0.47 
Hypertension   0.51 0.23 – 1.15 0.11 
Previous myocardial 
infarction 
1.20 0.06 - .058 0.03 
Smoking 1.41 0.18 – 0.95 0.04 
Time to Presentation 1.07 0.92 – 1.25 0.40 
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Logistic regression model for factors predicting negative ventricular remodelling. 
 
 
5.4.4.3.2 Multivariate predictors of negative remodelling 
Using the univariate model results a forward multivariate regression model was built adjusting 
for: age, sex, hypertension, diabetes, smoking, hypercholesterolaemia, peak troponin, previous 
myocardial infarction and history of angina as well as MMP- 9. This indicated that total monocyte 
count, Mon 1 and phagocytic activity of Mon 2 were independent predictors of LV remodelling 
(p= 0.001, 0.003, 0.03 respectively). Phagocytic activity of Mon 1 and Mon 2 were also increased 
the likelihood for developing negative ventricular remodelling (p= 0.04 and 0.007 respectively 
(Table 31).  
 
Table 30: Multivariate regression model for prediction of negative ventricular 
remodelling 
 
Time to recruitment  1.00 0.93 – 1.08 0.99 
Obesity 0.59 0.20 – 1.66 0.33 
Hypercholestrolaemia 0.62 0.28 – 1.37 0.24 
LAD infarct 2.03 0.89 – 4.67 0.09 
Peak Troponin  1.00 1.00 – 1.00 0.55 
Peak CK 1.00 1.00 – 1.00 0.92 
Total WCC 1.032 0.97 – 1.09 0.30 
MMP- 9 at recruitment 3.58 1.21 – 10.57 0.02 
TNF-α at recruitment 4.11 1.24 – 13.64 0.02 
MMP- 9 at 14 days 0.85 0.014 – 52.47 0.94 
TNF-α at 14 days 30 0.008 – 11.7 0.42 
 
Phenotypic and functional characteristics of monocyte subpopulations 
 
 
 
 
 
Day 1 
Total Monocyte 
count/ 1 cell 
 
1.002 
 
0.001 – 0.004 
 
0.001 
Mon 1, per  1 cell 1.003 0.001 – 0.004 0.003 
Mon 2 /1 cell 1.004 0.002 – 0.007 0.03 
Mon 3/ 1 cell 1.003 0.994 – 1.012 0.54 
IKKβ Mon 1 (MFI) 0.991 0.974 – 1.008  0.29 
IKKβ Mon 2 (MFI) 0.992 0.974 – 1.010 0.37 
IKKβ Mon 3 (MFI) 0.990 0.972 – 1.008 0.26 
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The model adjust for adjusting for: age, sex, hypertension, diabetes, smoking, hypercholesterolaemia, peak 
troponin, previous myocardial infarction, history of angina, TNF-α and MMP- 9 
 
  
5.4.5 Monocytes correlation with deformation study:   
Subclinical changes of the cardiac function measured by deformation assessment of the global 
longitudinal and circumferential strain were correlated with total monocyte count, Mon 1, Mon 2 
and Mon 3. At day 1 impaired global longitudinal and circumferential strain were associated with 
higher counts of total monocyte count (R2=0.37, p <0.0001; R2=0.24, p <0.0001 respectively). 
The association was weaker at 14 days post infarction albeit it being significant (R2=0.17, p 
<0.0001; R2=0.06, p= 0.02) (Figure 26).  
 
Total monocyte was equally strongly associated with global longitudinal strain at day 1 (R2=0.36, 
p <0.0001). The correlation with global circumferential strain was stronger compared to total 
monocyte count with R2=0.26 (p <0.0001). When compared with day 2, Mon 1 was also weekly 
negatively associated with global longitudinal and circumferential strain (R2=0.14, p= 0.0003; 
R2=0.07, p= 0.01 respectively) (Figure 27). 
With significance level determined to be <0.01, Mon 2 was not associated with global 
longitudinal and circumferential strain at day 1 post infarction (R2=0.06, p =0.01; R2=0.02; 
p=0.13). There was also no association at day 14 between Mon 2 and strain studies (R2 =0.08, 
p=0.01; R2 =0.02, p=0.24) (Figure 28). 
 
Mon 3 conversely were very weekly, but significantly, associated with global longitudinal strain 
and global circumferential strain at day 1. There was no association when Mon 3 were correlated 
with deformation studies at day 14 (R2= 0.01, P=0.01- for global longitudinal strain; and R2= 
<0.000, P= 0.93) (Figure 29).  
Phagocytosis Mon 1 
(MFI) 
1.013 1.001 – 1.026 0.04 
Phagocytosis Mon 2 
(MFI) 
1.015 1.004 – 1.26 0.007 
Phagocytosis Mon 3 
(MFI) 
1.001 0.982 – 1.001 0.945 
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Figure 26: Total monocyte count association with deformation study: A- Mon association 
with global longitudinal strain (GLS) and B- global circumferential strain (GCS) at day one. 
There was a week correlation that was not statistically significant (P>0.01). C- Mon association 
with day 14 GLS and D- GCS, there remained to statistically significant association was found 
between Mon and global longitudinal deformation at day 14. 
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Figure 27: Mon 1 association with deformation study: A- Mon 1 association with global 
longitudinal strain (GLS) and B- global circumferential strain (GCS) at day one. There was a 
week correlation that was not statistically significant (p >0.01). C- Mon 1 association with day 
14 GLS and D- GCS, there remained to statistically significant association was found between 
Mon 1 and global longitudinal deformation at day 14. 
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Figure 28: Mon 2 association with deformation study A- Mon 2 association with global 
longitudinal strain (GLS) and B- global circumferential strain (GCS) at day one. There was a 
week correlation that was not statistically significant (p >0.01). C- Mon 2 association with day 
14 GLS and D- GCS at day 2, no statistically significant association was found between Mon 2 
and deformation studies at day 2.  
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Figure 29: Mon 3 relationship with GLS and GCS at day 1 and 14: No meaningful significant 
association was found between Mon 3 and GLS or GCS at any time point.  
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5.5   Discussion 
My study is the largest study that has investigated the effect of monocytes on ventricular 
remodelling post STEMI. It is also the study that has allowed for the longest recovery period post 
STEMI, with follow up echocardiograms being performed after six months from the index 
STEMI, other studies followed patients for 4, 6 or 12 weeks month (Maekawa et al., 2002, van 
der Laan et al., 2002). My study used echocardiogram and body surface area indexed volumes to 
assess ventricular remodelling as an easily accessible, highly reproducible least intrusive imaging 
modality for investigating ventricular remodelling.  
I opted to utilise echocardiography for the assessment of LV volumes and measurement of EF. 
Compared to CMR, echocardiography is the most readily available clinical modality with least 
intrusion to patient care acutely within the first 24 hours post myocardial infarction. Even though 
end systolic and end diastolic volumes have been shown to be systematically underestimated on 
echocardiogram compared to cardiac magnetic resonance studies, however as I performed all the 
echocardiogram studies myself with a good inter-observer variability (table 20), the uniformity 
of the data would have been attained despite underestimated volumes.   
Echocardiography also provided robust information on subclinical changes to LV systolic 
function i.e. deformation studies. At the time of patient recruitment CMR obtained deformation 
studies were still being validated as a research utility.  
As this was an echocardiographic based study, LV mass was not measured in this given the 
inherent changes in the left ventricular wall geometry following STEMI: with the likelihood of 
thinning of ventricular wall in the infarcted zone with segmental hypertrophy in non-infarcted 
segments as a compensatory mechanism. This non uniform myocardial response to infarction 
undermines the assumptions of homogeneity of contractility assumed by both mathematical 
equations utilised in calculating LV mass using echocardiography (Lang et al., 2006). 
I illustrate that high counts of total monocytes as well as monocyte populations 1 and 2 measured 
in the first 24 hours post infarction correlated with ejection fraction and tie index, both as 
measu1res of LV systolic function. The tie index is not dependent on volumes changes and hence 
is not affected by preload and afterload alteration. This correlation remained significant at 6 
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months with the final remodelled ejection fraction being negatively associated with total 
monocyte count, Mon 1, Mon 2 as well as the phagocytic activity of Mon 1 and Mon 2. Higher 
quartiles of total monocyte count, Mon 1 and Mon 2 were all associated with lower ejection 
fractions. This reflects the possible inflammatory function of the Mon 1, as well as the newly 
described Mon 2.   
As illustrated by other groups, MMP- 9 was predictive of negative ventricular remodelling due 
to its well established effect on increasing LV geometry eventually leading to an increase in 
ventricular volumes. MMP- 9 is secreted by monocytes on stimulation by acute insult (Brunner 
et al., 2010) . For the first time we illustrate the monocyte total monocyte count and Mon 1 as 
well as Mon 2 are predictive of negative ventricular remodelling in a multivariate model that is 
adjusted for MMP- 9.   
I describe for the first time that phagocytic effect of Mon 1 and Mon 2 are independent predictor 
factors of negative remodelling in STEMI patients. I’ve discussed the monocyte role in 
phagocytosis in Chapter 3. Here phagocytosis is illustrated to be the mechanism through which 
Mon 1 and Mon 2 exert their deleterious effects on reduced systolic function. This is in keeping 
with findings from Panizi et al. in murine models (Panizzi et al., 2010). None of the human studies 
in the area of monocytes so far has described a functional parameter to account for the effect of 
monocytes on myocardial salvage, microvascular obstruction or reduced EF. The role of impaired 
phagocytome clearance, i.e. delayed apoptosis, could explain the discrepancy in the literature.  
Tumour necrosis factor- α (TNF-α) is a pro-inflammatory cytokine secreted by activated 
macrophages and T cells, and is instrumental in the mediation of vascular inflammation. TNF-α 
production is in increased concentrations in patients with acute myocardial infarction (AMI). 
Furthermore, plasma TNF-α concentrations are predictive of death and recurrent ischaemic events 
following AMI (Satoh et al., 2008, Schlitt et al., 2004). This study indicates that in a multi variate 
model, including the effect of TNF-α, Total monocyte count, Mon 1 and Mon 2 remained 
independent predictors of ventricular remodelling.   
There was no effect on IKKβ in predicting ventricular remodelling. There was also no difference 
in IKKβ levels in patients who developed negative ventricular remodelling. Even though NFκB 
pathway has been associated with developing heart failure, this study does not reflect this finding. 
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No doubt NFκB pathway has an inflammatory role, however as discussed in chapter 4, there are 
two presumed functions of NFκB pathway, one cardiotoxic and the other cardioprotective (Han 
et al., 2001). 
Given the complexity of cardiac fibre alignment and dynamic contractility of the cardiac fibres 
in different planes during contraction, subclinical cardiac contractility dysfunction could arise. 
Global longitudinal and circumferential strain provide measurement of subclinical impairment in 
the contractility of myocytes prior to patients frankly developing signs or symptoms of heart 
failure. In the era of rapid revascularisation with PCI, and thus reduction in the number of patients 
overtly presenting with heart failure complication initially, the importance of assessment of 
subclinical parameters of heart muscle dysfunction is paramount. Global longitudinal and 
circumferential strain have been shown predictive of negative outcome in the future as well as 
developing overt heart failure on prolonged follow up (Lyseggen et al., 2005, Skulstad et al., 
2006, Vartdal et al., 2007). This is the first study that investigates the effect of monocyte subset 
counts on monocyte longitudinal and circumferential strain rate. There was a significant 
relationship between total monocyte, Mon 1 and Mon 2 both in global longitudinal and 
circumferential strains. Indicating the monocyte effect not just on the global function of the heart 
but also on subclinical parameters.  
 
5.6   Conclusion 
Mon 1 and Mon 2 are predictive of negative ventricular remodelling with phagocytosis appearing 
to be the functional parameter through which this is implemented. Total monocyte count, Mon 1 
and Mon 2 correlate well with deformation studies.   
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Chapter 6 
Monocytes counts and function in depicting major 
adverse cardiac events (MACE) in patients post 
STEMI 
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6.1  Introduction 
As described earlier in chapter 1 a plateau has been reached in optimizing management of patients 
sustaining acute coronary syndrome with an urgent need arising to investigate alternative 
pathophysiological parameters for therapeutic intervention during management of coronary 
occlusion. A plethora of literature identified an association of inflammation with progression of 
stable coronary artery disease with patients with a leukocytosis, and specifically monocytosis 
being at higher risk for progression of stable coronary artery disease and developing an adverse 
cardiovascular event, as well as the involvement of monocytes in the progression of the 
atherosclerotic plaque formation and fibrous cap rupture, as discussed in chapter one.  
It has long been recognized that an increase in the peripheral white cell count correlates with the 
outcome of MI. A large-scale study with 153,213 patients aged 65 years or older with MI 
demonstrated that a higher WBC count within 24 h of admission was associated with higher 
mortality within 30 days. However, leukocytosis immediately after MI is caused by the release 
of neutrophils pooled in blood vessels, spleen and liver, and in that case, the peripheral WBC 
count changes within hours. Horne et al. in a large retrospective study of 3227 patients, confirmed 
that leukocytosis is an independent predictor of future myocardial infarction or death (Horne et 
al., 2005). Maekawa et al. also described monocytosis as a predictor of LV aneurysm formation 
and LV rupture post infarction (Maekawa Y et al., 2002). During acute MI, the number of 
circulating classical and intermediate monocytes increased acutely over 3 days and were 
associated with impaired left ventricular function and larger infarct size. Furthermore, preferential 
accumulation of CD14++CD16– cells in the infarct border zone has been observed in the 
myocardium of STEMI patients (Libby et al., 2008). Interesting, compared with cells in patients 
with stable coronary artery disease, circulating classical monocytes (likely to present Mon 1 and 
Mon 2 in this study) are more adhesive and increase in number in patients with heart failure. 
A number of small observational series described an increase in Mon 1 and Mon 2 subpopulations 
counts in STEMI patients up to three days post infarction with a negative correlation to ejection 
fraction. A small scale cardiac magnetic resonance based study recruiting 50 patients, with a short 
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follow up period of six months, indicated that a negative correlation between classical monocytes 
and ejection fraction as well as microvascular obstruction. Elsewhere, assessing non-culprit 
coronary plaque size in 90 acute MI patients during the acute phase and 7-month later found that 
peak monocyte counts in the blood independently predicted plaque progression after ST-elevation 
MI. 
In humans very few studies have investigated the effect of the newly described intermediate 
monocyte (this is represented as Mon 2 in this study) in clinical conditions.  In a large prospective 
cohort of 951 patients undergoing elective coronary angiography, increased numbers of 
intermediate CD14++CD16+ monocytes (similar to Mon 2 in this study) independently predicted 
cardiovascular death, myocardial infarction (MI) and stroke over a period of 2 and a half years 
(Rogacev et al., 2012). On the other hand, recently a small study of 60 diabetic patients who 
sustained a STEMI were matched to 60 non-diabetic STEMI patients and followed up for 6 
months. Here intermediate monocytes were found to be positively correlated with ventricular 
remodelling, suggestive of a probable reparative role for Mon 2.  
Hence, given the paucity and conflicting data from small studies with short follow up, it became 
essential to device a study with longer follow up and adequate statistical power to investigate the 
effect of monocyte subsets, especially the intermediate subset Mon 2, on clinical outcome post 
STEMI. Furthermore, the need for investigating the translational and functional pathways to 
explain the above observations strongly presents itself as an important unanswered question.  
 
6.1.1 Risk stratification of STEMI patients 
Physicians sometimes rely on clinically derived scoring symptoms to risk stratify patients’ 
mortality risk and thus aid the decision making process of balancing risk versus benefit on making 
process to ensure better outcome for the patient. A number of scores are currently available for 
the assessment of risks in STEMI patients, including the GRACE score, TIMI score, and 
SKOWELL scores (Morrow et al., 2000). However due to the inherent medical emergency of 
STEMI, the current clinical pathways in patient management demand intervention/thrombolysis 
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to restore flow to the infarcted cardiac myocardium within 30 minutes of presentation to hospital. 
Hence these scores are mainly for retrospective assessment of mortality risks and do not all apply 
to STEMI patients, but include other parameters of the acute coronary syndrome, i.e. NSTEMI 
(Yan et al., 2005).  
The TIMI STEMI scores accounts for clinical parameters including blood pressure at 
presentation, anterior ST elevation, heart rate at presentation, as well as time delay in presentation 
and body mass index (Table 31). Amongst the above mentioned clinical risk stratification scores, 
no score accounts for inflammation at the time of STEMI. Investigating the efficacy of these 
scores in predicting outcome with the inclusion of inflammatory markers could provide a new 
venue for refining prediction of mortality in STEMI patients.  
 
Table 31: TIMI score criteria and calculated 30 day mortality 
TIMI score criteria Points 
awarded 
Calculated Score and 30 day 
mortality risk after an 
myocardial infarction 
Diabetes mellitus, hypertension, or angina 1 Total Score 30 day 
mortality 
(%) 
Systolic blood pressure less than 100 mmHg 3 0 0.8 
Heart rate greater than 100 BPM 2 1 1.6 
Killip class II-IV 2 2 2.2 
Body weight less than 67 kg 1 3 4.4 
Anterior lead ST elevation or left BBB 1 4 7.3 
Time to treat more than 4 hours 1 5 12 
Age  6 16 
       >= 75 years old 3 7 23 
       65-74 years old 2 8 27 
       Less than 65 0 9-14 36 
 
Incorporating inflammatory markers, e.g. monocyte count, in the risk stratification score would 
add another parameter that could possibly improve the sensitivity of these scoring mechanisms 
in predicting patient mortality. This could also determine which patients could potentially benefit 
from targeted anti-inflammatory medication post infarction. The efficacy of such a model was 
never investigated before.  
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The effect of monocyte counts, Mon 1, Mon 2 and their functional parameters on predicting 
outcome on prolonged follow up period is not clearly described. The effect of the newly described 
Mon 2 subpopulation is particularly unclear. There is no data in humans describing a cause and 
effect relationship of monocytes subsets in STEMI patients. 
 
6.2   Aims and Hypothesis 
In this study the aim is to assess the predictive value of monocytes and their functional parameters 
in predicting clinical outcome of STEMI patients post infarction. We also aim to investigate the 
effect of adding monocytes into existing risk stratification score to improve their predictive 
performance. 
The hypothesis is that total monocyte count, Mon 1, and Mon 2 are independent predictors of 
patients’ clinical outcomes. Functionally, IKKβ activity of Mon 1 and Mon 2 as well as their 
phagocytic activity are likely to be predictive of poor clinical outcome.  
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6.3   Methods 
6.3.1 Patient recruitment 
Patient population were recruited as described in appendix I and chapter 2, section 2.3.1 
 
6.3.2  Flow cytometry 
Flow cytometry studies to measure monocytes, phagocytic activity and IKKβ and were carried 
out as described in chapters 2, 3 and 4 respectively: sections 2.3.3; 3.3.2; 4.3.2.1  
 
6.3.3  TNF-α and MMP- 9 
ELISA measurements of MMP-9 and TNF-α were carried out on stored plasma as described in 
chapter 4, sections 4.3.3 and 4.3.4 respectively. 
 
6.3.4  Defining MACE 
Primary endpoints of adverse cardiac events (MACE) was defined as death, recurrence of acute 
coronary syndrome and revascularisation, new clinical diagnosis of heart failure based on patient 
symptoms in conjunction with echocardiographic features suggestive of left ventricular 
dysfunction. Patients were followed up using electronic hospital records from each recruitment 
site. I contacted GP surgeries for patients who were not reviewed in hospital post STEMI. All 
events were adjudicated by myself and I was blinded to monocyte data.  
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6.3.5  Statistical analysis 
Data management and statistical analysis were performed using SPSS 21 (SPSS, Inc., Chicago, 
Illinois). Two-sided p values 0.05 were considered significant. Categorical variables are 
presented as percentage of patients and were compared using chi-square tests. 
Normally distributed data are expressed as mean ± standard deviation. Whilst non-parametric 
data are expressed as median and quoting the interquartile range. Differences between patient 
groups were compared using independent t-test for normally distributed data or Mann-Whitney 
U tests for non-parametric data. Long term MACE events after STEMI were assessed by a Cox 
proportional-hazards model. This was initially carried out as a univariate model, and then a 
multivariate model was built to analyse the relationship between monocyte subsets, IKKβ and 
phagocytic activity with event free survival after adjusting for risk factors for cardiovascular 
disease, biochemical profile. I also adjusted independently for TNF-α as a marker for 
inflammation and MMP- 9 extracellular matrix remodelling factor. 
Subjects were divided into 4 groups (quartiles) according to their total monocyte counts and 
monocyte subset counts. Kaplan-Meier survival curves were used to compare event-free survival 
(i.e., time until first occurrence for an adverse cardiac event) between groups. The log-rank test 
was used to test the hypothesis that at least 1 of the survival curves depicted by the different 
quartiles differs from the others and then a pairwise comparison between strata was performed to 
interrogate the relationship between different quartiles. Statistical significance was determined at 
5%. ROC curves were calculated for total monocyte count, and individual monocyte subsets with 
the area under the curve being compared for each subset as well as for troponin and the TIMI 
score. The monocyte count reaching the maximum sensitivity and specificity (at least 75% and 
25% respectively) was then used as a cut off level to convert the continuous data in the Cox 
regression model into dichotomous data. A multivariate Cox regression model was built again 
using the dichotomous variables.  
Comparison of differences between area under the curve was carried using Z statistics (DeLonge 
et al., 1998) (Analyse-it®, Excel 2013).  
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6.4   Results 
6.4.1  Recruited Patients 
Between March 2011 and Dec 2012 I solely recruited 209 patients from the three different sites. 
Patients were followed up for a mean 33 ± 17 months during which there were 75 MACE events 
recorded. MACE cases were recorded in total 75 events mainly driven by heart failure diagnosis 
(n= 36); need for repeat revascularisation (n=27); death (n=12). 
Patients who suffered an adverse cardiac event were significantly older (64±11 years vs 59±11) 
than those who had an uncomplicated post MI recovery and recuperation. There was also a 
predominance of male patients (75% males, p=0.02) amongst the MACE group. This is in keeping 
with already established epidemiology of ischaemic heart disease population. Interestingly there 
was a higher WCC amongst patients who developed MACE (p=0.03), this is in agreement with 
previously reports (Table 33).  
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Table 32: Demographics of patients developing MACE 
 
        MACE 
       N = 75 
   No MACE 
      N = 134 
p 
Value 
 
 
Age 
 
64±11 
 
59 ±11 
 
0.01 
Gender (male/ %) 72 59 0.02 
 Peak Troponin  11431 ± 
20817 
4497 ± 7915 0.03 
 Peak Creatinine Kinase 1578 ± 1491 1405 ± 1393 0.43 
Patient’s Total WCC (mmol/L) 12 (9 – 14) 11 (7.6 – 12) 0.03 
demographics Estimated GFR 71 ± 17 75 ± 16 0.06 
 Total Cholesterol (mmol/L) 5 (4.5 – 5.3) 4.8 (4.3 – 
5.3) 
0.99 
Time from symptoms onset to 
presentation to hospital 
(hours) 
5.2 ± 2.6 4.5 ± 2.6 0.08 
 Time from hospital 
presentation to recruitment to 
study (hours) 
20 (16 – 25) 19 (17 – 22) 0.27 
  
Diabetes 
 
           20 
 
27 
 
0.40 
 Hypertension 56 51 0.56 
 Smoking 56 57 0.99 
 Hypercholesterolaemia 39 49 0.19 
 Heart failure 11 11 1.00 
Past History of angina 2 9 0.04 
medical Previous myocardial 
infarction 
12 21 0.11 
history (%) Obesity 15 16 0.84 
 Cerebrovascular events 8 9 0.80 
 Previous CABG 4 5 0.73 
 Previous PCI 8 11 0.45 
 COPD 16 11 0.41 
 Anterior infarct 46 38 0.24 
 Inferior infarct 29            43 0.06 
  
Aspirin 
 
40 
 
35 
 
0.54 
 Clopidogrel 2.7 2.3 0.98 
 Statin therapy 37 29 0.29 
Drug Calcium channel blocker 19 24 0.37 
history at  Beta blocker 15 21 0.34 
recruitment 
(%) 
Loop diuretic 14 16 0.69 
 Thiazide diuretic 10 8.1 0.80 
 ACE inhibitor 36 50 0.54 
 Nitrates 
 
7.8 5.4 0.77 
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Data are expressed as mean ± standard deviation (SD) for normally distributed data; or median 
with (interquartile range) for non-normally distributed data 
 
 
6.4.2 Monocyte counts and functional parameters of patients developing 
MACE 
Patients who sustained a MACE event had higher total monocyte counts, Mon 1 and Mon 2 as 
well as Mon 3 counts compare to patients who have not developed MACE (p <0.0001 for total 
monocyte count, Mon 1 and Mon 2; p= 0.03 for Mon 3). The phagocytic activity of Mon 1 was 
significantly higher in day 1 in patients who developed MACE (p= 0.004). This is in conjunction 
with a significantly higher phagocytic activity for Mon 2 at day 14 (p= 0.005). There was no 
difference in the IKKβ levels, and hence NFκB pathway activity, between patients who developed 
MACE and those who did not have MACE events (Table 34)  
At day 14, there remained to be a significantly higher count of Mon 1 and Mon 2 amongst patients 
who developed MACE events (p= 0.03 and p=0.002 respectively) (Table 34)  
Table 33: Difference in monocyte subset counts and functional assessment in patients who 
developed MACE vs no MACE 
 MACE (n= 75)  No MACE (n= 134) p Value 
Total Monocyte 
count  
1064 ± 272 736 ± 239 <0.001 
Mon 1 (cells/µl) 794 ±  221 546 ±  203 <0.001 
Mon 2 (cells/µl) 200 ±  122 134 ± 104 <0.001 
Mon 3 (cells/µl) 70 ± 46 56 ± 34 0.03 
IKKβ Mon 1 
(MFI) 
70 ± 24 72 ± 27 0.48 
IKKβ Mon 2 
(MFI) 
65 ±  22 68 ±  23 0.41 
IKKβ Mon 3 
(MFI) 
71  ±23 72 ± 23 0.75 
Phagocytosis Mon 
1 (MFI) 
129 ( 110 – 152) 114 (95 – 146) 0.004 
Phagocytosis Mon 
2 (MFI) 
111 ( 84 – 141) 105 (105 – 149) 0.005 
Phagocytosis Mon 
3 (MFI) 
27 (31 – 60) 38 ( 27 – 52) 0.47 
Day 14 results (phase 2) at follow up 
 
Total Monocyte 
count  
608 ± 206 537 ± 327 0.14 
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Mon 1 (cells/µl) 433 ± 177 379 ±  121 0.03 
Mon 2 (cells/µl) 117± 80 78 ± 43 0.002 
Mon 3 (cells/µl) 58 ± 41 47 ± 21 0.08 
IKKβ Mon 1 
(MFI) 
64 ± 20 64 ±  24 0.87 
IKKβ Mon 2 
(MFI) 
67 ± 26 63 ± 23 0.45 
IKKβ Mon 3 
(MFI) 
69 ± 16 65 ± 20 0.29 
Phagocytosis Mon 
1 (MFI) 
115 (96 – 139) 114 (95 – 141) 0.93 
Phagocytosis Mon 
2 (MFI) 
114 ( 93 – 149) 113 (90 – 141) 0.89 
Phagocytosis Mon 
3 (MFI) 
43 ( 23 – 70) 42 (28 – 55) 0.63 
 
Data are expressed as mean ± standard deviation (SD) for normally distributed data; or median 
with (interquartile range) for non-normally distributed data 
 
 
 
6.4.3 Univariate Cox regression model 
A univariate Cox regression model indicated that independent predictors of MACE amongst 
recruited patients were age and gender from the patient demographics (HR of 1.03 and 1.89, p= 
0.008 and 0.03 respectively) (table 34). Male gender nearly doubled the risk of MACE, with 
higher age and impaired kidney function marginally increasing risk of adverse cardiac event. 
CVA, cerebrovascular accident; CABG, previous coronary artery bypass grafting were not 
predictive of MACE in our patient population. 
Biochemically having a high troponin level and impaired renal function also predicted MACE in 
recruited patient population risk, (HR 1.002, p=0.003; HR 0.99, p=0.03). This is in keeping 
withtraditional cardiovascular disease risk factors, 
  
Table 35: Univariate Cox regression of factors predicting MACE 
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Patient Demographics 
Unadjusted Cox regression 
Hazard 
Ratio 
CI p Value  
Age 1.03 1.007-1.050 0.008 
Gender 1.89 1.04 – 3.47 0.03 
Diabetes Mellitus 1.22 0.75 – 1.99 0.42 
Hypertension 1.18 0.75 – 1.87 0.47 
Hypercholesterolaemia 1.32 0.84 – 2.08 0.23 
CVA 1.41 0.65 – 3.07 0.39 
Smoking 1.04 0.66 – 1.64 0.88 
Obesity 1.07 0.56 – 1.99 0.83 
History of Ischaemic Heart 
disease 
   
     Previous myocardial 
infarction 
1.71 0.98 – 2.98 0.06 
     Previous CABG 1.31 0.48 – 3.60 0.59 
     Previous PCI 1.39 0.67 – 2.90 0.38 
     Angina 2.55 1.17 – 5.56 0.02 
Time to Presentation/hour 1.07 0.99 – 1.08 0.08 
Time to recruitment / hour 1.02 0.97 – 1.07 0.40 
LAD infarct 1.33 0.85 – 2.10 0.21 
Inferior STEMI 1.63 0.99 – 2.68 0.05 
Peak Troponin (ng/ml) 1.002 1.001 - 1.002 0.003 
Peak CK  1.000 1.00 – 1.00 0.49 
Total WCC  1.003 0.99 – 1.007 0.12 
eGFR ml/min/1.73m2  0.99 0.97 – 0.99 0.03 
Inflammatory markers    
     MMP- 9 2.50 1.45 – 4.32 0.001 
     TNF-α levels at day 1 3.15 1.72 – 5.76 <0.001 
 
Phenotypic and functional characteristics of monocyte subpopulations 
 
 
 
 
Day 1 
Total Monocyte count/ 1 
cell 
1.002 1.002 -1.003 ‹ 0.0001 
Mon 1 / 1 cell 1.003 1.002 - 1.004 ‹ 0.0001 
Mon 2 /1 cell 1.004 1.002 - 1.005 ‹ 0.0001 
Mon 3/ 1 cell 1.005 1.000 - 1.005 0.056 
Total Monocyte count/ 
100 cell 
1.277 1.202 - 1.356 ‹ 0.0001 
Mon 1 / 100 cell 1.329 1.232 - 1.433 ‹ 0.0001 
Mon 2 / 50 cell 1.197 1.100 - 1.302 ‹ 0.0001 
Mon 3 / 50 cell 1.053 0.99 – 1.528  0.061 
IKKβ Mon 1 / MFI 0.997 0.99  - 1.007 0.56 
IKKβ Mon 2 / MFI 0.996 0.986 - 1.007 0.47 
IKKβ Mon 3 / MFI 1.000 0.990 -1.01 0.98 
Phagocytosis Mon 1/ MFI 1.012 1.005 - 1.019 0.001 
Phagocytosis Mon 2/ MFI 1.008 1.003 - 1.014 0.001 
Phagocytosis Mon 3/ MFI 1.010 1.002 - 1.019 0.020 
 
 
 
 
Day 2 
 
 
Total Monocyte count/ 1 
cell 
1.002 1.001 - 1.003 <0.0001 
Mon / 1cell 1.002 1.000 - 1.003 0.03 
Mon 2 /1 cell 1.005 1.002 - 1.008 0.001 
Mon 3/ 1 cell 1.005 0.999 - 1.011 0.12 
IKKβ Mon 1 / MFI 1.001 0.989 – 
1.013 
0.89 
IKKβ Mon 2/ MFI 1.005 0.995 - 1.016 0.33 
IKKβ Mon 3/   MFI 1.010 0.996 - 1.023 0.16 
Phagocytosis Mon 1/ MFI 0.999 0.991 - 1.006 0.72 
Phagocytosis Mon 2/MFI 1.000 0.994 - 1.007 0.97 
Phagocytosis Mon 3/MFI 1.008 0.997 - 1.018 0.16 
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6.4.4 Multivariate Cox regression model:  
Using this data a multivariate model was built including: age, sex, peak troponin, peak CK, total 
WCC, renal function (as demonstrated by eGFR levels), the patient sustaining an anterior infarct, 
and the time delay of patient presenting to hospital. The model also included previous history of 
myocardial infarction, angina, hypertension, diabetes, hypercholesterolaemia, and being a current 
smoker. Also levels of MMP- 9 and TNF-α at recruitment point. This multivariate model 
indicated total counts of monocytes, monocyte 1, and monocyte 2 as well as the phagocytic 
activity of Mon 1 and Mon2 measured at the index event as well as Mon 2 counts measured in 
the recovery phase 2 weeks post recruitment, were predictive of MACE (Figure 30). 
 Table 36: Multivaraite Cox regression model  
 
 
 
Multivariate model demonstrates that total counts of monocytes, Mon 1, and Mon 2 as well as 
the phagocytic activity of Mon 1 and Mon2 measured at the index event are positively predictive 
of MACE (the hazard ratio and p Values are summarised in table 36). 
 
 Hazard ratio CI p Value 
Total Monocyte 
count (/ 100 
cells) 
1.528 1.288 - 1.791 <0.0001 
Mon 1 (/100 
cells) 
1.639 1.186 – 2.266 0.003 
Mon 2 (/100 
cells) 
1.280 1.049 - 1.563 0.015 
Phagocytosis 
Mon 1 (MFI) 
1.022 1.005 - 1.039 0.011 
Phagocytosis 
Mon 2 (MFI) 
1.017 1.002 - 1.032 0.022 
Phagocytosis 
Mon 3 (MFI) 
1.010 0.996 - 1.024 0.167 
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Figure 30: Forest plot of independent factors predicting MACE on multivariate analysis: 
Total Mon1 and Mon 2 count at day 1 as well as the phagocytic activity of both subsets were 
independent predictors of MACE with significant hazard ratios.  
 
6.4.5 Monocyte count quartiles and clinical outcome 
6.4.5.1 Higher counts of Total monocyte counts predict worse clinical outcome 
After stratifying the study cohort by monocyte subsets cell counts into quartiles, higher counts of 
total monocytes, Mon 1 and Mon 2, but not Mon 3 were univariately associated with any MACE 
events as illustrated by Kaplan Meier survival curves (Figures 31, 32, 33 and 34 respectively). 
Significant higher counts for the monocyte subsets were presented in the third and fourth quartiles 
of each subpopulations.  
The effect of higher total monocyte count in predicting MACE continued for 400 days post index 
event (Figure 31) 
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Figure 31: Total monocyte count quartiles and ability to predict MACE: There was a 
significant increase in mortality in patients who had higher total monocyte counts presented in 
the third and fourth quartiles compared to counts in the first two quartiles. Eighty per cent of 
outcomes occurred in patients whose total monocyte counts were in the third and fourth quartiles. 
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6.4.5.2 Higher Mon 1 counts predict worse clinical outcome 
Patients who had Mon 1 counts in the higher third and fourth quartiles were strongly predictive 
of MACE events an effect that was maintained for more than 600 days (Figure 32).   
 
Figure 32: Mon 1 count in Kaplan Meier survival curve: There was a significant increase in 
mortality in patients who had Mon 1 in the third and fourth quartiles compared to the first two 
quartiles. Eighty per cent of outcomes occurred in patients whose total monocyte count were in 
the third and fourth quartile. 
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6.4.5.3 Higher Mon 2 counts predict worse clinical outcome 
There was a significant increase in MACE events in patients who had monocyte counts in the 
higher third and fourth Mon 2 counts compared to the first and second quartile counts. This effect 
persisted 333 days post index event. 
 
Figure 33: Mon 2 count in Kaplan Meier curve: There was a significant increase in mortality 
in patients who had higher Mon2 in the third and fourth quartiles compared to the first two 
quartiles.  
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6.4.5.4 Higher Mon 3 counts do not predict outcome in STEMI patients 
Higher quartiles of Mon 3 did not increase risk for MACE events. There was no difference in the 
effect of the four quartiles of Mon 3 on clinical outcome at follow up.  
 
Figure 34: Mon 3 quartiles does not increase risk for developing MACE in STEMI 
patients: There was no statistically significant difference between the four quartiles of Mon 3 
counts.  
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6.4.6 C statistics for total monocyte count, Mon 1 and Mon 2 
C statistics analysis was performed to assess the performance of monocytes in addition to the 
already clinically established TIMI STEMI score in risk stratifying patients’ risk of mortality at 
30 days. Receiver operator curve (ROC) analysis showed that total monocytes and Mon1 had the 
best predictive performance for MACE (area under the curve of 0.85, p<0.0001; and 0.81 
p<0.0001 for total monocyte count and Mon 1 respectively) (Table 37). In our cohort the TIMI 
score had poor discriminatory capacity for MACE as reflected by the c-indexes in Figure 35. 
Area under the curve for the TIMI scoring system is 0.64 
 
Figure 35: Receiver operator curves (ROC) comparing the discriminatory power of total monocyte 
counts, Mon 1, Mon 2, TIMI score and peak CK levels. The paramter of Mon 1 shows the highest 
discrimnatory power (area under the curve of 0.85, p<0.0001) and the CK parameter showing no 
discrimnitaory effect. The legend gives the indices in order of increasing area under the curve.  
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Table 34: Area under the curve of the TIMI Score  
 
Parameter Area under curve 95% CI p Value  
Total Mon count 
(cells/ µl) 
0.85 0.78 – 0.89 <0.0001 
Mon 1 (cells/ µl) 0.81 0.74 – 0.87 <0.0001 
Mon 2 (cells/ µl) 0.69 0.61 – 0.77 <0.0001 
Creatine Kinase 0.55 0.46 – 0.63 0.31 
TIMI Score 0.64 0.56 – 0.72 0.001 
 
 
6.4.6.1 Total monocyte count  
Nevertheless, after incorporating total monocyte count to the TIMI STEMI model, the sensitivity 
of model in predicting poor outcome improved (Figure 36) with an area under the curve of 0.77 
(TIMIMon score in Table 37)  
 
 
Figure 36: Receiver operator curves (ROC) comparing the discriminatory power of total 
monocyte counts, Mon 1, Mon 2, TIMI score and TIMIMon score. The paramter of Mon 1 
shows the highest discrimnatory power. The combined TIMIMON paramter has higher 
discriminatory power (Area under the curve of 0.77) than TIMI score and Mon2 as separate 
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paramters (area under the curve of 0.65 and 0.67 respectively). The legend gives the indices in 
order of increasing area under the curve.  
 
Table 35: Area under the curve for monocyte counts 
 
 
 
 
 
 
Finally comparing the difference between the areas under the curves for each of ROC curves was 
carried out. It indicated that the differences between total monocyte count vs Mon 1, Mon 2 and 
TIMI score were significantly different (0.03, 0.2, 0.2 respectively, p<0.0001 respectively) (Table 
36).  
 
Table 36: Comparison of area under the curve 
 
Comparison of area under curve between different comparison models for predicting MACE. Total 
monocyte count vs TIMI, Total monocyte count Cs Mon 1; Total monocyte count vs Mon 2; Mon 1 vs 
TIMI; Mon 1 vs Mon 2; and Mon2 vs TIMI. Statistical analysis for difference between areas under the 
curve was done via Z- statistics (Analyse-it ®- Excel 2013).  
 
Parameter Area under curve 95% CI  pValue 
Total Mon count 
(cells/ µl) 
0.85 0.80 – 0.90 <0.000 
Mon 1 (cells/ µl) 0.82 0.76 – 0.80 <0.000 
Mon 2 (cells/ µl) 0.67 0.59 - .75 <0.000 
TIMI 0.65 0.57 – 0.73 0.001 
TIMIMon Score 0.77 0.70 – 0.83 <0.001 
ROC 
comparisons of 
area under 
curve 
Difference of 
ROC 
95% 
confidence 
Interval 
Z Test pValue 
Total 
Monocyte vs 
TIMI 
0.20 0.11 – 0.29 -6.50 <0.0001 
Total 
monocyte vs 
Mon 1 
0.03 0.01 – 0.06 -24.9 <0.0001 
Total 
Monocytes vs 
Mon 2 
0.20 0.11 – 0.25 -8.95 <0.0001 
Mon 1 Vs 
TIMI 
0.17 0.08 – 0.27 -6.79 <0.0001 
Mon 1 vs 
Mon 2 
0.15 0.06 – 0.25 -7.19 <0.0001 
Mon 2 vs 
TIMI 
0.02 0.09 – 0.12 -8.97 <0.0001 
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6.4.7 Dichotomous data in Cox regression model 
Using the ROC analysis curve, I was able to determine the total monocyte count, Mon 1 and Mon 
2 counts that provided the best combination of sensitivity and specificity in predicting adverse 
clinical outcome. These counts were 818 cells/ml; 620 cells/ml; 117 cells/ml for total monocyte 
count, Mon 1, and Mon 2 respectively. As discussed in statistics section, I created dichotomous 
variable for total monocyte count, Mon 1, and Mon 2 and included that in a multivariate Cox 
regression model. This indicated that higher total Monocyte count, Mon 1, and Mon 3 carry a 
higher hazard ratio (HR) in predicting MACE events if higher monocyte subset counts are studied 
(HR 5.2, p < 0.0001; HR 4.6,  p<0.0001; HR 2.6, p=0.005).  
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6.5   Discussion 
In this section of the study the results of follow up of the 209 recruited patients and the MACE 
events incurred are described. The predominant adverse cardiac event was developing heart 
failure, based on echocardiographic findings and clinical symptoms. My study is the largest 
prospective study with the longest follow up of consecutive STEMI patients treated with 
percutaneous coronary intervention (PCI) and receiving adequate antiplatelet therapy during PCI 
according to ESC guidelines for revascularisation for STEMI.  
A landmark paper investigating the effect of intermediate monocyte on the outcome of 900 
patients undergoing coronary angiography, indicated that solely Mon 2 was associated with 
cardiovascular outcome at three years follow up. My study now confirms the negative predictive 
effect of the CD14++CD16+CCR2+ Mon 2 subset, equivalent to intermediate monocyte, in 
STEMI patients both acutely and at the beginning of recovery phase. The fact that total monocyte 
count and Mon1 at the index point were predictive, in contrast to the Rogacev et al. paper, could 
be explained by the differences in the populations studied (Rogacev et al., 2011) whilst I studied 
acute myocardial infarction they followed up patients with stable coronary artery disease 
undergoing coronary angiography.  
The phagocytic activity of monocytes appeared to be the monocyte functional mechanism 
affecting patients’ outcome with no role from NFκB activation pathway. This is in keeping with 
presumed increase in phagocytic activity of monocytes in the acute phase post infarction. As 
MACE events were driven by development of clinical and echocardiographic features of heart 
failure, an increase in the number of local monocyte and their phagocytic activity can lead to 
adverse cardiac remodelling hence increased rate of MACE.  
The results of this section of my study provide more evidence on the function of the recently 
identified monocyte subset 2, suggesting an inflammatory role for Mon 2. My study also suggests 
that the phagocytic activity of monocytes is the predominant function of subset 1 and subset 2. 
These results suggest that monocytes subsets especially subset 1 and 2 pose important information 
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for future patient prognostication as well as forming a possible focus for new medical therapies 
in improving patient outcome.  
There was no effect of measuring IKKβ and clinical outcome. Despite the well proven association 
of the NFκB pathway and developing heart failure, it is important to acknowledge that most of 
these studies were done in murine models. Human based studies were not performed with long 
follow up period, until my study was carried out.  
ROC analysis and C- statistics of total monocyte counts, Mon 1 and Mon 2 indicate a very good 
area under the curve indicating that patients with higher monocyte counts, Mon 1 and Mon 2 are 
more likely to develop an adverse cardiac event compared to patients with lower counts. The area 
under the curve was better for monocyte subsets compared to Troponin levels and TIMI score 
independent. This provides an immediate avenue for the utilisation of monocyte counts 
measurement in clinical practice. The ability to risk stratify patients likely to develop adverse 
cardiac events depending on their monocyte subset counts, would be able to tailor secondary 
preventative medical therapy to those patients who are at risk. This is likely to improve both the 
cost effectiveness of secondary preventative therapy as well as scientifically individualising 
patient care.   
6.6   Conclusion 
This study is the largest study with the longest follow up period investigating the impact of three 
different monocyte subsets on long term outcomes. It investigated the impact of monocytes both 
at the time of infarct as well as 2 weeks into recovery. It indicates that higher total count of 
monocytes, as well as Mon 1 and Mon 2 are associated with worse outcome This was associated 
with an area under the curve of 0.85 and 0.6 for Mon1 and Mon 2 respectively. The phagocytic 
activity of monocytes was the functional mechanism that significantly and negatively impacted 
on patients’ outcome. There was no statistically significant effect from the NFKB activation 
pathway suggesting that it is the overzealous activity of the phagocytic of monocytes.  
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Chapter 7 
Conclusions 
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7.1   Final Conclusion 
This thesis was the largest study investigating the phenotypic and functional characteristics of the 
three monocytes subpopulations, as defined of recent years [Mon 1 (CD14++CD16-CCR2+); 
Mon 2 (CD14+CD16+CCR2+); Mon 3 (CD14-CD16++CCR2-)], in STEMI patients. After a 
plethora of descriptive data on surface markers of monocyte subsets to try to establish their 
functional characteristics, in this study I investigate two of the functional pathways through which 
monocytes implement their function: namely inflammation and phagocytosis.  
In chapter two for the first time, we describe that the monocyte subset distribution counts in 
peripheral and coronary circulation are not statistically different. This finding supports the 
concept of utilising peripheral sampling to study monocyte subset in whole venous blood. In this 
chapter the effect of STEMI on monocyte counts is characterised. All three monocyte subsets 
were significantly increased in STEMI patients compared to healthy individuals and patients with 
underlying stable coronary artery disease.  
I studied the phagocytic activity of monocyte subsets in chapter 3. A robust, reproducible, rapid 
flow cytometry based assay for the assessment of monocyte subset phagocytic activity in whole 
blood is described. The method was validated in multiple physiological states. I demonstrated 
that 24 hours post exercise there was an increase in phagocytic activity of Mon1 and Mon3 in 
response to extreme exertion. I also illustrated that the phagocytic activity of monocytes were 
higher for all monocyte subsets in STEMI patients compared to healthy controls and patients with 
stable coronary artery disease. There was also a no significant change in Mon 1 and Mon 3 
phagocytic action at the second phase post STEMI. However there was no reduction in phagocytic 
activity of Mon 2 at 14 days. This persistent activity of Mon 2 could explain the effect of Mon 1 
and Mon 2 in ventricular remodelling and clinical outcome. Indeed in chapter 5, I describe for 
the first time that the phagocytic activity of Mon 1 and Mon 2 were independent predictors of 
negative ventricular remodelling. Later in chapter 6, I describe that the phagocytic activity of 
Mon 1 and Mon 2 were independent predictor of major adverse cardiac events and increased the 
risk of mortality.   
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Chapter 3 demonstrated a small pilot study of monocyte chemotaxis in STEMI patients in 
response to MCP-1. Interestingly there appeared to be an inhibitory effect in the plasma of 
patients sustaining STEMI and those patients with stable coronary artery disease, however this 
inhibitory effect was lost in patients who sustained a MACE therefore leading to an exponential 
rapid attraction of monocytes.   
I then investigated the inflammatory role of monocytes in chapter 4, studying the effect of 
monocyte activated NFκB inflammatory pathway through assessment and measurement of IKKβ 
activity in STEMI patients. The method was validated in isolated CD14+ve monocyte. There was 
no correlation between monocyte subset and IKKβ levels. Even though the methodology has been 
validated, studying this pathway did not further our understanding of monocytes effect on this 
particular inflammatory pathway. This may be due to the interaction of several other 
inflammatory pathways at cellular level, e.g. effect of reactive oxygen species release and 
activation of heat shock proteins on inflammatory pathways. The complexity of the micro-
environmental milieu at infarct level with various autocrine effects on multiple interconnected 
inflammatory pathways, makes it difficult to target a specific inflammatory pathway during 
infarct, as has been shown in clinical trials utilising immunosuppressant medication, with 
minimal benefit to improving patient outcome. In chapters 5 and 6 there was also no relationship 
between IKKβ and ventricular remodelling or clinical outcome respectively. In chapter 4 total 
monocyte count, Mon1, and Mon 2 as well as phagocytic activity of Mon 1 correlated with TNF-
α and MMP- 9.  
In chapter 5, I demonstrate that total monocyte counts, Mon 1, and Mon 2 are independent 
predictors of ventricular remodelling in STEMI patients, this was indicated in both the univariate 
and multivariate linear regression models. The monocyte quartiles were negatively associated 
with EF with higher counts of total monocytes, Mon 1 and Mon 2 being associated with lower 
EF.  
In this study I report for the first time Mon 1, Mon 2 and phagocytic activity of Mon 1 as being 
independent predictors of MACE. Kaplan Meier survival curve indicated that patients who had 
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higher quartiles counts of total Monocyte count, Mon 1 and Mon 2 developed a MACE event 
earlier than patients who were in the lower quartile groups with 80% of patients who sustained a 
MACE had monocyte counts in the 3rd and 4th quartile of total monocyte count, as well as Mon 
1, and Mon 2. 
In summary, in this study I describe that Mon 1 and Mon 2 are predictive of negative ventricular 
remodelling, MACE and earlier mortality. Phagocytosis appears to be the functional mechanism 
through which monocytes exert their action. Results from this study suggest that despite surface 
expression of VCAM and ICAM, Mon 2 has a similar inflammatory role to Mon 1. This is in 
contrast to the angiogenic and fibrotic role (similar to that of Mon3) that Mon2 were previously 
thought to effect. It might be that it is time to consider the nomenclature of monocyte subsets, 
and start referring to Mon 1 as phagocytic monocytes, rather than inflammatory monocytes as 
more and more data becomes available from human subjects.    
7.2   Limitations 
This was a well powered study that achieved all its endpoints. The lack of fate mapping studies 
of the three different monocyte subsets was a drawback of this study. Investigating the role of 
reactive oxygen species in STEMI and their association with monocyte activity could have helped 
us to establish another functional role of monocyte subsets.  
Immunological imaging of monocytes journey during an infarct would add more information on 
the function of these subsets. Iron based tagging of monocytes was also not available in our local 
facilities and hence were not possible to perform. The number of patients completing two 
echocardiogram scans was 60% of the recruited study however as the study was well powered 
this still met targets for assessing LV remodelling.  
This study did not record the glucose level of patients at the point of admission and there was no 
subgroup analysis of diabetic patients.  
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7.3   Future Direction 
This project adds functional information to the descriptive data that are already available on the 
possible inflammatory role of the three monocyte subsets and particularly on the intermediate 
monocyte subpopulation. It provides more evidence supporting an inflammatory role for Mon 2 
but very little information is available on this population’s transit time before becoming 
macrophages. It also comes in contrast to a recently published data by Lu et al. investigating 70 
patients with NSTEMI and diabetes and concluding that Mon2 has a beneficial effect on cardiac 
remodelling (Lu et al., 2014). Besides a much bigger sample, our project investigates all comers 
and not just diabetic patients. As discussed, the admission blood glucose levels were not studied. 
Future studies need to investigate diabetic patients separately.  
This study raises multiple questions for future study: the lifespan of Mon2 subpopulations and 
fate mapping experiments are the second natural step following on from my research. Addressing 
the question of whether monocyte sub population 2 matures into macrophages 1 or 2 would be 
important to answer as the resulting macrophages are likely to be resident in myocardial tissue 
for longer duration compared to monocytes thus allowing for targeted medical intervention. It is 
now an accepted fact that full eradication of resident macrophages could be detrimental to patient 
outcome hence partly accounting for the failure of anti-inflammatory medication to show, as yet, 
any promise in reducing adverse patient outcome. Finally, studying the role of monocyte mRNA 
in humans might be able to shed more light onto the differentiating capacity of monocyte subsets.  
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8  Appendices 
I- Patient recruitment: 
Patients with STEMI admitted to Heartlands Hospital, Queen Elizabeth Hospital and Sandwell 
and West Birmingham Hospitals (SWBH) NHS Trust. Patients who met the study criteria were 
recruited between March 2011 and December 2012. Details of patients recruited are included in 
the appendix A. from both the City Hospital and Sandwell General Hospital sites within the Trust. 
The cardiology Consultants within the Trust work at both sites and undertake PCI for 
management of STEMI patients. All operators adhere to the Trust policy on management of 
patients with STEMI, and hence there is little variation in practice and management of patients 
with STEMI. 
For the longitudinal study, two hundred and nine patients with ST elevation myocardial infarction 
(STEMI) were recruited. Patients were approached in 5 teaching hospitals (City, Sandwell 
District General Hospital, Birmingham Heartlands Hospital–serving a population catchment of 
1.2 million overall. Patients were recruited within 24 hours post-admission. 
ST elevation myocardial infarction is defined by well-established clinical grounds, with a history 
of typical chest pain and concurrent electrocardiographic (ECG) changes, as defined using the 
European Society of Cardiology guidelines. All recruited patients had undergone a PCI as the 
default reperfusion strategy. As part of the standard clinical care, patients will have received high 
dose aspirin and another antiplatelet therapy (namely clopidogrel, prasugrel or ticagrelor). They 
will have also received standard cardiovascular prevention drug therapies (statins, ACE 
inhibitors, beta-blockers as well as antiplatelet therapy). Informed consent has been obtained from 
all patients. 
 
II- Control Subjects 
Data from control subjects were utilised to compare counts in a cross sectional study with the 
main STEMI population patients. Hence 20 stable coronary artery disease patients were recruited. 
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These are identified as patients with stable coronary artery disease, confirmed during elective 
coronary angiography, with no hospital admission for ≥ 9 months. This group was recruited from 
cardiology outpatients or cardiac rehabilitation programmes. 
Healthy controls are identified as subjects who had no apparent risk factors for ischaemic heart 
disease and who did not suffer from vascular, metabolic, neoplastic or inflammatory disease. This 
was confirmed by careful history, examination and routine laboratory tests. They were recruited 
from a general practice facility (Baldwins Lane Surgery, Hall Green, Birmingham). The patients 
satisfying the inclusion criteria were approached in surgery during a pre-planned visit. If patients 
consented for participation they were recruited and a single peripheral venous sample was 
venesected from the antecubital fossa.  
 
III- Statistical methods 
III-i Power Calculation 
Power calculations were based on the results by Larose et al. who have shown that 20% of ACS 
patients have cardiovascular events during one year (Larose et al., 2010). This was performed by 
resident statistician prior to the study commencing. Briefly, in order to achieve 80% statistical 
power to detect the difference in the MACE (death, new diagnosis of heart failure and recurrent 
ACS) (with p<0.05) in count of the monocyte subsets, at least 35 MACE events were needed. 
Thus, at least 175 patients were to be recruited to provide additional confidence and to manage 
potential drop-out, we aimed to recruit 200 patients for this part of the study. The impact of 
monocyte subsets and their functional characteristics on cardiac remodelling were assessed by 
the differences in LV ejection fraction and volumes between tertiles of monocyte parameters. In 
order to detect 0.5 standard deviation differences in parameters of cardiac remodelling, at least 
35 patients were analysed for each quartile (i.e. at least 105 patients) for the echocardiographic 
study. However 120 patients were recruited for further confidence. Similarly, at least 20 patients 
were be recruited for each group of healthy individuals and patients with stable coronary artery 
disease in the cross-sectional part of the study 
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